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EDITORIALS 
HIV/AIDS and Cultural Evolution 
Friedrich Nietzche professed that illness was vital for cultural development. When one evaluates the history of catastrophic afflictions which have beset 
humankind, the veracity of this notion is obvious. The 
Greeks had blindness, Medieval Europeans had the 
Bubonic Plague, and 19th century Europe had 
tuberculosis. 1 Presently, the truism is manifest as the 
scourge of HIV I AIDS. Culture is an inclusive term which 
encompasses a society's art, science, spirituality, 
commerce, and patterns of interaction; it denotes a 
group's Worldview. In the Western world, every facet of 
the population has been given voice by the AIDS 
pandemic. 
Explanations for the origins of HIV are numerous. 
Theories range from accidents in U.S . and Soviet 
laboratories involved in biological warfare, to green 
monkeys that harbored the disease and propagated it to 
Man in Africa2, to Patient Zero, allegedly a promiscuous 
Canadian male homosexual airline steward, who 
recklessly spread his own rare illness. 
Demagogues, in some cases, revel in self-satisfied 
assuredness as their preaching seems validated: just as the 
biblical cities of Sodom and Gomorrah were destroyed for 
licentious behavior, Cardinal Ratzinger of the Roman 
Catholic church cited HIV I AIDS as God's wrath against a 
permissive society and the abomination of 
homosexuality. 2 
The artistic community has exploited its pulpit in the 
media, and has been a visible, if not venerable 
philanthropic force. The AIDS Awareness Ribbon was 
inspired by the yellow ribbons worn on jacket lapels, 
during the Persian Gulf War, to honour American 
soldiers. Conceived by Visual AIDS, a New York based 
charity group of professional artists, they chose the colour 
red because of its connection to blood, and its symbolic 
association with emotions such as anger and passion.3•4 
Worn by host Jeremy Irons at the 1991 Tony Awards, the 
AIDS Ribbon made its public debut. 
A militant faction of skeptics exists, and alleges that in 
14 years, the "HIV hypothesis" has been unproductive, 
and non-predictive, due to the fact that AIDS is neither an 
infectious epidemic, nor is it caused by HIV.5 Activist 
groups, such as Continuum, seem to be belligerent in their 
denial of the HIV I AIDS crisis. Expounding their premise 
that HIV does not exist as a unique exogenous lentivirus, 
they argue that the global promotion of anti-viral drugs is 
responsible for the spread of AIDS-like symptoms. They 
have crafted a hypothesis which states that the condition 
is the iatrogenic consequence of a despotic medical and 
pharmaceutical conspiracy. 
Championing the war against HIV I AIDS, medical 
professionals and community based agencies have indeed 
experienced their share of triumphs and disappointments. 
Retroviruses were first postulated, and then discovered, in 
the early 1970's. 6 By 1982, HTLV-1, the firs t human 
retrovirus had been isolated and characterized.5 In 1980, 
the first scientific report on the subject was published. It 
concerned homosexual males, from the Los Angeles area, 
who had presented with unusual skin infections and 
cancers.2 An early bias, which is perpetuated even today 
by ignorance and hatred, was established in 1981: based 
solely on the demographics of the earliest, isolated cases, 
the disease was named Gay Compromise Syndrome.7 This 
term, with its negative connota tions, was eventually 
replaced by the acronym AIDS. The virus responsible for 
AIDS was isolated in 1983 by researchers at the Pasteur 
Institute in France, and they called it Lymphadenopathy-
associated Virus (LAV). The International Committee on 
the Taxonomy of Viruses recommended the use of the 
term Human Immunodeficiency Virus (HIV) in 1986.2 
1997 has been deemed a pivotal year in the ongoing 
battle against HIV I AIDS. Combination therapies, known 
as "drug cocktails" are widely prescribed, and declines in 
the rate of death from AIDS in developed countries have 
been reported. Plasma HIV-1 RNA determinants have 
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Editor1a 
usurped CD4 cell counts as the most important marker of 
HIV progression and prognosis. Nonetheless, a daunting 
reality remains. It is stated in a recent commentary in the 
CMAJ that drug resi s tance and inaccessibility of 
therapeutic agents, as well as a resurgence of new 
infections in key populations, pose continuing challenges.8 
Community health units and educators fear that an 
attitude of complacency has resurfaced amidst the 
optimism of promising recent developments. 
Services available to those whose lives have been 
affected by HIV I AIDS are as diverse as the patient 
population itself. From the throes of suffering has 
emerged a climate of medical urgency and social 
awareness and tolerance. 
The University of Western Ontario Medical Journal has 
devoted this issue to the topic of HIV I AIDS because it is 
relevant to medical practitioners at all levels, and in all 
fields. We hope that this issue will serve to educate our 
readers, and to supplement the information regarding 
HIV I AIDS that is currently presented in the medical 
curriculum at Western. Q 
BECTON 
DICKINSON 
Joraan '13. Sofmon 
'Etfitor-In-Ciiief 
:M'EVS 1998 
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ETHICS 
EDITOR: D AVID SATIN 
A Practical Method for 
Approaching Bioethical Issues 
I ndividuals entering the field of medicine come from varied and diverse backgrounds; as a result, some people have had little or no experience in the study of 
biomedical ethics, whereas others have multiple degrees 
in the field. Nonetheless, every medical student will come 
to a point in his training where he will encounter a 
situation that will demand ethical analysis. More to the 
point, he will be forced to make decisions that he will have 
to justify to his supervisors, colleagues and patients. The 
purpose of this article is to introduce a practical method of 
analysis that students can adopt and improve upon as 
their careers progress. 
Presented here is an approach for examining ethical 
dilemmas which was developed by Dr. Keith Arnold from 
the Department of Philosophy at the University of Ottawa. 
This approach is a very practical one for medical students 
since it is straight forward, case-specific, and allows for all 
aspec ts and viewpoints of a particular issue to be 
presented. This is neither the only method for examining 
moral problems, nor is it necessarily the best -- it is simply 
one particular procedure which students can use, modify 
or even discard, as they deem appropriate. 
INTRODUCTION 
Before methods for examining ethical issues can be 
discussed, it is important to form ulate agreed upon 
definitions of certain terms. The most important of these 
concepts would have to be that of an ethical dilemma. An 
ethical dilemma can be seen as a conflict which arises 
when two or more parties disagree; to do good for one 
party may be to do harm to another. Essentially, it is a 
situation wherein one is not simultaneously able to satisfy 
everyone's wants, needs and rights. From this definition, it 
follows that a blanket term such as "abortion" does not in 
itself constitute an ethical dilemma. Instead, this concept 
has to be applied to a specific situation. For example, we 
could have a situation in which a couple disagrees, as the 
woman desires an abortion and the male wishes to 
prevent the abortion (i.e. the 1989 Jean-Guy Trembley v. 
Chantal Daigle case). Essentially, the example 
demonstrates that an ethical dilemma by definition arises 
only when we have two opposing viewpoints. 
ABOUT THE AUTHORS 
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PRINCIPALISM VS. PROCEDURALISM 
In the field of Biomedical ethics, there are two general 
approaches for examining moral problems. Principalism, or 
' the engineering model', involves applying a set of rigid 
principles to a case. Proceduralism involves the evaluation 
of each case based upon the specific data presented. It is 
this latter approach that will be focussed on. 
Principalism is also called the ' top-down approach' as it 
implies that the process of ethical problem solving is 
deductive, rather than inductive. The principles used are 
insensitive to the facts of different cases, and there is an 
implied certainty to the answer that results . The four 
principles are: 
1. Principle of Respect for Persons (Autonomy): states that 
one should respect all those involved in a dilemma as 
persons, with dignity, freedom and the capacity for self-
determination. A person should never be used as a 
means to an end. 
2. Principle of Non-maleficence: one should attempt to inflict 
no harm. If one cannot do good without doing harm, then 
one should forego that course of action. 
3. Principle of Beneficence: one should attempt to maximize 
benefits and decrease harm. 
4. Principle of Justice: one should treat equals equally and 
unequals unequally. The goal is to appreciate the 
difference between the encumbered and the 
unencumbered. For example, it is obvious that a person 
in a wheelchair differs in some respects from an able-
bodied person, thus in the spirit of leveling the playing 
field, the individual in the wheelchair may be entitled to 
certain privileges the able-bodied person does not have. 
Recently, there has been a shift away from Principalism 
to Proceduralism, or the 'data driven method'. This method 
of ethical analysis involves the examination of each dilemma 
on a case by case basis. In this approach, there are no set 
standards with which to evaluate a case. Instead, each case 
is seen as unique, and we see a bottom-up methodology. 
The reasoning involved is inductive. It is vital to 
acknowledge the many points of view of all those involved 
in order to appreciate the perspectives from which the case 
can be viewed. To this end, the procedural approach uses 
strategies for examining different viewpoints. The goal is to 
utilize the different strategies and then to see if one still 
arrives at the same conclusion. An advantage of the specific 
procedural approach presented here is that one's own 
personal beliefs are incorporated, as are the aforementioned 
principles, as well as pertinent laws, codes and medical 
facts. 
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THE PROCEDURAL APPROACH 
I. CASE SPECIFICATIONS 
This initial step is perhaps the most crucial link in 
the chain of steps implemented in the procedural 
approach. The center of the entire procedural approach 
stems from the consideration of the specifics of each 
case. By developing a micro-his tory of the case, the 
uniqueness of situation is recognized. 
II. IDENTIFY STAKEHOLDERS 
Ethical dilemmas encountered in the health care 
profession are often not limited to one or two 
individuals, but instead involve a multitude of people 
who will eventually be influenced by the issue. As such, 
a stakeholder is defined as any individual who has an 
interest in, and will be affected by, the decision being 
made. There are three kinds of stakeholders: 
First Party: The individual who is directly affected 
by the decision being made. Most often the patient is the 
primary stakeholder. 
Second Party: Any individual who is involved in the 
decision making process, which will ultimately 
influence the first party. This includes the physician, 
and nurses. 
Third Party: Any other individual who is indirectly 
affected by the decision being made. This includes 
family, friends, and others. 
III. IDENTIFY MORAL DILEMMA 
Any attempt to reach common ground in such 
situations requires that all parties involved recognize 
the same basic ethical dilemma. The following is an 
example of a specific ethical dilemma: A physician's 
right to breach patient confidentiality in order to protect 
the health of other individuals vs. a patient's wish that 
confidentiality be upheld at all costs. 
IV. IDENTIFY COMMUNITY STAN DARDS 
Society and the perspective of the community at 
large will tend to influence the outcome of an ethical 
dilemma. The opinion of the community at large can 
follow one of two patterns: 
1. ull H ypothesis : The community at large is in 
agreement regarding the issue, and thus the greater 
percentage of people lie on one side of the argument. 
2. Moral Equipoise: The community is divided equally 
in terms of percen tage for and against a specific 
argument. As such, no community s tandard exists. 
V. CONSIDER PERSONAL VA LUES 
At this s tage of the ethical analysis, it is suggested 
that one should introduce his own personal values and 
beliefs. These personal opinions are not meant to be the 
ultimate factor in reaching a decision, but instead play a 
role of guidance. By doing this, the examiner brings 
himseli closer to the case and thus ensures that the final 
decision reached will be as humanistic as possible. 
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VI. CONSIDER PERSPECTIVES OF 
STAKEHO LDERS 
The perspective of all the stakeholders who will be 
influenced by the decision being reached must play a role 
in the decision making process. This is yet another link, in 
the chain, which emphasizes and allows for the 
recognition of the uniqueness of each case. Certainly, 
identical ethical dilemmas will appear time and time 
again, however the individuals involved in the dilemma 
will differ from situation to situation. As such, this step 
will ensure that the needs, rights, and wants of any 
indiv idual are not overlooked due to generalizations 
which might stem from previous experiences. 
VII. EXAMINE CASE INDEPENDENT VARIABLES 
Despite the emphasis placed on examining the 
uniqueness of each situation, there are stages when the 
examiner must consider factors that are consistent from 
case to case. It is important to recognize that these 
parameters should not pla y the role of an ultimate 
authority in the decision, but instead should offer some 
guidance in the decision making process. The following 
are some example of case-independent variables: 
1. The four pillars of the procedural approach: Principles 
of autonomy, non-maleficence, beneficence, and justice 
(discussed earlier) 
2. Codes of ethics : There are various codes that are 
expected to regulate the conduct of physicians, nurses, 
and other members of the health care team, and thus 
offer protection to those who will be influenced by the 
decision. These codes include the Canadian Charter of 
Rights and Freedoms, Ontario Human Rights Act, 
Canada Health Act, and Canadian Medical Association 
Code of Ethics. 
3. Pertinent laws: The Criminal Code of Canada, and 
several other bills provide guidance to physicians and 
health care workers when making decisions regarding 
ethical dilemmas. onetheless, there are continually 
new situations arising which the law has not been 
exposed to, and thus can not regulate. 
4. Medical facts : The medical background of the case 
being considered, and the success rates of the various 
options should be considered. 
VIII. APPLY PROCEDURAL STRATEGIES 
The procedural approach offers strategies that the 
examiner can apply in order to facilitate the case analysis. 
This stage is particularly useful, because it ensures that 
experiences from previous cases are not transferred into 
the analysis. The four strategies are: 
1. Role/ Reversal: The examiner considers the situation as 
if he was in place of the first party. As such he will 
ensure that none of the actions taken will treat the first 
party unfairly. 
2. Hard I ew cases: The examiner changes the case to 
Eth i cs 
make it more difficult. In this instance the examiner 
considers the viewpoints of family members and other 
stakeholders, by placing people who are close to him in 
the position of the first party. Analysis of this new and 
more complicated case facilitates the analysis of the 
original one. 
3. Maxi-Mini / Mini-Max: The examiner should follow a 
course of action which will maximize the benefits and 
m inimize the harms . The worse outcome should be 
avoided at all costs. 
4. Universal consequences: The examiner should consider 
the consequences if all other identical cases were 
handled in the same manner. What would happen if all 
others did what he is about to do? 
IX. COME TO A DECISION 
The end result of every ethical dilemma is that a 
decision has to made. After all the information has been 
gathered and the perspective of all those involved has 
been considered, the examiner can reach a conclusion 
regarding the best possible plan of action. In doing so the 
examiner will consider the arguments for and against each 
side of the dilemma. It is important to note that certain 
arguments will be more influential than others. Regardless 
of the conclusion reached, the examiner must strive to 
ensure that the final outcome is fair (or at least is not 
unfair) to all the stakeholders. 
The control over life and death associated with the 
medical profession, today more than ever, implies that 
future physicians can expect to repeatedly encounter new 
and unanticipated ethical dilemmas, many of which will 
have no laws or precedents to refer to for guidance. It is 
hoped that the material presented here will be of use to 
medical students in formulating their own strategies to 
deal with ethical issues. 
Q 
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DOCTOR'S CALL 
T he set is a mirror image framed by two small tables holding telephones with answering machines. Within the tables' boundaries stand Toni, stage right, and Tony, 
stage left. Toni is a 40 year old woman _in moderate make ~p, 
business suit (reasonnbly casual) over a lzght sweater. Tony zs a 
40 year old man wearing sport jacket, open shirt and casual 
trousers. They stand back to back in freeze, centre stage. They 
then take one step lateral and one forward, and freeze. After 5 
seconds tandem monologue begins. 
TONI & TONY (in unison): My parents christened me 
TONI: Antoinette 
TONY: Anthony 
TONI & TONY (in unison): My friends call me Toni(y). 
TONI: I came home from the ritual post-work physical 
ablution that grants my home serenity. 
TONY: My answering machine glance (they indicate respective 
answering machines) was met by the usual red staccato 
response. 
TONI: This message lay waiting one hour ago. 
DOCTOR'S VOICE (tape reveals a fatigued, worried female 
voice): Hi Toni(y), it's Norma Evans. Cou ld you 
please call me when you get home . . . um . .. It 's kind 
of important . .. sigh . .. please call me. (click, tone) 
TONI (points to answering 1n11chine): My family doc~or, No~a 
Evans, requesting return of her call ... tonzght . .. zn 
such despairing voice. 
TONY: The despair in her voice chilled me ... Nor1n11 is one of 
the most upbeat people I know. (brightens) We went to 
medical school together. 
TONI: Everyone responds upbeat to my tape's effervescent a 
capella invitation. Though more my tr~sted doc.tor 
than friend, Norma usually responds zn matchzng 
accent and musical motif (countenance darkens; gazes 
ahead sadly). 
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TONI & TONY (in unison): But not tonight. 
TONY (serious): Her tone bore hollowness to my core. You see 
a few days ago I went to Norma's office (pause) for an 
HIV test. 
TONI: As my relationship with Bob was stable, (pensively) 
what am I saying stable? I'm sure he's the soulmate 
I've sought ... for so many years, and since I started the 
pill four months ago, I felt it was time we could "de-
condomize" our relationship. I know Bob wants to "de-
condomize", really wants to "de-condomize". Even 
though I was not "at risk" for HIV, responsibility 
dictated I first have an HIV test. 
TONY: I was to see Susan on the weekend and obviously 
wanted the all-clear as soon as possible. 
TONI: But Norma explained that though the blood is 
couriered to the lab, it usually takes two weeks before 
the results are 1n11il-returned. 
TONY: Considering our mail system, I resigned to three weeks; 
but the fact that Norma was calling me in just three 
days ... in such sadness ... must mean that she was called 
by the public health lab to contact the HIV "carrier" 
(pause, points to self) immediately to ensure no further 
spread of the virus. 
TONI: As I replayed the tape, my doctor's voice inflected no 
chromatic quality to contrary convince. 
TONY: My immediate phone to my physician's home heard 
babysitter words apologize "Dr. Evans is working late 
in her office; she'll be home in about an hour." 
TONI: Controlled fingers purposefully pressed each offered 
number ... only to receive a receptionist's cheery taped 
message, (mimic) "''m sorry, the doctor's office is 
closed and will reopen at 9:00 a.m. tomorrow. In case 
of emergency page the doctor on call." (pause) Before 
my whispered "please 1n11y my doctor be on call", her 
associate's name pierced my prayer. 
TONY: I could not reach my doctor to certify my sentence. 
TONI: To commute my condemnation. 
TONY: The babysitter's approximation of Norma 's ETA to 
confirm my already accepted sentence, afforded an hour 
to reflect my source of HIV and how to tell my loved 
ones. 
10 
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TO I: I've been in two prior relationships. Oral 
contraceptives protected me from pregnancy, but 
obviously not from HIV. At that time, I perceived no 
need for condom precaution. I'm sure my partners 
were strictly heterosexual. And I don't think they were 
unfaithful to me. 
TONY: My previous partner is also a physician. I don't think 
she ever submitted for an HIV test. Could she have 
picked up HIV in the office, the ER? I know that's 
impossible . . . what am I saying (can 't believe self 
shaking head)--l'm a physician! 
TONI: I know you need a significant inoculation of the virus, 
more than you can get from looking down a patient's 
throat or being coughed upon. Oh my god, I can't 
believe what I'm saying! I'm a physician! 
TONY: I'm sounding like the fearful uninformed, afraid to 
come close to, or administer care to, people with HIV. 
I'm a physician ... I should be enlightened ... I should be 
sympathetic. 
TONI: Was my previous partner always faithful to me? I 
never questioned his faithfulness before. But there were 
times, especially toward the end of our relationship, 
when things were quite bad between us. I didn't even 
want to be near him. I'm sure he knew it. 
TONY: Until this minute, I never perceived my previous 
partner could have been unfaithful. My Pollyanna 
ethos assumes everyone as loyal as I... but the 
possibility exists. I never felt with anyone the emotional 
unity sewn so completely with Susan. I didn't know it 
could exist until Susan. Perhaps my former partner 
felt my disconnection and sought intimacy elsewhere. 
TONI: Could Jim have picked up HIV from some woman and 
passed it to me? Some woman who gave him the 
comfort I couldn't. Woman? ... Oh ... Could it have been 
a man? Could Jim be bisexual? I don 't think so. But 
how would I know? 
TONY: How could I be so stupid? To succumb my sons to 
their father 's slide through Hell, to being fatherless at 
the age they need me the most. (pause) I broke faith 
with my sons when I trusted the faithfulness of others. 
TONI: How could I be tempted by trust? 
TONY: I can't believe I hear my voice condemning others for 
what is clearly my responsibility. Have I descended to 
seek share of responsibility? It's my fault for my 
misfortune, full stop! Not misfortune ... foolishness . 
TONI: There was a patient during whose surgery a large-
gauge needle went through my glove, (looking at 
fingers) Jar into my finger's flesh . 
Ethics 
TONY: I clearly remember my run to employee health right 
after surgery for blood tests, to see if I needed a 
hepatitis shot. I had not thought about that man in 
years. 
TONI: But I remember his face so clearly now. I see his eyes 
when, just as he was ready to leave hospital, I asked 
him to be tested for HIV. 
TONY: I really did ask him. Physically holding back coercive 
consonants in the name of respect for his freedom to 
choose, to choose whether or not to be tested. 
TONI: But I did compassionately encourage him to be tested. 
TONY: I remember how relieved I was when he consented to 
the HIV test. 
TONI: Although his HIV test was negative then, he could still 
have had HIV. What if he picked it up within the 
previous 6 months? His blood may not yet have 
converted to HIV positive. 
TONY: If he eventually became HIV positive, you would think 
that he would have called the hospital to warn us, but 
how would he know unless he was re-tested? Or 
developed symptoms of AIDS? 
TONI: Symptoms could take years to surface. 
TONY: But he wasn't gay. At least, I don't think he was gay. 
But that's not something we asked about in those days. 
TONI: And though sexual orientation is part of one's social 
history, I'm not sure we ask about it today. 
TONY: I'm not sure we should ask about it today. 
TONI: Will I ask my patients about sexual orientation from 
now on? (freaking) What am I talking about? There is 
no "from now on"! What patient in their right mind 
would want me for their doctor? 
TONY: Will I have to inform each patient of my HIV status 
before I accept them into my practice (pause) or touch 
them? Is that what those doctors with HIV do? 
TONI: (exacerbated) Is it fair to ask a patient to remain in my 
care or consent to physical exam? 
TONY: Some may say yes to please me, but I know how great is 
the fear of AIDS. I feared it myself 
TONI: (exhausted) I see myself leperized: patients not shaking 
hands, making sure I don 't come too close, backing out 
of my examining room. 
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TONY: I see them looking for a sink 
TONI: To wash their hands, 
TONY: To cleanse each pore of possibility, 
TONI: Before they get in their cars, 
TONY: Carry contagion (pause) 
TONI: To their partners (pause) 
TONY: To their kids. 
TONI & TONY (in unison): Do I change my practice? 
TONI: Restrict my care to others same virus infected? 
TONY: Rather than worrying my patients? 
TONI: Rather than worrying about my patients? (pause) 
TONY: When I asked my doctor for an HIV test, she asked if I 
wanted to "number-code-conceal" my name. (slowly 
nodding) I eagerly embraced anonymity. 
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TONI (defensive): Not that three days ago I was the slightest bit 
worried it would be HIV positive. 
TONY: I just didn't want people to think I was worried about 
being HIV positive. 
TONI: Think I was promiscuous. 
TONY: Think I was gay. 
TONI & TONY (in unison): Think less of me. 
TONY: I reaped reassurance from the requisition's check-box 
inquire of the reason for the HIV test. 
TONI: Sex with women? 
TONY: Sex with men? 
TONI: Blood transfusion? (confused) 
TONY: My eyes riveted the requisition, refusing their leave 
until I saw the "sex with women" box secured. 
TONI: I have been unwell of late. (questioning, thinking) A 
series of minor maladies, that I merely shrugged off as 
bad luck. 
TONY: But I had been always so healthy before, (slowly) and 
now viewing through my acutely focus ed 
retrospectoscope, I recognize these were symptoms of 
early AIDS. 
TONI: Upper respiratory tract infections, fatigue , brittle 
fingernails, (pause) skin eruptions that were most 
certainly herpes zoster. 
TONY: What am I saying? That my body is already depleted 
of its immune defenses? That I already have fulminant 
AIDS? Oh, I wish Norma Evans would call. 
TONI: Oh how I wish she'd call. 
TONY (pause quietly): I've heard so many times (quoting) 
"HIV will touch us all." 
TONI (still quiet, but getting louder): "We will all suffer its 
existence." 
TONY (getting louder): "We will all have a friend or a loved 
one who AIDS will torment." 
TONI (getting louder): "Will kill." 
TONY: But I never thought it would be me. 
12 
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TONI (stop; look up): Five years ago HIV killed a friend of TONI: How do I tell my children? 
mine. 
TONY (pause, reflective, voice lower): Stuart was a physician ... a 
kind person ... a man with whom I swam many pool laps, 
shared dechlorination, cerebrated solutions to our medical 
system's frustrations. 
TONI: His death, the waste of the second half of his life, spoke to 
me in decibels beyond the cadavers of celebrities in 
Hollywood or New York. 
TONY (pause): I'm not sure if Stuart was gay. I never considered 
that he might be gay until AIDS pummeled his person. It 
wasn't important then. (pause) It's important now. 
TONI: How do I tell my parents? 
TONY: I saw how they aged rapidly during my sister's recent 
illness. 
TONI: And although my sister is now well, my parents have not 
recovered. 
TONY: I saw how they shared my sister's suffering. I know how 
deeply they will share mine, long before I suffer. 
TONI: I know they will deny my diagnosis. 
TONY: Deny it to me. 
TONI & TONY (in unison): Deny it to themselves. 
TONI: They will demand exceptional therapy. They will insist 
insight of the best AIDS physicians in the world, for 
second, third, thirteenth opinions. 
TONY: As many as it takes. 
TO I: To be treated. 
TONY: To be cured. 
TO I: They will want to take my HW from me, (gesturing with 
hands) give it to themselves. 
TONY (pause): My distant death will be their proximate death. 
TONI (relieved): I know my sister will be okay. She 'll be 
wonderfully supportive. My friends will be supportive too. 
TONY: Though some will twinkle prescience of "wayward 
encounter", they will stand by me, help when the time 
comes. Oh, how I wish that phone would ring. 
TONY: Two teenage boys ... 
TONI: I see their disbelief .. 
TONY: I feel their pain ... 
TONI: I refute their refusal to accept my diagnosis. I provide 
optimistic but reasonable prognosis ... as I explain what 
has happened, (pause) what will happen. 
TONY: Previewing that conversation, I admonish words 
adamantly assuring my HET-er-o-sexuality 
(defensively), insistif!g my innocence. (amazed, angry at 
selj) I thought myselj enlightened enough not to fei!l this 
need, foster this prejudice. I cri~e the clarity in my_ voice 
emphasizing I contracted HW om a woman or from a 
patient. I hate myself for this eclaration. It diminishes 
gay men. (pause amf quieter) It diminishes me. It's like a 
;oke I heard and hated ten years ago, in which a man after 
learning he has AIDS tries to convince his parents he's 
Haitian. I encourage m}lself that this heterosexual 
assurance is for my kids well-being ... not that they'd 
think less of me ... we have always had an open loving 
relationship, but heterosexual assurance might obviate 
schoolyard smiles and knowing nods ... Why must a 
heterosexual ribbon adorn death' s victory? 
TONI: What about my partner ... 
TONI & TONY (in unison):My life's love? 
TONI: Bob. 
TONY: Susan. (pause) We hold each other in a magnetic field 
of oneness. 
TONI: Although Bob 's been using condoms, could I have 
given hzm HW through my secretions? Could licking 
or even kissing pass on the virus if you did enough of 
it? What am f saying? I'm a physiczan, I should know 
better! 
TONY: How do I tell Susan? I mean, we've only been together 
for six months, but I feel the sun follow her face, 
wrapping me in rainbow of her warmth. I carry her 
with me everywhere ... Is there any chance I could have 
infected her? .. . We've been using condoms, and they 
never broke ... but I wasn't really super careful. The 
sheets sometimes are secretion soaked. Could I have 
infected her? (starts agitated walking) It 's unthinkable 
(negatively shaking head) ... it's just unthinkable.. . I 
don't care about me having HW, (pleading) but please, 
please not Susan. 
TONI (cold): I will sever all ties with Bob .. . with love ... with 
the future. Once the doctor's call (pause) confirms the 
condemnation I already know. 
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TONY: Somewhere in the next 24 hours, I will tell Susan that 
though I love her beyond what I believed love was 
possible, my HIV means our dream of together must 
dissolve. 
TONI: Bob will tell me that it doesn't matter. .. and you know, 
he'll actually mean it. He'll say that he wants to see 
this through with me ... he'll mean that too.. . But I 
can't do that to him. It's over. I'll face the future alone. 
TONY: Susan can easily find a better partner, much better 
than me, better than I ever was, ever could be. That's a 
certainty. She's so bright ... beautiful to her soul. I will 
miss Susan. I will miss her touch, her eyes, her smell, 
her mind ... I miss her already. 
TONI (crying; thinks): You know, losing Bob is what hurts 
most. (hesitates) How do I retreat from his rightness, 
his rightness for me? 
TONY: I am already empty. Empty not feeling Susan's future 
entwined with mine. 
TONI: Somehow we must tune a new attitude, a new 
permission to admit vulnerability in relationship, 
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TONY: A new responsibility to protect our partners, 
TONI: To protect ourselves, 
TONY: A new acceptance that any of us who have ever had sex 
unprotected by condoms could be carrying HIV. 
TONI (pause): Why have I so calmly acquiesced a curtain that 
an hour ago I would have railed against, protested its 
possibility? 
TONY: Is this calm a shroud, or peace allowed when battle 
beckons? 
TONI: Is this calm carved by my training that emotion lessens 
objectivity, lessens us? 
TONY: Is this calm a fa~ade, or a blanket quenching the 
immutable verdict's venom? 
TONI: This calm is a gift, a gift to sift skill from sentiment, to 
claim competence required to help loved ones through 
their imminent anguish. 
TONY: This calm will remain till the call, 
TONI: Through the call, 
TONY: To explain the call 
TONI & TONY (in unison): To those /love. 
TONI: This calm will remain till the .. . 
Phone rings; Toni and Tony stare at respective phones. It rings 
a second time. They remain transfixed by the tone, 
then slowly they symmetrically lift the receivers to 
their stage lateral ears. Their eyes move up and 
slightly stage center as they answer. 
TONY & TONI: Hello? 
The tape comes on. They stare motionless while the doctor's 
voice is heard. 
DOCTOR'S VOICE (fatigue and sadness strung): Hi Tony, so 
glad you got my message. I have something 
unfortunate to tell you ... your HIV test .. . it needs to be 
repeated ... They wrote the number code on the 
requisition and your name on the blood tube, so they 
automatically discard the sample. You can have it 
repeated tomorrow (lights out). 
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HUMOUR 
EDITOR: DR DAVID COLBY 
Nuclear Medicine 
This past summer I turned down a tremendously unprofitable minimum wage job for the tremendously keen undertaking of electives. 
Armed with a full year of medical education (what more 
do yo u need to know?), I felt ready to tackle real 
medicine in a clinical setting. So, I grabbed the Alumni 
Binder to find a doctor who would show me the way. 
One of the listings in my hometown was in Nuclear 
Medicine. That sounded vaguely interesting, even 
though I knew absolutely nothing about the field . I 
promptly consulted the Merck Manual (every PBL 
tutor's worst nightmare and every student's most 
valuable, and perhaps only, resource), to find out 
exactly what this "nuclear medicine" was all about. I 
found out that it was "the medical application of 
unsealed radioactive materials for diagnosis and 
therapy".1 Great! I was as ready for this as for any PBL 
session, so off I went. 
The little child in me was excited upon entering the 
uclear Medicine department for the first time: "Look at 
a_ll the neat toys to play with! " I was disappointed to 
find out that the doctors do not actually get to play with 
all the equipment--there are technicians that do all that 
for them. This initial letdown was quickly displaced by 
panic as the doctor put up a can and asked me what I 
thought. For anyone who has never seen the pictures 
generated in Nuclear Medicine, they are fondly referred 
~o ~s. "fuzzograms" because the y are remarkabl y 
mdtshnct to the untrained eye, which is the category I fit 
into. Not only did I not know how to interpret this 
result, I ~id not even know what part of the anatomy I 
was lookmg at. Once we had sorted out that it was a 
lung scan, my mind frantically raced back to the 
respiratory physiology lectures while the doctor 
exp~ained the subtleties of this diagnostic modality. The 
patient had a V / Q mismatch, which was actually 
observable without reliance upon the eye of faith, and 
suddenly uclear Medicine seemed really interesting! 
I spent a fair amount of time with this doctor, and I 
definitely know a lot more about this field. I also have a 
deeper respect for it. A few important points to m y 
fellow students, so that you have not totally wasted 
your time reading this article, and also so that you know 
more about Nuclear Medicine than the first line of 
Merck: 
ABOUT THE AUTHOR 
Ian Mcllraith is a second year medical student at the 
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school, he completed a Bachelor of Science degree in 
combined Honours Biology and Philosophy at McMaster 
University. 
Beyond Merck 
By Ian Mcllraith, MEDS 2000 
1. Nuclear Medicine uses radiopharmaceuticals which 
are introduced into the patient, so that unlike 
ra~iology, the patient is the source of radioactivity. 
This allows many "fuzzograms" per exposure. 
2. While x-rays display anatomy, Nuclear Medicine 
images display physiology. This is an important 
distinction, and it hints at the unique uses of this 
modality; it would be difficult to see a V / Q 
mismatch on an x-ray. 
uclear Medicine is typically lumped together with 
radiology and pathology as a "lifestyle" choice, and 
indeed it has all the benefits associated with such a 
specialty. However, there is also the potential for more 
extensive patient contact (whole, live, conscious 
patients!) than these other fields. Nuclear Medicine 
o~erlaps with Internal Medicine in that thyroid 
dtsorders are generally treated by Nuclear Medicine 
specialists. These doctors are qualified to administer the 
radioio_dine u~ed to ablate hyperactive thyroid glands, 
and this provtdes the opportunity for counseling and 
educating patients. 
Perhaps the most important thing that I learned is 
that Nuclear Medicine is extremely interesting. As 
Henry . Wagner wrote, "the excitement of nuclear 
medicine remains the best kept secret in medicine."2 You 
will not find that in Merck. 
For those of you who are interested, here are some 
Internet resources related to Nuclear Medicine: 
1. UWO Nu_clear Medicine Residency Program page: 
HTTP: I I JOhns.largnet. uwo.ca I nucrad I nucres.html 
2. A couple good information pages: 
HTTP: I I www .mallinckrod t.nl / nucmed/ no frames I 
general/ nucmed.htm 
HTTP: I I www .louisville.edu / sahs/ nmt/ whatisnmt.htm 
3. For those who want to view a few nuclear medicine 
scans: 
HTTP:/ /www.radiology.arizona.edu/ -nucmed/title.htm 
HTTP:/ /www.aloha.net/ -peters/ organ.html 
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EDITOR: MATTHEW CRYSTAL 
Health Fact 
Statement: Sexually Transmitted Diseases (STDs) are 
more common in the Middlesex- London 
region. 
True: STDs are 29% more common in the 
Middlesex-London region than in the rest of 
Ontario . Of all the infectious diseases, 
reported cases of Chlamydia accounted for 
84% of the total.1 Chlamydia is transmitted 
through unprotected sex wi th an infected 
partner . In order to effectively explain the 
higher incidence in the Middlesex-London 
region, more research into the specific 
demographics and diagnostic practices will be 
necessary. When comparing all of the regions 
in Southwestern Ontario there is no apparent 
reason for the rates to be exaggerated in 
Middlesex. 
Statement: Death rates from AIDS have increased almost 
300% between the years 1987 and 1992 in both 
men and women. 
False: Mortality rates for women were unchanged 
from 1987 to 1992. Men, however, have seen 
an increase in mortality rates approaching 
300% for the same time period.2 Does this 
statistic imply that women need not be 
concerned? No, women should be quite 
concerned because the demographics of the 
disease are changing drastically as AIDS 
continues to infiltrate the heterosexual 
population in o u r socie ty . The Human 
Immunod eficiency Virus (HIV) does not 
target men specifically, bu t the spread of the 
disease initially through the gay population 
erroneously led to the belief that AIDS was a 
disease of homosexual males. 
A demographic analysis of Southwe tern 
Ontario showed that AIDS mortality had the 
highest incidence in the Middlesex and Essex 
regions. 
Statement: !h~ Southwestern Ontario region has a higher 
mc1dence of STDs when compared with the 
rest of Ontario. 
False: Chlamydia has been the most prevalent 
communicable disease reported in the 
Southwestern Ontario region, but the 
ABOUI' THE AUI'HOR 
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or Fiction 
By Matthew Crystal, MEDS 2001 
incidence rates in this region are still below 
those for the rest of Ontario. The incidence of 
chlamydia being reported was 120 per 100,000 
which is below the Ontario incidence of 
approximately 135 per 100,000. The incidence 
of gonorrhea and AIDS were considerably 
below the levels for the rest of Ontario . 
Gonorrhea showed an incidence of 15 per 
100,000 and the incidence of AIDS was 3 per 
100,000 in the Southwestern On tario region, 
well below the Ontario rates of 45 per 100,000 
for gonorrhea and 5 per 100,000 for AIDS. 
Looking at the big picture, STDs were 
reported 144 times per 100,000 in 
Southwestern Ontario which is significantly 
lower than the 190 reported cases per 100,000 
in the whole of Ontario.2 
Statement: Teenagers and young adults are at the highest 
risk of acquiring a sexually transmitted 
disease. 
True: The highest rates of chlamydia infections, for 
example, are in the 15 -24 age group. In 1991-
92 there were over 1300 reported cases among 
Southwestern Ontario 15-19 year olds. 1 When 
comparing the rates of incidence by age in 
Ontario and Southwestern Ontario, the 
distributions are very similar, albeit with 
lower incidences in the Southwestern Ontario 
region. What causes the rates to be so high 
within this group? The practice of unsafe sex 
among this age group is extremely prevalent, 
accounting for the inflated incidences. 
Statement: London residents are well aware of their 
community's health status. 
False: A random telephone survey asking London 
residents about their knowledge of their own 
community showed that Londoners 
underestimated their community's lifestyle 
and health problems.3 If knowledge is a key 
weapon in conquering health and lifestyle 
issues, then what can be done to prepare 
Londoners and other Southwestern Ontario 
residents to become integral components of 
active health promotion? Public health units 
have taken the s tance that, "The effective 
control of infectious diseases requires multiple 
strategies to prevent the occurrence of disease 
in suscep tible populations, interrupt the 
transmission of infectious agents from one 
person to another, and treat infected 
individuals and their contacts." 2 
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Education is the key to slowing the spread of 
infectious agents. Resources include Internet 
searches, library visits and trips to the local 
health unit. Public Health Units are 
instrumental in creating ways of 
disseminating information to the public as a 
whole, but it is the responsibility of each and 
every public health official to promote proper 
lifestyle choices for their own community and 
all the patients they specifically interact with. 
Understanding the socioeconomic conditions 
of patients is a vital first step toward ensuring 
that patients consider the options and 
treatments that are available. The role of the 
physician is to aid in the prevention of disease 
transmission and to promote healthy lifestyle 
choices, while recognizing the limitations of 
the patient's resources. We must remember 
that words of encouragement or 
discouragement by a physician hold a great 
deal of weight; this responsibility cannot be 
ignored. 
1. Mai V, Alder R, Lueske B. Did you know ... The Community Health 
Reporter 1(1):1 
2. Mai V . Major Notifiable Diseases. ln: Alder R, Vingilis E, Mai V, eds . 
Community Health and Well-Being in Southwestern Ontario 1996: 159-71. 
n 
Southwestern Ontario's Leading Centre for Patient 
Care, Teaching and Innovation 
LONDON 
Health Sciences Ce11tre 
Congratulates the UWO Faculty of Medicine 
Graduates. 
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MEDICINE ON THE INTERNET 
EDITOR: ANAND PANDYA 
REVIEW 
Urinary 
OF MULTIMEDIA SOFTWARE: 
Tract • 1 n Infection Women 
The pain and discomfort of urinary tract infection is well known to women. For some, urinary tract infection may be an ongoing problem, often leading 
to extensive and costly treatment as well as feelings of 
frustration. 
Therefore, Axia knowledge products introduces a first 
in health education - a powerful and user-friendly CD 
ROM software package for women to learn more about 
the causes, treatments and prevention of urinary tract 
infection. The goal is to provide an innovative learning 
environment to uncover the fundamental knowledge and 
skills needed for people to be proactive in their own health 
care. 
The program is divided into four sections. The Guided 
Tour is a great place to start to get the most out of the 
program. It shows you how information is organized and 
how to navigate through the program. Next, the Overview 
summarizes key information on urinary tract infection -
cause, treatment and prevention. The Learn UTI (urinary 
tract infection) section integrates multimedia, sound, and 
graphics to permit the user to develop an understanding 
of the subject. Finally, the Test Yourself section lets you 
assess your learning and allows you to move at your own 
pace. 
There are two main themes that make this a 
blockbuster program. First, it is patient focussed and deals 
with a sensitive subject matter in a candid, 
straightforward manner. The program is very 
comprehensive. The informative presentation is very 
human because it uses patient-doctor conversations to 
bring out important points. You feel as if you are in a 
doctor's office getting your questions and concerns 
addressed and resolved . Thus, this program has an 
outstanding potential in health care at an entry level 
because it could serve as an excellent teaching tool in 
doctors' waiting rooms and clinics. 
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By Mona Grady and Anand Pandya, MEDS 2001 
Creative use of multimedia technology to present 
medical information is the second theme that makes this 
program impressive. Throughout the program there are 
audio and video clips that entertain as well as reinforce 
the information. For instance, one video clip shows an 
excerpt from a patient doctor interview that mentions the 
signs and symptoms of bladder infection. Medical 
specialists in the field of microbiology, urology, and 
nearly thirty women have contributed their experiences 
towards the development of these clips. Furthermore, the 
use of diagrams and animation gives this program an 
attractive design that captures the audience's attention. 
The traditional method of presenting this information 
would be either in the form of a pamphlet or a 
videocassette. This CD ROM is revolutionary because it 
begins a new era in interactive learning through novel and 
meaningful application of computer technology. 
This program has much strength that makes it a top 
quality product. Its only weakness is a temporary one; 
there is an "online" button that links directly to the 
Urinary Tract Infection in Women Internet site. This site is 
not yet developed, but will evolve over time to include 
chat sessions, bulletin boards, and news on urinary tract 
infection, treatment and prevention. 
In conclusion, Urinary Tract Infection in Women CD 
ROM receives our highest commendations for being a 
pioneer in educating both doctors and patients using 
computers. There is tremendous potential here to develop 
other educational CD ROMs in areas like Heart Disease, 
Cancer and Diabetes. 
Evaluation: Two Thumbs Up 
Rating: General Audience 
Axia Multimedia Corporation 
600-1040 7th Avenue SW 
Calgary, Alberta, Canada, T2P 3G9 
Tel: (403) 231-1709 
Internet: www.axia.com 
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T he world-wide web has generated much publicity despite having been formed only seven years ago. The promise of the web continues to be the ability 
to access the information of the world when you want 
it. The reality, after all these years, is still inconsistent 
quality and fragmented information, or incomplete 
sites. With access to traditional information sources, 
the health care professional may well ask "why bother 
with the Internet?" At least part of the answer has 
come from recent developments as covered by both the 
popular and scientific press. On the one ha~d, m~ny 
people with rare diseases have found the tdenhty, 
treatments, and support groups that their local health 
authorities were unable to provide them with. On the 
other hand, the darker side of the web has been seen 
with the spreading of illegal, antiquated conco~tions, 
and biased, inaccurate information. It is almost wtthout 
question that world-wide web users will surf 
themselves to both good and bad health, increasingly. 
Therefore, most of the information from the web must 
be viewed critically by checking (1) What is the 
authority of the information? (2) Does the information 
serve the sponsor's interest? (3) Is it fact or opinion? 
The goal of this article is increase medical 
awareness by presenting reputed web-sites. 
NEWS 
The health care professional should be prepared for 
patients' questions about late-breaking news, often as 
een in the newspaper or more recently cable and 
web-based sources such as C . A number of web-
sites carry feeds from various news-wires. Most 
notable in the area of health-care are (of newspaper 
fame) HTTP:/ /www.reutershealth.com, and CNN (of 
cable television fame) HTTP:/ /www.cnn.com/HEALTH. 
Rather than the large general news sites, many will 
find the more specific speciality news sites more 
useful. Sites such as the Doctor's Guide to the Web at 
HTTP:/ / www.pslgroup.com / docguide.htm, contain 
news from conferences and the net in many disease 
areas. Even more specific, and dealing with this 
journal's theme, is the Canadian AIDS News site at 
HTTP:/ / www.cpha .ca/CPHA/canews which 
specialises in the latest developments in AIDS research 
and treatment. 
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M ed i c in e o n t he Int e r ne t 
the Internet 
By Richard Cleve and Anand Pandya, MEDS 2001 
LITERATURE 
Because of the rising costs of publications, and the 
rapid pace of breaking news, many journals n~w make 
available online full articles, search engmes, or 
supplemental material to their paper journals. Links to 
most of the major medical journals can be found at one 
of two sites: HTTP:/ /www.webmedlit.com and 
HTTP:/ /www.medscape.com. The CMA's journal can 
be found at HTTP:/ /www.cma.ca/journals /cmaj /. 
After coming to the realisation that many people 
who needed access to Medline did not have access, the 
ational Library of Medicine (US), 
HTTP:/ /www.nlm.nih.gov, made Medline searches 
freely available to all. This free implementation ~f 
Medline contains the complete database; however, 1t 
lacks the sophistication of the commercial 
implementations of Medline. 
PHARMACEUTICALS 
Arguably one of the fastest cha.ngin~ areas. in 
medicine is the field of pharmaceuticals, mcludmg 
recommendations and alternative therapies. The world-
wide web is ideally suited for presenting this kind of 
material. However, one should be especially cautious 
here; the use of information from the web requires 
extreme discretion since many of the sites are either 
ALEXANDRIA HOSPITAL 
INGERSOLL, ONTARIO 
Located in Southwestern Ontario, a community 
hospital with a large catchment area is searching for 
family physicians who wish to have the small town 
atmosphere and yet be located only 20 minutes from 
the lovely city of London. 
Opportunities exist for solo, traditional group and 
in-hospital practices. Must be willing to cover 
emergency call on a rotating basis. Obstetrics, 
surgical assisting and anesthesia are optional. 
The hospital was the first rural hospital in Ontario 
to establish an alliance with an academic centre, the 
London Health Science Centre. This has aUowed us 
to reduce costs, meet and exceed government 
benchmarks and expand your clinical services to the 
community. 
If you are a physician candidate who would like to 
visit our friendly community please caU or write to: 
Alexandra Ho pita! 
Attention: Sandy WhittaU, Site Admini trator 
29 oxon Street 
Ingersoll, Ontario 5C 3V6 
(519) 485-1732 Ext. 231 
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sponsored by a supply company, or are set up by non-
medical authoritie s. Medicine et, 
HTTP:/ / www.medicinenet.com, is a comprehensive site 
organised by disease, clinical trials, expert-opinions, and 
by medication side-effects. Featuring an encyclopaedia of 
drugs, and various discuss ion groups, Pharminfo, 
HTTP: / / www .pharminfo .com, provides a valuable 
resource. Finally, HTTP:/ / www.pitt.edu / cbw / Internet/ 
offers information on alternative medical treatment and 
includes information on AIDS. 
RESOURCES 
An ongoing project at the ational Libraries of 
Medicine (US) is to create an online anatomical " isible 
human ." Currently, they are s till collec ting 
radiographic representations of the human body. Their 
ultimate aim is a completely seamless interface. 
HTTP: / / www.nlm.nih / gov / research / visible / vi ible_ 
human.html. 
The Family Doctor, HTTP: / / www.familydr.com, 
and Medscape, HTTP:/ / www.medscape.com, are 
supersites because they contain reams of practical 
information aimed at patients, medical students, and 
the practising professional. Included between the two 
are medical dictionaries, "clinical pearls", frequently 
asked question files, and pharmacy information. 
Finally, Achoo, based on the popular search engine 
Yahoo!, strives to be the best medicine search engine 
available at HTTP:/ / www.achoo.com. 
Essentially, the sites mentioned above are 
interesting starting points for patients who want to 
play an active role in their health management, and for 
doctors who want to keep up-to-date in the rapidly 
changing world of medicine. 
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MEDICINE AND THE LAW 
EDITOR: MITCHELL SINGER 
VICARIOUS 
AND 
LIABILITY OF HOSPITALS 
THEIR PHYSICIANS 
I. INTRODUCTION 
It has been over 17 years since the Court of Appeal ruled 
in Yepremian v. Scarborough General Hospital, that 
hospitals were not liable for the negligent actions of their 
doctors. Since that time there have been significant advances 
in Canadian tort law, yet the law in many cases regarding 
vicarious liability of medical institutions has not changed 
that much. The recent Krever report on the blood inquiry 
offers us a unique opportunity to examine liability issues for 
health service workers, and the liability of those institutions 
that employ them. The size and scope of medical services is 
staggering by any account. ation wide the consolidated 
federal, provincial and territorial health expenditure tops 
almost 47 billion dollars. Over 10% of the population in 
Ontario alone is employed in health services, and the 
province spends an average of $2,614 per patient. The Krever 
inquiry demonstrates the potential for mishaps in the system 
and the widespread effect of those mistakes on citizens. 
This paper will examine the liability issues involved for 
medical workers, doctors and students employed in health 
services. Specifically, it will examine the concept of vicarious 
liability and circumstances in which liability for medical 
mishap in the course of employment can be transferred or 
imputed to hospitals or health organizations such as the Red 
Cross. It will argue that in many cases, liability for medical 
mishap should rightly be imputed to hospitals or medical 
organizations and that the present view of practitioners as 
independent contractors is outdated. 
Initially it is necessary to define vicarious liability as it is 
legally understood. The doctrine of respondeat superior or 
vicarious liability is defined as "the imposition of liability on 
one person for the actionable conduct of another, based 
solely on a relationship between the two persons." In an 
employment context, vicarious liability deals with the degree 
to which an employer can be held responsible for the acts of 
his / her employee. Or more simply, whether an employer 
can be held liable based solely upon the relationship between 
the two parties 
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II. OBJECTIVES 
As Justice Blair correctly recognized in Yepremian, the 
acknowledgment of a duty of care in situations invariably 
involves a policy decision. When courts and legislatures 
assign liability it is usually intended to accomplish two 
tasks. At one level the imposition of liability is intended to 
compensa te injured parties at the expense of the party 
responsible. At a second level liability is designed to deter 
prohibited or unwanted behavior. 
For the employer, vicarious liability is usually imposed 
for one of four reasons. First, the employer is likely to have 
created the circumstances in which the employee acted, and 
should bear responsibility for it. Second, the employer is in 
the position to minimize the act by allocating certain staff to 
specific duties. Third, the employer is in a position of 
authori ty and is able to discipline the employee for 
wrongdoing or profit from good work. Fourth, by imposing 
liability, it is hoped that employers will take appropriate 
measures to avoid liability situations. A more cynical view 
promoted by some authors may be that vicarious liability is 
imposed simply to satisfy judgments that ordinary 
employees may not be able to do. This 'deep pocket' 
analysis has evolved from a belief that many employees are 
judgement proof and may not have the assets in order to 
satisfy large law suits. 
Critics of vicarious liability maintain that instead of 
acting as a deterrent, employers take a distribution theory 
approach to liability issues. It is argued that employers are 
inclined to simply pass on the costs of insuring employees 
down to the customers in the form of higher prices. It must 
be noted however that such decisions take place within the 
context of the market place and are based on an assessment 
of the willingness of customers to shoulder those extra costs. 
A vicarious liability model does not prevent employers 
from suing offending employees for indemnification in 
order to recover the costs of litigation. 
Ill. VICARIOUS LIABILITY/RESPONDEAT SUPERIOR 
Currently, there are three requirements that must be 
satisfied in order to impose vicarious liability upon an 
employer. First, there must be an employment relationship; 
second, there must be fault in the legal sense; and third, the 
act of the employee must have taken place within the scope 
of employment. 
Employment Relationship 
The first threshold to be addressed is whether the 
parties are in an employment relationship. In Armstrong v. 
Mac's Milk Ltd , the High Court of Ontario considered 
whether there could be an employment relationship in the 
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absence of a written contract. The court concluded that 
whether a party was in a employment relationship was 
determined by examining the content of the relationship 
between the parties. Specifically, Holland J. applied a 
"control test" to look at whether the individual was subject 
to the control and directions of the employer in resp ct to 
how the job was to be completed. Justice Holland noted 
however that changes in corporate structure such a the 
advent of independent contractor could make that test 
inv alid . In those circumstances it would be more 
appropriate to apply an "organizational test" to examine 
whether the individual's duties formed an integral part of 
the business. 
In the medical context, identifying an employment 
relationship is a critical threshold to overcome and will 
depend on the role that is exercised by the individual in 
question. Hospitals will normally be responsible for the 
actions of their employees; but who is a hosp ital 
employee? urses are usually employees of the hospital, 
as are orderlies, since they are supervised by the ho pital 
and paid directly by the institution. But what about 
temporary positions, or people paid by third partie that 
are brought in from the outside to perform services? The 
law is not as clear in these situations, and an analysis must 
proceed on a case by case basis. For example, medical 
Residents have been considered employees even though 
there may not be the same degree of control exercis d by 
the hospital as on an orderly or nurse. In so doing, the 
court has given consideration to their status within the 
hospital and the agreement between the hospital and the 
university. 
Hanover and District Hospital 
Hanover, Ontario 
has immediate vacancies for: 
General Practitioners 
Community with young group of GP' s want to recru it new phy icians 
On Call Respon ibilitie one in 14 
Catchment Population of 15,000 
Good chools, Shopping, Re taurant and Entertainment 
Large ew Indoor Aquatic Centre and Library 
Major Recreational Facilitie 
Plentiful and Affordable Hou ing 
2 hours from Toronto, London and Hamilton.45 min. from Owen ound 
Interested applicants hould make enquiries 
or send a completed curriculum vitae to: 
Mrs. Katrina Wilson, Executive Director 
or 
Dr. Bruce Edington, Chief of Medical taff 
Hanover District Ho pita! 
90 7th A venue 
Hanover, Ontario 
4 I I 
Tel. (51 9) 364-2340 
Fax (51 9) 364-6602 
''HANOVER IS THE PLACE TO BE" 
Current Canadian law does not recognize hospitals as 
being liable for the actions of doctors in their professional 
duties. Physicians who are accredited to practice are not 
considered employees of the hospital to whom vicarious 
liability applies, but instead are considered independent 
practitioners. The present law that insulates hospitals from 
liability for the acts of doctors is problematic as 
employment law has now expanded greatly since the 1980's 
and under current tests it may fail. By virtue of being the 
workplace the hospital exercises a great deal of control over 
the doctor in maintaining a site, granting access to facilities, 
and scheduling. In Brown et al. v. YMHA Jewish 
Community Centre of Winnipeg the Supreme Court of 
Canada considered the definition of 'employee' under the 
Payment of Wages Act, S.M . 1975, c.21 , and the 
Construction Industry Wages Act R.S.M. 1970 c. C190 (am 
1980-81, c. 38, s. 3) in Manitoba. The court concluded that 
'employee' was a broad and inclusive term. In determining 
whether an employment relationship existed it was not 
necessary to prove that there was a contract, or that the 
employees were paid by the employer directly. However, 
the court still required that the employer control and direct 
the employee to evidence employment. In addition, recent 
cases have also concluded that neither payment by an 
employer, nor evidence of a contract is determinative if 
finding an employment relationship. These factors 
combined may serve to demonstra te an employment 
relationship in a situation traditionally excluded from that 
designation. 
Fault 
The second thre hold that must be overcome is whether 
the employee was at fault in the matter. If there is no fault 
in a negligence sense, then the courts will not impose 
liability upon the employer for the employee' s acts. 
Vicarious liability is " ... still an action for negligence, and the 
ordinary rules of negligence liability are still applied to it..." 
egligence of the employee, especially a medical employee 
is a question of fact that must be determined by the courts. 
Much has been written about medical negligence or 
malpractice and this paper will not expand upon that 
wealth of information. Aside from stating that under a 
vicarious liability model, the analysis of malpractice will 
not change. The law does not require that doctors and 
hospitals perform miracles in the care of patients. Courts 
instead question whether doctors and health care workers 
have exercised a reasonable amount of care that is 
commensurate with that provided by other practitioners of 
the same experience and standing. In cases against hospitals 
alleging vicarious liability for hospital employees, the 
plaintiff has focused upon determining whether the 
hospita l has been negligent in its care, either through 
overlooking details or otherwise. 
Scope of Employment 
The third threshold, and the most difficult to prove, is 
whether the employee's conduct was within the scope of 
their employment. For sound practical reasons employers 
are not ordinarily responsible for acts committed by their 
employees while not under their control or supervision. 
The recognition of vicarious liability for hospitals does not 
create a new level of tort analysis. Thus, even if the court 
recogrtizes vicarious liability in application to the doctor, 
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ho pitals will still not be responsible for acts committed by 
doctors, nurses or orderlies employed by a hospital that 
are considered outside the scope of employment. 
Understandably, determining what constitutes the scope of 
employment has been the subject of much litigation. 
In Jennings v . C.N.R. the British Columbia Court of 
Appeal [hereinafter the B.C.C.A.] considered whether a 
c_onductor who_ a~saulted a passenger while collecting 
hckets acted Within the scope of his employment. The 
B.C.C.A. concluded that the collection of tickets was within 
the scope of his employment. The court went on to 
conclude that a carrier owed a clear duty of care to its 
passengers in order to ensure their safety, and thus had a 
duty to restrain the conductor's conduct where it conflicted 
with that duty. In Lockhart v . Canadian Pacific Ry. Co. the 
Supreme Court of Canada considered whether the 
approval of the employees' method was necessary to 
ren?~r an act within the scope of employment. In its 
deoswn the court held that liability would extend to an 
employer even though the manner in which the business 
was being carried out was contrary to express instructions. 
The rule in Lockhart further restricts the ability of 
employers to escape liability for employee acts. 
The court in Yepremian expressly rejected this 
analysis. _Instead the court has responded by holding that 
the hospital owes no duty of care to the patient for the 
provision of medical care as practiced by a doctor. Thus, 
negligent medical acts carried on by doctors in the 
hospital, under the hospital's supervision, and with the 
hospital's facilities are not within the scope of employment 
within the hospital. 
(i) Outside the Scope 
ot every act of an employee will be imputed to an 
employer . The following cases illustrate situations in 
which the court determined that the employees acted 
outside, or independent of their employment. In 
Consolidated Mining v. Murdoch, the Supreme Court of 
Canada (SCC) held that an employer who carried on 
operations at a remote site, was not liable for the fire 
started by his two employees. The court concluded that the 
scope of employment was contained in the employment 
contract which, in this case, specifically excluded the 
situation in which the fire took place. This reasoning was 
upheld by the Supreme Court of British Columbia in 
Barrett v. The Ship "Arcadia" et al . In that case an assault 
perpetrated by an officer steward posing as a passenger 
steward was deemed not to be the responsibility of the 
employer. In its reasoning the court concluded, like 
Jennings, that a carrier was not absolutely liable for acts of 
its employees, but was responsible to take all reasonable 
steps to safeguard its passengers. Barrett did not disturb 
the courts earlier position that a carrier would be liable if 
the act contested had been conducted in the scope of 
employment. In so doing the Supreme Court of British 
Columbia has maintained a key element of vicarious 
liability, namely, the requirement that the impugned act be 
found to have occurred not only while the individual is 
employed but within the scope of their employment. 
Tests 
In addition to the aforementioned criteria the court has 
expanded the definition of the employee - employer 
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situations through the development of several common law 
tests. These tests are designed to look at the totality of the 
employee-er relationship in order to determine whether an 
employment relationship exists beyond terminology. 
IV. ANALYSIS 
From the above discussion it should be clear that courts 
now look beyond mere titles in order to determine whether 
an employment relationship does exist. The totality of the 
working conditions combined with the perception of an 
employment relationship may result in a sufficient finding 
of fact in order to justify the imposition of liability. In terms 
of doctors it may be argued successfully that sufficient 
control elements exist to make hospitals liable for their 
negligent conduct. In Yepremian, where the negligent act of 
an Internist resulted in brain damage, the plaintiffs were 
successful at trial on the basis that the hospital owed a "non-
deleg~ble duty of care to the patient." The Court of Appeal 
revers~g, held that there was no evidence of such a duty of 
care bemg owed. The majority also found that the Internist 
was an independent contractor by virtue of the fact that he 
was not paid directly by the hospital, he billed OHIP for 
servi~es, even though he was provided with space by the 
hospital and was allowed to make use of hospital facilitates. 
We will never know what would have happened had 
Yepremian been appealed to the Supreme Court. However, 
the minority decisions both made strong statements in favor 
of recognizing such a duty. In particular Houlden J.A. 
conc~uded that the standard of review applicable to 
hospitals should be commensurate with their role in 
present day society. Yet, to date Yepremian has not be 
overturned successfully and has in fact been followed in 
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several cases. In Papp v. orth York Branson Hospital the 
court held that even in team work situations where both 
doctors and nurses were working together, the ho pital 
could not be responsible for the negligent acts of the 
combined team. One should note that in the present 
political climate of accountability, where the public is often 
referred to as 'customers' and 'clients' of public services, 
many if not most citizens would be surprised to learn that 
upon admittance to a health care facility, the doctor and not 
the hospital was liable for negligent conduct. American 
authors have concluded, correctly I belie e, that more often 
than not, patients view both the doctor and hospital as a 
single body with the doctor acting as an agent for the 
institution. 
Doctors and medical institutions should not be afraid 
about accepting a vicarious liability model. Such an action 
would be in line with policy objectives and likely reflect the 
reality of hospitals today. It is submitted that by placing the 
responsibility upon the hospital, courts and legislature 
would be placing the burden to avoid liability situations 
upon the body best able to deal with it. Hospital are 
probably in the best position to discipline doctors by 
restricting hours of work, and hospitals administrator are 
probably in the best position to allocate individuals in order 
to minimize potential problems. Further, vicarious liability 
may serve to streamline the system by providing a singular 
body accountable to the patient. All these efforts combined 
may in the long run serve the patient better by providing a 
higher quality of guaranteed service by the institution that 
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most patients would likely naturally identify as bearing that 
responsibility. While opponents of recognizing vicarious 
liability for doctors may argue that hospitals are ill 
equipped to deal with that responsibility, it must surely be 
noted that hospitals are already vicariously responsible for 
the acts of employee . Further, the imposition of liability 
would not remove the ability for the institution to seek 
indemnification from the doctor for negligent acts. 
V. CONCLUSION 
It is not difficult to mea ure when employers will be 
held liable for the actions of their employees. Given the 
range and scope of decisions, employers can "look forward" 
to being held responsible unless they can satisfy the court 
on a narrow band that they should not be held liable. For 
hospitals and health care facilities the ability to avoid 
liability is greater when it can be successfully argued that 
the individual is an independent contractor. As 
demonstrated, this may not be a reflection of the reality 
practiced daily in Canadian hospitals, nor what the public 
would expect of them. For the plaintiff in a malpractice 
situation he /she must establish more than just 
employment, and fault, but also sound policy reasons as 
well in order to assign liability against the institution. The 
argument on behalf of the hospitals is easier to demonstrate 
as currently doctors are not considered employees. Thus, 
unless there is a movement towards assigning institutional 
liability the current system is unlikely to change. Q 
M C I 
Live in Toronto! 
Bill100°/o 
No restrictions on your 
billing number 
Discover the benefits of MCI's Management Expertise 
Let MCI help you build your family practice 
0 Independence 
0 High Income 
0 Locum coverage 
0 No financial risk 
0 No investment 
0 No lease to sign 
0 Full or part time 
Locations in: 
Mississauga, Brampton, Thornhill, Concord, 
Woodbridge and Whitby 
MCI MEDICAL CLINICS INC. 
40 Eglinton Ave. E., Ste. 802, Toronto M4P 3A2 
Teri Kopel (416) 440-4040 Ext. 425 
e-mail: practice@mcimed.com homepage: home.istar.ca/- mcimed 
24 
------------------------- U. W.O. Medical Journal 67 (1) 1998 
PROFILES 
EDITOR: H ELE L EWANDOWSKI 
INTERVIEW W I TH DR. MICHAEL J. 
RIEDER, RECIPIENT OF 
DOUGLAS BOCKING 
1997 THE 
AWARD 
D r. Michael J. Rieder is a medical researcher and pediatrician who 
is also highly involved in 
medical education. Aside 
from his research in the area 
of Pharmacology, and his work 
at the Children's Hospital of 
Wes tern Ontario, he is the 
Chairman of the Phase 4 
(Clerkship) Committee at the 
Faculty of Medicine. He is also 
the father of three boys aged 
14, 12 and 7 years, whom he 
refers to as his "treasures". His 
interests outside of work include the American Civil War, 
mountain-bike riding and cooking for his family. He is also a 
fan of Baroque music and enjoys the poetry of Rudyard 
Kipling. . 
Recently, Dr. Rieder was awarded the Douglas ~g 
Award by Western's Faculty of medicine. This _is a seruor 
teaching award, given in the Faculty, at graduatior:', by the 
graduating class and the Dean's office. Rece~ving this awar? 
came as a surprise to Dr. Rieder: "I was surprised that I won It 
because it's traditionally won by people who do a lot of 
teaching in first and second year and I don't see anyone ~ the 
class until third year. So it's not an award ~t_someo~e m my 
line of teaching would normally win, which IS why It was a 
big honor". . 
Dr. Rieder has also received numerous awards outside 
Western. He is a distinguished researcher in the field of 
Pharmacology, and his research has focused on adverse drug 
reactions, with a special interest in HN. Dr. Rieder ~as 
designated Young Investigator of th~ Year by the C~adian 
Society for Clinical Pharmacology m 199~, and recei_v~d a 
s imilar award from th e American Soctety for Chmcal 
Pharmacology in 1996. He has also done work in_ the area of 
medical education, which was acknowledged this past year 
when he was appointed Harvard Macy Scholar at _Harvar? 
Medical School's Macy Institute of Medical Education. This 
scholarship brings together medical educators from across the 
U.S.A. and the world to focus on medical education, and Dr. 
Rieder was the first Canadian academic to ever receive it. 
ABOUT THE AUTHOR 
Helen Lewandowski is a first year medical student at 
UWO. Before entering medical school, she e~med ~ Bac_helor 
of Science degree in Psychology from McGtll Umversrty. 
By Helen Lewandowski, MEDS 2001 
TH E PATH TO LONDON 
What were the events that led up to you com ing to 
W estern? 
My university career began at the Universi ty of 
Saskatchewan in Pharmacy. However, in my second year, 
I realized that although I wanted to do research and liked 
working with people, I didn't like the commercial asp~ct 
of Pharmacy . So I applied to med ical sch o ol m 
Saskatchewan, was accepted, and after graduation in 1980 
went to Wayne State University in Michigan to d o _my 
Pediatric Residency. I then came back to Canad~ and di? a 
Fellowship in Emergency Medicine a t the Hospttal for Stck 
Children in Toronto. During my Residen cy, I h ad an 
interest in p harmacology since my w hole f~mil~ i~ in 
Pharmacy except for me . I go t in teres ted m chmcal 
pharmacology, so I did m y Ph.D. in Pharm~cology at the 
University of Toronto. After that, I was looking for a staff 
job and London seemed most attractive. 
Why London? 
It was a combination of things. To be blunt, I liked the 
size of the city. I'm from a small town of 700 people~ and 
both my wife and I are small town people so we like a 
smaller city. I like the feel of a university t~wn, w~ch 
London is . I turned down a job a t the Hospttal for Stck 
Children a t U ofT to come here because the research 
opportunities were broader here than in Toronto. My 
interes ts are immunity and immunopharmacology, and 
my research career here has done quite well. 
IMMUNOPHARMACOLOGY AND ADVERSE DRUG 
REACTIONS 
Could you describe the main research areas that you are 
currently exploring? 
The primary research area tha t I am involved in is 
basic science research. More specifically, this includes the 
study of the role of drug metabolism in the production of 
adverse drug reactions, with a special interest in HN .. My 
main interest right now is looking at how ~~ r~actions 
occur. The current focus is on the sulfa antibiOtics and 
how they produce adverse drug reactions. There are two 
questions we are working on in this area. One is how HN 
U. W.O. Medical Journal 67 (1 ) 1998------------------------ 25 
Profiles 
infection influences sulfa metabolism and sulfa sensitivity. 
A secondary interest is how some of the sulfa metabolites 
interfere with, or act upon, the immune system. Also on 
the topic of adverse drug reactions, we are doing some 
work on agents such as Cephaclor and the antipsychotic 
Clozapine. That's the primary thrust of our research, but 
I've also done some work on drug exposure during 
pregnancy, such as with Cyclosporine. In addition, I have 
done some educa tional research, which was m ostly 
related to the evaluation of medical students. 
What is the relevance of your research on adverse drug 
reactions to HIV and AIDS? 
It's important in HN because the most common index 
case diagnosis for HIV remains pneumocystis carinii 
pneumonia, and this also remains the most common 
opportunistic infection in HIV in North America and 
Western Europe. Sulfa antibiotics remain the drug of 
choice, and indeed, until the advent of combina tion 
retroviral therapy, it was safe to say that the only drugs 
which were known to prolong life in HN patients were 
the sulfas. AZT probably did not prolong life, so the only 
effective drugs were sulfas. Unfortunately, about 40-50 % 
of people who take sulfas and have AIDS develop adverse 
drug reactions, which is about 10 times the incidence of 
the general population. This is a big problem because of 
the increase in mortality and morbidity. Why it occurs has 
been the focus of our interest. We have demonstrated that 
sulfas can be broken down to reactive metabolites and that 
there appears to be a difference in the sensitivity of cells to 
these different metabolites. We knew that this occurs in 
adults but recently we have also shown that it occurs in 
children for the first time in the study of adverse drug 
reactions. This will be published in a couple of months, in 
the Journal of Pediatrics and Infectious Diseases. So this 
phenomenon is important, it's common across the age 
spectrum, and now we're trying to figure out why these 
HN cells are so sensitive. We want to know what types of 
sensitivity occur and how the drug or its presentation can 
be changed to make it safer. We are also looking a t the 
possible relationship between viral burden and sensitivity 
of cells to drugs. We know now that viral burden is not 
constant, it's very dynamic, and we are trying to see if 
there is any relationship to drug sensitivity. 
What are some of the research avenues that you think 
seem promising for the future of HIV research? Do you think 
tha.t the virus can be brought under control? 
Right now the big thrust is combination retroviral 
therapy. I'm going to share with you right now that I don't 
think it's going to work. I think that it will have orne 
success in controlling the disease but if you look at the 
success rate in clinical practice, it 's not as high as in 
clinical trials, which is no surprise. I think that the virus is 
persistent, it's cunning and it's simple. It follows a very 
simple paradigm: it will mutate its way past any retroviral 
drugs. I think that retroviral therapy is promising, I think 
that it's important, but I think that it's going to be a 
constant struggle. There will also be new adverse 
reactions to these drugs and new problems tha t will 
develop, so I think that we are in for a long, tough battle. 
A viral vaccine is another possibility, and it might work, 
but I think that HN will be with us for a long time due to 
the nature of the beast. 
EVALUATION OF MEDICAL STUDENTS 
Shifting gears now to your involvement with Clerkship 
and your research on medical student evaluations, could you 
describe what that has been about? 
Well, I'm interested in evaluations in the broades t 
sense because one of the things that I don't think we do 
very well as clinical educators here at Western (and it's not 
unique to Western, I don't think anyone does it very well) 
is evaluate students . So I think that the evaluation 
component of our clinical education is not strong, and I've 
been looking at different ways to improve that. I think that 
the problem with evaluating students clinically is 
knowing what to evaluate, and evaluating things that are 
clinically relevant. To be blunt, although people get into 
medical school on the basis of marks, there is no evidence 
that marks are related to clinical performance. Traditional 
evaluations using tests and multiple choice questions 
don't evaluate skills and attitudes, so you need a different 
way to look at it. There are two possible approaches-one is 
that you can be a nihilist, and like many clinical educators 
say that there is no way to evaluate this, so they throw up 
their arms in despair. I think that we can be more 
innovative, and that there must be ways to evaluate those 
skills, so we just have to be more clever about it. The 
problem with clinical evaluation is that it is a lot of work. 
Good clinical evaluations do require a concerted effort 
and a certain mindset on the part of the evaluator. But 
there are certain problems with that-I think that our 
system does not reward good evaluators. People who give 
appropriate criticism are not rewarded for it, and it just 
results in a lot more work. Therefore, several 
unsatisfactory behaviors on the part of the students are 
not monitored, especially in relationships with colleagues. 
Also, often students are not rewarded for a job well done, 
and we work hard in addressing that issue. 
ON MEDICAL STUDENTS 
I think that the two most important attributes in a 
student are honesty and reliability. If you know when to 
ask for help, you won' t get into trouble. It's important to 
be able to reach a rational diagnosis in a reasonable period 
of time, to know how to access information to treat the 
problem, and to communicate it effectively. I think that 
that is more important than, say, being able to recite the 20 
differential diagnoses for asymptomatic hypercalcemia, 
for example. 
In my mind, the most important characteristics of a 
clerk are those which define a competent physician. For 
example, in the pediatric rotation, what's important is 
being able to talk with a child, talk with the family, and 
come up with a differential diagnosis of things that are 
common and important. 
In terms of things of value, when someone is 
functioning clinically, one of the most important things is 
getting along with people. Medical students are an 
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interesting bunch in that they tend to be self-selected, but 
you can't select your patients or the people you work with. 
So you have to get along with people from a wide range of 
backgrounds and personalities. That's the reason that in 
clerkship, if someone has a problem working with clerk A 
or clerk B, my response would be that they have to work 
through it. Otherwise, it would tend to become divisive. 
THE FUTURE OF CLERKSHIP 
Do you foresee any changes in the Clerkship portion of 
the medical curriculum? 
Well, we now have a patient-centered curriculum so 
Cle rkship will probably mov e towards being more 
patient-centered , although i t could be argued that 
Clerkship is patient-centered anyway. I think that there 
will have to be changes in Clerkship due to the changes 
occurring in London. Ten years ago, we had 3 adult 
hospitals and 1 children's hosp ital with 3000 beds, and 
now we'll have 1000 beds only in the city. So we'll have to 
rethink about how we do Clerkship . People won' t be 
spending their whole Clerkship in London, that's for sure. 
I think we'll also have to think about how Clerkship is 
divided. Does the issue of blocks make sense? I think they 
probably don 't, and that there will have to be some 
changes in that area. One thing that has recently changed, 
and that will be a huge advantage for the class of 2001, is 
that Phase 3 has been eliminated, which means that 
Clerkship will now start at the end of August and end in 
"Buy value 
P r ofiles 
September. Right now Clerkship ends in October, then 
you do your electives and you only have time to do 2-3 
electives before the CaRMs match. Now, there will be 
more time for electives, which will be a major advantage. 
Perhaps a key to Dr. Rieder's success in combining his 
roles as researcher, medical educator, teacher and clinician 
lies in his personal philo ophy: "I believe that when I do a 
job, I want to do it as be t as I can. Personal responsibility 
and pride in a job well done are the things I was brought 
up with. I believe in finding the three or four things I like 
the most in my work and focusing on them". Dr. Rieder's 
role model is Frederick the Great, a man whose 
'singularity of purpose' he finds appealing. He believes 
that at the Faculty of Medicine and Dentistry at Western 
"our goal should be excellence .. . to produce the best 
undergraduates we possibly can." Clearly, Dr. Rieder is a 
man with tremendous energy, who truly enjoys what he 
does. 
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PROMOTION AND PREVENTION 
EDITOR: DAN MENDO <;A 
CHANGING AIDS-RISK BEHAVIOUR: 
A Strategy Based 
Psychological 
On Underlying 
Processes 
The spread of Human Immunodeficiency irus (HIV) is a subject which periodically grabs the public's attention. Recently, for instance, the media 
has drawn a disturbing picture of the sky-rocketing 
prevalence of HIV in Asian countries. Efforts to pre ent a 
worsening HIV pandemic center on modifying risk 
behaviours, and education would seem to be the sole 
instrument for effecting such change. Unfortunately, the 
issue of educating people about their own reproductive 
health is a highly contentious one. Most will concede, 
however, that at the very least, individuals must be made 
aware of how sexually transmitted diseases are spread, 
and of how the risk of such infection may be reduced. 
During the first decade of the AIDS epidemic, public 
health officials advised that to protect against HIV, one 
should either abstain from sexual intercourse, use 
condoms consistently, or enter into a monogamous 
relationship with a trusted partner. As a re ult, 
monogamy came to be regarded as a substitute for AIDS 
preventive behaviours such as condom use. Monogamy, 
however, ceases to be a fail-safe alternative if it refers in 
practice to a series of sexually monogamous 
relationships. In fact, it is in these types of relationships 
that sexual activity is often unprotected, and engaged in 
with partners who are unlikely to have been tested for 
HIV. 
Safety, in a monogamous relationship, demands that 
both partners are assured of their own HIV negative 
status. This may be because neither has ever engaged in 
unprotected sex (or had exposure to other risk factors), 
or because both have tested negative for HIV after 
abstaining from all risky practices during a "window 
period" of two to six months. These criteria d o not 
characterize most sexually active individuals, who 
typically became sexually active in their teens, and who 
are unlikely to have had the same partner since that time. 
Relatively few people have been tested for HIV, and this 
is especially true for persons in long-term relationships. 
Furthermore, HIV testing is not protection against HIV 
imported as a result of one partner's non-monogamous 
behaviour during the relationship. 
ABOUT THE AurHOR 
Dan Mendonca is a student in his second year of medical 
school at UWO. Prior to entering Medicine, he completed a 
Bachelor of Science degree in Biology at the University of 
Western Ontario. 
By Dan Mendonca, MEDS 2000 
In the case of heterosexual university students and 
many other single individuals, much unprotected sexual 
intercourse takes place within what individuals perceive 
to be close relationships. The initial practice of safer sex 
(generally condom use) is eroded with the development of 
trust in one's mate. Many switch from using condoms to 
using oral contraceptive pills as the relationship becomes 
more serious.1 The emphasis is on contraception rather 
than on safer sex. 
There has been much research on the promotion of 
AIDS-preventive behaviours . Successful interventions 
need to involve elicitation research to clarify the specific 
needs and sensitivities of the target population. As well, 
they should draw upon empirically validated models of 
behaviour change. One such research effort, spearheaded 
at Western, has resulted in the formulation of an 
information-motivation-behavioural skills (1MB) model 
for changing AIDS-risk behaviourY This model 
conceptualizes preventive behaviour as being dependent 
on an individual's information about AIDS, motivation to 
reduce AIDS risk, and behavioural skills for performing 
acts related to risk reduction. Currently, the 1MB model is 
being used by educators in London-area high schools, and 
is the basis for Health Canada's national guidelines on 
reproductive health promotion for primary care 
physicians. •.s 
INFORMATION 
Efforts to assess the AIDS prevention knowledge of an 
individual should seek to identify the spontaneous, ready-
to-use AIDS facts which are utilized in real-life situations. 
To get at this type of knowledge, open-ended 
questionnaires might be used, as well as focus groups in 
which individuals discuss their beliefs about AIDS 
prevention. 
Researchers have found that heterosexual university 
students and members of many other groups invoke 
"implicit theories of partner AIDS risk" when determining 
whether or not to practice safer sex. That is, an attempt is 
made to detect risky partners on the basis of how the 
partners dress, how they act, and where the y are 
encountered. To the same end, students may use 
inaccurate AIDS prevention heuristics, or cognitive short-
cuts in their decision-making. 6•7 (TABLE 1, 2). 
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TABLEt. 
Inaccurate Theories Concerning Partner AIDS Risk 
Partner is deemed unlikely to be HIV positive, if .. . 
TABLE 2. 
Inaccurate AIDS-Prevention Heuristics 
"Trusted partners are safe partners." 
"Monogamy is safe" 
"It's too-late-anyway" 
MOTIVATION 
Having up-to-date information i no guarantee that an 
individual will be motivated to practice AIDS preventive 
behaviour. Individuals may possess negative attitudes 
concerning condom use (or abstinence), may perceive 
condom use (or abstinence) as socially stigmatizing or 
may feel little personal vulnerability to HIV. To reach 
individuals with negative attitudes towards condom use, 
one might stress its normativeness in popular culture. To 
addre s perceived invulnerability, videotaped scenarios 
might be shown in which indiv iduals in trusting 
relationships recount their story of having contracted 
AIDS through unprotected intercour e. 
Persons in monogamous relationships may feel that 
addres ing issues of safety could jeopardize the stability of 
their relationship . In this instance, individuals might 
titrate their perception of risk against how intimate they 
are with their partner. 
Motivation may also be explored from a population 
perspecti ve. It is possible that in certain societies, for 
example, women might succumb to unsafe sexual activity 
due to gender based differences in ocial power, economic 
dependence on their partners, or normative influences 
which are opposed to female initiative in exual matter 
(TABLE 3). 
Pr o m o tion and Pr e v e ntion 
• there is self-serving attributional bias operating e.g . 
"Someone to whom I am attracted could not possibly 
have an STD." 
• he I she is dissimilar to one's prototype of an HIV-
infected per on. 
• he I she has a respectable social network 
(e.g. from a good neighborhood and family). 
Once partners begin to trust one another, they decide that 
they can trust their partner not to have engaged in 
behaviours that could make them HIV positive. Trust is 
een, in effect, as a sub titute for condoms or HIV testing. 
Monogamy is not a substitute for AIDS preventive 
behaviour unless both partners are completely certain that 
they are HIV negative. 
Many people are unaware of the po sibility that a person 
can have repeated, unprotected sexual contact wi th an 
HIV infected person and not develop HIV. 
TABLE3. 
Issues Undermining Motivation to Engage in AIDS 
Preventive Behaviour 
Some discussion topics are seen as potentially harmful 
to relationships and are avoided if possib le. Many 
believe, for instance, that discussing AIDS prevention 
will lead their relationship partner to become 
suspicious about their past or even current behaviour. 
An increasing sense of interdependence in a 
relationship often brings about a shift in focus from self-
enhancement and elf-protection to relationship 
maintenance. 
HIV testing may be perceived as a "milestone" in a 
relationship, signifying a new level of commitment 
w hich a less committed partner may find threatening. 
Entertaining the possibility that one's partner 
previously engaged in risky and perhaps stigmatizing 
behaviour is a prospect individuals are motivated to 
avoid 
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BEHAVIOURAL SKILLS 
It is crucial that informed, motivated individuals obtain 
the skills necessary for practicing AIDS-prevention. These 
skills include acquiring and updating accurate information 
about AIDS prevention, harmoniously yet assertively 
negotiating AIDS prevention, and exiting situations in 
which safer ex cannot be negotiated. One should also be 
able to engage in public behaviours, such as condom 
purchasing, consulting with physicians and seeking HIV 
testing. For many individuals, the ability to avoid drinking 
or drug use before sex has also been related to safer sexual 
behaviour. Finally, to the extent that condoms are 
associated with lower levels of sexual enjoyment, 
individuals might be encouraged to eroticize safer sex. 
Behavioural skills that are nece sary but lacking should 
be taught and then rehearsed so that they are readily 
translatable into real world preventive action. This could 
include observing model enacting AIDS preventive 
behaviours, or per onally role playing such behaviour and 
receiving feedback. Interventions delivered to couples 
rather than individuals offer the opportunity for issues to 
be processed within a supportive context. Additional skills 
may be relevant for specific groups, for example, those 
characterized by ethnicity, sexual orientation, or chemical 
use tatus. 
PARKE D AVIS 
SlmviNG To MAKE MIRACLES HAPPEN 
A LrrrLE SooNER 
Miracles can happen. 
But behind every miracle is hard work and determination. 
The determination to make our lives a little better, 
the hard work necessary to get closer to a cure. 
It doesn't happen overnight; it often takes years of 
dedicated research. But when that research culminates in 
a breakthrough or a new pharmaceutical, 
miracles become possible. 
Committed to hard work, determination and cnring. 
Tile qualities that cnn make miracles happen. 
PAIIKE·IMIIIS 
Scarlx>rough. Ontario MIL 2N3 
CONCLUSION 
For the most part, individuals are free to be sexually 
active. Along with ownership over one's own sexuality, 
however, comes inherent responsibility. People must take 
seriously issues involving reproductive health. This is 
especially true in view of the growing prevalence of HIV 
infection and other viral STDs. AIDS preventive behaviour 
can be a sound and effective solution to this growing 
problem. Consistent condom use and HIV testing must be 
used for primary and secondary prevention of infection. 
It has been shown, for example, that the seroconversion 
rate among AIDS patients and their uninfected partners is 
very low when condom u e is maintained. 
While the spread of sexually transmitted disease is 
preventable, it continue to be a major cause of human 
suffering and economic loss. Human papillomaviru 
infection, for instance, is a lesion which can predispose to 
developing cervical cancer. Similarly, the spread of pelvic 
inflammatory disease is usually via sexual routes, and can 
result in chronic pelvic pain or infertility. It is essential, 
therefore, tha t physicians motiva te their patients to 
practice prevention. 
Educators have found the IMB model for AIDS-risk 
behaviour change to be a practical tool for teaching STD 
pre ention. The behavioural cience community continue 
to evaluate and improve upon such methods, and their 
re earch has proven extremely valuable in the global fight 
against AIDS. 
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THINKING ON YOUR FEET 
EDITOR: MAso Ross 
A C A 5 E 
A 28 year old male presents to the emergency room with a rash, dry cough and a fever. He presented to his family physician three week earlier with flu-
like symptoms, dry cough and mild dyspnea, although he 
looked well. He was told he had a community-acquired 
infection and was prescribed Septra. 
Two weeks later, he had lo t his appetite. His cough 
and dyspnea were wor e, and he became tachypneaic 
upon wa1kin9 for a few minutes. He was referred to the 
local hospital s Emergency. 
While in the Emergency Department, several test 
were ordered. The che t x-ray hawed bilateral perihilar 
infiltrates and interstitial disea e pattern. His blood gases 
showed hypoxia. His p02 was 50 mmHg and his ~C02 
was 28mmHg. His CD4+ count was <200 cells/nun. His 
temperature was 38.5°C and his WBC was 1500 cells/mm3. 
He did not know he was HIV positive. 
Consider the following questions: 
1. How doe the CD4 count help in monitoring patients 
who are infected with HIV? 
2. What do the bilateral perihilar infiltrates and the 
interstitial disease pattern on the chest radiograph mo t 
likely indicate? 
3. What is the pathogenesis of PCP? 
4. What is the significance of fever in a person with 
advanced HIV iilfection? 
ANSWERS TO THE CASE STUDY 
1. The stage of HIV di sease can be inferred from 
evaluation of clinical parameters and laboratory tes ts. 
Examples of clinical parameters include weight lo and 
decreasing functional capacity. The CD4 count is an 
example of one of the lab tests . CD4+ count is a 
quantitative measure of the lymphocytes to which HIV 
oinds specifically, and which may become depleted as a 
result of HIV infection. Measuring the number of CD4 
lymphocytes has until recently been the primary test for 
monitoring immun e function. In addition to 
establishing the s tage of HIV infection, it help with 
establishing a prognosis, and helps to determine the 
appropriateness of initiating antiretroviral therapy and 
prophylaxis for opportunistic infections. 
2. Pneumocystis carinii pneumonia 
3. P. carinii has such low virulence that the initial infection 
in an immunocompe tent person is suppressed b y 
ABOUT THE AUTHOR 
Romy Saibil is a second year medical student at UWO with a 
B.Sc. from the University of Western Ontario. 
OF AIDS 
By Romy Saibil, MEDS 2000 
normal host defense mechanisms and causes no 
ob ervable damage . In immunocompromised hosts, 
PCP is usually a reactivation of a latent infection as a 
re ult of childhood exposure. HIV-infected individuals 
are at greatest ri k for PCP when the CD4+ T -cell count 
is <200 mm3 or <20% of total circulating lymphocytes, 
or when they have had a previous episode of PCP. 
4. Fever i a very non pecific problem in patients with 
advanced HIV infection. The development of a new 
fever should prompt a careful his tory and physical 
examination. There are a number of opportunistic 
infections that may present as a fever of unknown 
origin in a patient with immune deficiency. In addition 
to the large spectrum of infections that can produce a 
fever, there are a number of noninfectiou processes, 
such as malignancies and drug reactions, that should be 
considered. 
The following section is designed to te t and expand your 
knowledge of Acquired Immunodeficiency Syndrome. 
How many questions can you an wer correctly? 
Scoring: [1J-15l=superior knowledge, [10-12 ] =above 
average, [8-91= adequate, l5-7l=fair, [1-4l=sub-par. 
1. Which one of the following cancers is 
nQ! associated with AIDS? 
a) Carcinoma of the cervix 
b) Ovarian Cancer 
c) Kapo i's Sarcoma 
d) B-cell Lymphoma 
2. Define Cytomegalovirus (CMV) 
a) vi ru s of the genu Cardio irus found in Africa, 
South America, and elsewhere. 
b) virus which many people carry for a lifetime without 
causing any illnes , but which in an individual with 
immune deficiency may infect the eyes, lungs, gut 
and other organs. 
c) an epidemiologic class of viruses that are acquired 
by close contact (incl uding sexual contact) or 
injection and cause persistent infection. 
d) an epidemiologic class of viruses that are acquired 
by inhalation of fomites and replicate in the 
re piratory tract, causing generalized reaction. 
3. The following are all methods for detecting HIV except: 
a) Southern Blot 
b) ELISA (enzyme-linked immunoabsorbent assay) 
c) Western Blot 
d) lmmunoblotting 
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4. The following are drugs used to interfere with the ability 
of HIV to reproduce itself, which have also been shown 
to improve the outcome for many people with AIDS, 
except: 
a) Zidovudine~ 
b) Retro · 
c) 
d) izoral~ 
5. The following are drugs used in treatment of 
pneumocystis carinii pneumonia, except: 
a) Septra~ 
b) Fansid 
c) Pentamidine~ 
d) Cymevene~ 
6. Shingles is 
a) a rare, self-limited blistering cutaneous disorder, of 
unknown origin. 
b) a group of acute infections caused by herpes simplex 
virus type 1 or type 2. 
c) an acute infectious disease believed to represent 
activation of latent varicella-zoster virus in those who 
have been rendered partially immune after a previous 
attack of chicken pox. 
d) primary cutaneous herpes simplex acquired by direct 
exogenous infection of traumatized skin lesion, 
usually associated with localization of lesions to area 
of trauma and regional lymphadenopathy. 
7. Which of the following is not a type of transmission of 
HIV? 
a) Venereal transmission 
b) Parenteral transmission 
c) Respiratory transmission 
d) Perinatal transmission 
8. Reverse Transcriptase 
a) helps integrate cD A into host D A 
b) copies viral RNA genome into double-stranded 
eDNA 
c) reverses the process of AIDS. 
d) cleaves the envelope glycoprotein, gp 160, into two 
subuntis, gp 140, and gp 120. 
9. Adverse drug reactions in HIV positive individuals are 
increased by what factor? 
a) 2X 
b) 5X 
c) lOX 
d) 20X 
lO.The average time of onset of AIDS from time of 
contraction of HIV virus is 
a) 2 years 
b) 5 years 
c) 8 years 
d) 10 years 
11. Pnemocystis carinii is due to 
a) virus 
b) bacteria 
c) protozoa 
d) fungus 
ANSWERS TO THE MULTIPLE CHOICE QUESTIONS 
1. Which one of the following cancers is not associated with 
AIDS? 
b) Ovarian Cancer 
2. Cytomegalovirus (CMV) 
b) virus which many people carry for a lifetime without 
causing any illness, but which in an individual with 
immune deficiency may infect the eyes, lungs, gut and 
other organs. 
3. The following are all methods for detecting HIV except: 
a) Southern Blot 
4. The following are drugs used to interfere with the ability 
of HIV to reproduce itself, and which has been shown to 
improve the outcome for many people with AIDS, except: 
d) Nizoral~ 
5. The following are drugs used in treatment of 
Pneumocytstis carinii pneumonia, except: 
d) Cymevene~ 
6. Shingles is 
c) an acute infec tious disease believed to represent 
activation of latent varicella-zoster virus in those who 
have been rendered partially immune after a previous 
attack of chicken pox. 
7. Which of the following is not a type of transmission of 
HIV? 
c) Respiratory transmission 
8. Reverse Transcriptase 
b) copies viral RNA genome into double-stranded 
eDNA 
9. Adverse drug reactions in HIV positive patients are 
increased by how many times? 
c) lOX 
lO.The average time of onset of AIDS from time of 
contraction of HIV is 
c) 8 years 
11. Pneumocystis carinii is due to 
c) protozoa 
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VOCABULARY 
EDITOR: ZAKlR ESUFALI 
MEDICAL VOCABULARY 
This section is designed to test and expand your 
knowledge of medical terminology. How many items can 
you correctly define? 
Scoring:[ 13-15 ]=Superior knowledge, [ 10-12]=Above 
average, [B-9l=Adequate, ls-7l=Fair, [1-sl=Poor 
1. Hegar's Sign 
a) Softening of the lower uterine segment during 
pregnancy. 
b) Dark blui h and congested appearance of the 
vaginal mucosa during pregnancy. 
c) Softening of the cervix and vagina during 
pregnancy. 
d) The characteristic facial expre sian of Hagar. 
2. Roth's Spots 
a) White or gray oft-edged opacities in the retina 
seen in diabetes, hypertensive retinopathy, and 
SLE. 
b) The appearance of the choroid as a red circular area 
urrounded by gray-white retina, as in Tay-Sachs 
disea e. 
c) Light brown macule characteristic of 
neurofibromatosis and Albright's syndrome. 
d) Round or oval white spots sometimes een in the 
retina in the cour e of ubacute bacterial 
endocarditis. 
3. Apraxia 
a) Failure of m uscle coordination. 
b) Loss of the ability to carry out familiar or 
purposeful movements. 
c) Defect or lo s of power of expression by peech, 
writing or signs, secondary to an insult to the brain 
center. 
d) Inability to recognize familiar objects. 
4. Pseudoseizure 
a) A seizure which is feigned for the purpose of 
attaining a specific goal. 
b) An absence seizure. 
c) An attack resembling an ep ilep tic seizure but 
having purely psychological causes. 
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d) An attack re embling an epileptic seizure but which 
can always be stopped by physically restraining the 
patient. 
5. Chvostek' s Sign 
a) Electric-like shocks spreading down the body upon 
forward flexion of the head, typically seen in MS. 
b) A tingling sensation in the dis tal end of a limb 
when percussion is made over the site of a divided 
nerve. 
c) Spasm of the facial muscles elicited by tapping the 
facial nerve in the region of the parotid gland. 
d) In meningiti , flexion of the hip and the knee upon 
flexion of the neck. 
6. McBurney's Operation 
a) A radical operation which includes excision of the 
vermiform appendix. 
b) Radical surgery for the cure of inguinal hernia. 
c) Urethroplasty for hypospadias repair. 
d) Surgery performed for repair of urinary 
incontinence in women. 
7. Apoptosis 
a) Programmed cell death. 
b) Paralytic drooping of the upper eyelid. 
c) Forward displacement or bulging, especially of the 
eye. 
d ) A condition marked by the presence of small 
whitish ulcers, e pecially in the mouth. 
8. Weber's Syndrome 
a) evus flammeu distribution over the trigeminal 
nerve. 
b) Ptosis, s trabismus, and loss of light reflex and 
accommodation secondary to paralysis of the 
oculomotor nerve. 
c) Premature aging of an adult, with early graying, 
hair loss and cataracts. 
d) A neuropsychiatric disorder due to thiamine 
deficiency, most often due to alcohol abuse. 
9. Hypertropia 
a) Farsightedness. 
b) Strabismus in which there is pronounced deviation 
of the visual axi of one eye toward that of the other 
eye. 
c) Inflammation of the eyelids. 
d) Strabismus in which there is permanent upward 
deviation of the vi ual axis of one eye. 
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10. Meniere's Disease 
a) Deafness, tinnitus, and dizziness in association 
with nonsuppurative disease of the labyrinth. 
b) Progressive, bilaterally symmetrical perceptive 
hearing loss occurring with age. 
c) Psychogenic hearing loss occurring in hysterics and 
malingerers. 
d) Hearing loss due to a defect of the sound-
conducting apparatus. 
11. Tumescence 
a) The production of foul-smelling compounds due to 
enzymatic decomposition. 
b) Any condition marked by the presence of a 
neoplasm. 
c) Swelling. 
d) An accumulation of fluid in a sac, cyst, or bursa. 
12. Balint's Sign 
a) Partial or complete external opthalmoplegia in 
Grave's Disease. 
b) Ocular motor apraxia. 
c) Sharp pain associated with pinching of the 
appendix between the thumb and iliacus in chronic 
appendicitis. 
d) Fine tremor of the tongue observed in sleeping 
sickness. 
13. Cheyne-Stokes Respiration 
a) Rapid, short breathing, with pauses of se eral 
seconds. 
b) Breathing with jerky inspiration. 
c) Air hunger. 
d) Breathing characterized by rhythmic waxing and 
waning of respiration depth, with regularly 
recurring apneic periods. 
14. Kayser-Fleischer Rings 
a) Pigmented rings at the outer margin of the cornea, 
seen in lenticular degeneration and 
pseudosclerosis. 
b) Circular ridges composed of collagen fibers 
surrounding the outer margin Descemet's 
membrane. 
c) White rings seen adjacent to the optic di k in 
ophthalmoscopy when the retinal pigment 
epithelium and choroid do not extend to the disk. 
d) Rings which are visualized the junction of the 
conjunctiva and the cornea. 
15. Coryza 
. 
a) Allergic conjunctivitis. 
b) Mucopurulent cough. 
c) Acute rhinitis. 
d) Painful mucous-containing defecation. 
ANSWERS TO MEDICAL VOCABULARY 
1. Hegar's sign: (a) Softening of the lower uterine 
segment; indicative of pregnancy, appearing 
approximately in the sixth weel< of pregnancy [(b) 
Chadwick's sign; (c) Goodell's sign]. 
2. Roth 's Spo ts : (d) Round or oval white spots 
sometimes seen in the course of subacute bacterial 
endocarditis [(a) Cotton-wool Spots; (b) Cherry Red 
Spots; (c) Cafe au Lait Spots]. 
3. Ap raxia : (b ) Loss of ability to carry out familiar 
purposeful movements in the absence of sensory or 
motor impairment, especially inability to use objects 
correctly [(a) Ataxia; (c) Aphasia; (d) Visual 
agnosia] . 
4. Pseudoseizure: (c) An attack resembling an epileptic 
seizure but having purely psychological causes, 
lacking the electroencephalographic changes of 
epilepsy, and sometimes able to be stopped by an act 
of will. 
5. Chvostek's Sign: (c) Spasm of the facial muscles 
elicited by tapping the facial nerve in the re~on of the 
parotid gland; seen in tetan)' [(a) Lhermitte s Sign; (b) 
Tinel's Stgn; (d) Brudzinski s Sign]. 
6. McBurney's Operation: (b ) Radical surgery for the 
cure of inguinal hernia [(c) Browne Operation; (d) 
Kelly's Operation] . 
7. Apoptosis: (a) Programmed cell death [(b) Ptosis; (c) 
Exopthalmos; (d) Aphthosis]. 
8. Weber's Syndrome: (b) Paralysis of the oculomotor 
nerve on the same side as the lesion, causing ptosis, 
strabismus, and loss of ligh t reflex and 
accommodation; also spastic hemiplegia on the side 
opposite the lesion with increased reflexes and loss of 
superficial reflexes [(a) Sturge-Weber Syndrome; (c) 
Werner's Syndrome; (d) Wernicke-Korsakoff 
Syndrome]. 
9. Hyper trop i a : (d) Strabismus in which there is 
permanent upward deviation of the visual axis of an 
eye [(a) Hyperopia; (b) Esotropia; (c) Blepharitis]. 
10. M eni e re ' s Diseas e : (a ) Deafness, tinnitus, and 
dizziness in association nonsuppurative disease of the 
labrynth [(b) Presbycussis; (c) Psychogenic Hearing 
Loss; (d) Conductive Hearing Lossj. 
11. Tumescence: (c) The condition of being swollen; a 
swelling [(a) Putrescence; (d) Hygroma]. 
12. Balint's Sign (b ) Ocular motor apraxia [(a) Ballet's 
Sign; (c) Bassler's Sign; (d) Castellani-Low Sign] 
13. Chey ne-Stok es Respiration (d) Breathing 
characterized by rhythmic waxing and waning of 
respiration depth, with regularly recurring apneic 
periods [(a) l3iot ' s respuation; (b) Cogwheel 
respiration; (c) Kussmaul's respiration] . 
14. Kayser-Fleischer Rings (a) Gray-green to red-gold 
pigmented rings at the outer margin of the cornea, 
seen in progressive lenticular degeneration and 
pseudosclerosis [(b) Scwalbe's rings; (c) Scleral rings; 
(d) Conjunctival rings]. 
15. Coryza (c) Acute rhinitis. il 
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FEATURE ARTICLES 
A REVIEW OF THE 
TRANSMISSIBILITY OF THE 
HUMAN IMMUNODEFICIENCY V I RUS 
Since the first cases of Acquired Immunodeficiency Syndrome (AIDS) were initially encountered in 1981, the disease has spread, and the epidemic is arguably the 
biggest medical crisis of our time. Due to the latency period 
(8 to 11 years) and significant under-reporting it is very 
difficult to accurately estimate the spread of the Human 
Immunodeficiency Virus {HIV) epidemic. However, the 
World Health Organisation has estimated that 5 to 10 
million people are currently infected with HIV world-wide, 
and this number is expected to rise to 15 million by the year 
2000. u Despite all the knowledge gained about the 
pathogenesis of the disease, and means to inhibit its 
progress, relatively few studies have focused on the 
transmissibility of the virus and the significance of various 
risk factors involved. HIV has been isolated from blood, 
seminal fluid, pre-ejaculate, vaginal secretions, and even 
urine, cerebrospinal fluid, saliva, tears, and breast milk of 
infected individuals. However, due to very small 
concentrations in most bodily fluids, three primary routes of 
transmission have been identified: sexual contact with an 
infected person, significant exposure to infected blood or 
blood products (including needles shared among 
intravenous drug users), and perinatally from an infectea 
mother to her child. The purpose of this paper is to attempt 
to answer some basic questions with respect to the 
transmissibility of HIV. Pertinent literature has been 
reviewed. 
I. SEXUAL TRANSMISSION 
Risk Factors For Transmission Among Homosexuals 
By far the most common route of transmission is 
through sexual contact. Among different sexual practices, 
homosexual transmission of the virus through penile-anal 
intercourse is the most documented and best understood. 
This represents over 60% of HIV infections in North 
America. The association between AIDS and homosexuals 
was noted with the first few hundred documented cases of 
AIDS. Even now, in North America, an estimated 30% of 
the gay population is HIV+ Y.J Many factors have been 
associated with this link. The principal reason for the higher 
incidence of AIDS in the male homosexual population is 
due to the fact that many cases among this group were 
reported early on, and because of its spread due to a high 
incidence of multi-partner sexual activity, in a sexually self-
contained group. 1n a study done by Winkelstein et al. 
within the male homosexual population in San Francisco, 
the men infected with HIV averaped 61 sex partners 
compared to 25 for the healthy group. 
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Aside from the demograJ?hics of this population, their 
sexual practices are also assoaated with an increased risk of 
transmission. Male homosexuals engage in a variety of 
sexual practices, several of which result in exposure to 
blood and semen. Epidemiological studies have established 
that among different sexua1 practices, receptive anal 
intercourse 1S associated by and large with the highest risk 
of HIV acquisition. This can be explained by the high rates 
of traumatization of the rectal mucosa. Other practices that 
traumatize the rectal mucosa such as doucbing, use of 
dildos, and fisting appear to increase further the infection 
risk for the receptive partner. Insertive anal sex could also 
place a man at IISk for HIV infection, although the insertive 
partner would be at lower risk than the receptive partner. 
Appropriately, these practices have been labelled as 
"unsafe ' sexual practices and are presently practised only 
with condoms &y many homosexual men, or have been 
abandoned by some. Although clearly safer than anal sex, 
several reports have also suggested that unprotected oral 
intercourse may also transmit fllV.-1.5.6.7 
HETEROSEXUAL TRANSMISSION 
Although heterosexual transmission still only accounts 
for 9% of AIDS cases reported in the United States, it 
comprises the most rapidly growing categoryY World-wide 
heterosexual transmission is the predominant mode of 
infection. In Africa, where seroprevalence rates of HIV are 
highest, acquisition through heterosexual contact accounts 
for 80% of ail HIV infections.• World-wide, prostitutes have 
been the key "vector" of HIV spread.5 Although the relative 
efficiency of transmission continues to be evaluated, both 
male-to-female and female-to-male transmission have been 
documented. 
Information on the heterosexual transmissibility of HIV 
and risk factors affecting this transmissibility has been 
obtained from studies of sexual partners of individuals 
known to be infected, also called "partner studies." The one 
consistent finding that emerges from all such studies is that 
male-to-female transmission seems to be considerably more 
efficient than female-to-male transmission. However, 
different authors seem to disagree on the relative 
differences. This lack of consistency seemingly arises, 
firstly, from the fact that such studies have been very few in 
number. The second problem is that due to the need to 
control for the many different variables (e.g., frequency of 
intercourse, use of condoms, other sexual partners, exact 
timing of infection) that come into play m designing a 
randomised-control study, it is very difficult to fina a 
large sample size, which is necessary to strengthen the 
statistical significance of a study. 
There are two methods that can be used to quantify 
sexual transmissibility through vaginal-penile intercourse. 
One way is to look at the number of exposures required 
per infection (i.e., the risk of infection per sexual 
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intercourse with an infected person). A second method 
looks at the percentages of steady sex partners of HIV-
infected individuals who have acquired the virus from 
their counterpart. This latter method, despite its 
weaknesses (frequency of intercourse is not accounted 
for), is very valuable, less problematic and can easily be 
done on a larger scale.5 
I) MALE-TO-FEMALE TRANSMISSION 
The predominant mode of documented heterosexual 
transmission has been male-to-female transmission. 
Retrospective studies of partners of HIV-infected 
haemophiliacs and their female sex partners have been 
particularly valuable because investigators have been 
able to enroll relatively large numbers of sexually active 
couples in which the female partners generally had no 
other risk factors and were much likelier to have a 
monogamous relationship.5 Published results of these 
studies suggest that approximately 10% of the regular 
female sex partners of infected haemophiliac men have 
themselves become infected with HIV.8 Other studies 
have determined this risk to be as high as 15% or even 
30% among other heterosexual groups (non-
haemophiliacs).2.9·10 The risk of infection through a single 
exposure is extremely low. In a study done by Padian et 
al., this risk was estimated at less than 0.002 per sexual 
encounter. However, this risk is very difficult to calculate 
since although some remain uninfected after hundreds of 
unprotected sexual contacts, others have become infected 
after only a few encounters. 11•12 It seems that this risk is 
different for different populations or geographic 
locations. For example, as mentioned before, in Africa 
where the HIV epidemic has the highest proportions, 
most of the viral spread has occurred through 
heterosexual transmissiOn, indicating a seemingly more 
efficient transmission than in North America. A 
community based cohort study done by Dr. Francis 
Plummer on prostitutes from one area in Nairobi 
demonstrated that 67% of 124 uninfected prostitutes 
seroconverted to HIV-1 over a 30 month follow-up. 13 This 
dichotomy between the heterosexual transmission of 
HIV in Africa and the West is a major unanswered 
question in the epidemiology of HIV-1 transmissibility. 
These findings ali imply that other factors come into play 
affecting the transmissibility of HIV. 
II) FEMALE-TO-MALE TRANSMISSION 
Female-to-male sexual transmission of HIV, like 
transmission of other STDs, appears less efficient than 
male-to-female transmission. Transmission from infected 
women to their male partners has been poorly studied. 
Even in regions where HIV is predominantly acquired 
through heterosexual contact, few data are available. It is 
impossible to confidently put a number on the risk of 
such transmissions. A partner study done by Padian et 
al. reported only one case of seroconversion among male 
partners of 72 monogamous heterosexual couples in 
which the female was HIV positive. However, in a 
similar study done by the European Study Group on 
Heterosexual Transmission of HlV, 19 of 159 (12%) of 
male partners became infected. Higher rates of female-to-
male transmission in this study compared to the findings 
of Padian et al. may reflect a different distribution of 
cofactors that promote transmission, unacknowledged 
risks among male partners, and random variation in both 
studies. Larger studies are needed in order to make more 
conclusive deductions. 9·12.14 
II. H IV TRAN SMISSION THROUGH BLOOD OR 
BLOOD PRODUCfS 
Transfusion Recipients 
The exact proportion of world-wide HIV infections 
through blood transfusions is unknown. In Africa, 
transfUsion recipients have been estimated to account for 
more than 10% of total HIV infections. In North America, 
this fraction is less than 3% (this includes individuals infected 
through tissue transplantation from HIV infected donors), of 
which 1/3 suffer from haemophilia or another coagulation 
disorder. In North America, almost all such infections have 
taken place before the initiation of HIV blood-donor 
screening programs in 1985. owadays, in addition to the 
laboratory screening tests, blood donors have to fill out an 
exhaustive questionnaire regarding their lifestyle. This is of 
course meant to screen out blood donations from people 
with any risk factors for HIV exposure. Currently, with the 
additional implementation of HIV-antigen testing, the risk of 
acquiring HIV infection through a olood transfusion in 
Canada is estimated at 1/600000. Nevertheless, at the present 
time, more than ten years after the implementation of HIV 
screen programs, the impact of HIV infection through blood 
transfusions is still very real, especially in the haemophiliac 
population. In 1988, 55% of the haemophiliacs throughout 
the United States were HIV positive.2.15·16 
Studies suggest that HIV transmission through blood 
transfusions is by far the most efficient mode. In one 
retrospective study 90% of recipients of HIV positive blood 
became infected. Again, this percentage varies depending on 
the study, and ranges from 70% to 90%, possibly due to 
factors such as the stage of the disease of the donor and the 
amount of transfused blood. Fortunately this mode of 
transmission is almost eradicated in most parts of the 
world.2.15 
VICfiMS OF NEEDLE-STICK INJURY 
Transmission of HIV through accidental needle-stick 
injuries, although very rare, is always a concern among 
health care workers, especially medical researchers 
working with concentrated virus. A health care worker's 
risk of HIV infection is a product of the prevalence of HIV 
infection in the patient population, the risk of hazardous 
exposure and the probability of HIV transmission through 
a single exposure. The amount of blood transmitted 
through such injuries is minute. Depending on the study, 
the calculated risk of HIV seroconversion from needle-
stick exposure ranges from 0.29% to 0.50%. Depending on 
the hospital and the precautions taken, investigators nave 
found the risk of percutaneous injury among U .S. 
surgeons to be between 1.2% to 3.0% per operation. 
Therefore the risk of HIV infection for a surgeon operating 
on an HIV ~ositive {unknown) patient is fhe product of 
(1.2% - 3.0 Yo) and (0.29 % - 0.50%). This results in a 
calculated risk ranging from 35 per million to 150 per 
million. 16 Although seemingly low, this risk could reach 
significant levefs when calculated over a period of a 
liFetime (career). Obviously the only way to reduce the 
risk is to follow universal blood and body fluid 
precautions, dispose of needles and other sharp objects 
properly, and follow other prudent infection control 
measures.2.17 
HIV Transmission in Intravenous Drug Users 
Transmission of virus through intravenous drug 
injection is another practice that mvolves exposure to 
infected blood. Injection in and of itself is not a risk factor. It 
is the sharing of needles and syringes with HIV infected 
individuals tnat allows viral transiDlSsion. Sharing needles 
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is a common practice among LV. drug u ers world-wide, 
largely driven by legal and economic necessity. As of 1992, 
I.V: drug users made up 29% of reported cases of AIDS in 
the United States. This group i also much more likely than 
the general population to be involved in other high risk 
behaviour . Therefore, it is very difficult, if not impossible, 
to estimate the number of people who have become 
infected olely through sharmg needles. Similarly, it is 
difficult to calculate the risk of infection through one 
exposure to an HIV contaminated needle. Using a complex 
mathematical model, in a study done by Kaplan and 
Heimer, this risk was estimated at 0.0067 per injection 
episodeY The risk of HIV infection among LV. drug users 
is dependent on the frequency of needle sharing, the 
number of partners with whom needle are sharea, the 
probability that the e partners are HIV infected, and even 
the manner in which sharing occurs. Among practice 
a ociated with a high risk of infection, it is worthwhile to 
mention the practice of 'boothing" (wa hing out any drug 
left in the syringe with the u er's own bfood while the 
yringe needle is still in the vein), and drug use at "shooting 
gallerie " (sites where drug are ola and injection 
equipment is made available for rental or sharing).3 
III. PERINATAL TRANSMISSIO N 
With the rapid spread of infection among women of 
reproductive age, perinatal transmission is now a major 
consequence of the HIV epidemic. According to the World 
Health Organisation, by 1992, more than 1 million HIV 
infected inJants were born. Thi mode of transmission is 
apparently very efficient. One in four infants born to 
eropo itive mothers is infected.u It has been shown that 
antiretroviral therapy throushout pregnancy, particularly 
during labour and delivery, significantly decreases this risk. 
Perinatal HIV transmission can occur both in utero, or at 
birth. Identification of maternal fac tors increa ing or 
decreasing the likelihood of HIV transmi ion may help to 
explain diJferences in transmissions rates. Such factors may 
include the mother's stage of HIV infection, her degree of 
immunodeficiency, amount of viral antigen, high HIV 
replication rate (m vitro), as risk factors, and maternal 
antibodies to viral components as potential protective 
factors . The mode of delivery itself has also been associated 
with an altered risk. Any kind of traumatic delivery, such 
as forceps delivery, or even inva ive fetal monitoring, has 
been sugge ted as potential risk factors. On the other hand, 
orne have suggested caesarean section as a protective 
measure a opposed to vaginal delivery that could expose 
the fetu to a greater amount of vaginal and cervical 
ecretions. Although no hard data is yet available, breast 
feeding has also been reported as a post-partum risk factor 
for viral transmission.u 
IV. RISK FACTORS OR CO-FACTORS INFLUENO NG 
HIV INFECTIO N 
Multiple factors probably influence the infectivity of 
an HIV infected person, or the susceptibility of an 
uninfected person to HIV infection. An understanding of 
these factors is potentially important for desi~g public 
health interventions that will decrease the mcidence of 
transmission. Several of the e factors, such as practice 
increasing the risk of trauma to the rectal mucosa in 
homosexual men, or to the uterus in pregnant women, 
have been di cussed. 
Of all potential co-factor , the most investigated one is 
the possiole association between HIV and other STDs. 
More than a hundred studies have looked at this 
interrelationship. It appears that both ulcerative and non-
Feature Articles 
ulcerative STDs increase the risk of HIV transmis ion 
approximately 3-to 5-fold. 14 Several reasons can be 
postulated for this finding. One aspect of the ho t 
response to STD that may contribute to BIV transmission 
is the recruitment of inflammatory cells, such as T-
lymphocytes or macropha~es, where HIV is more 
frequently found. Similarly, It has been sugge ted that 
these inflammatory cell constitute a more suitable 
environment for HIV invasion. Thus, STDs would increase 
both the infectivity of the reservoir and the susceptibility 
of the recipient. Another mechanism by which some STDs 
might facilitate HIV transmission is disruption of 
epithelial barriers in the genital tract. The integrity of the 
genital mucosa or epithelium appear to be an important 
protection against transmission, and is clearly breached in 
case of genital ulcer disea es such as chancroid, herpe 
and syphilis. Conversely, most studies have found that 
HIV induced immunosuppression almost certainly is a 
factor in prolonging the natural history and diminishing 
the response to therapy of some STD . At a community 
level this probable interplay between HIV infection and 
other STDs' incidence may well underplay the explosive 
growth of the HIV pandemic. in some communi tie . 
Other factor postulated to augment HIV infectivity 
are both symptomatic di ea e and early infection. Thi 
would be intuitive considering the state of high viremia in 
either ca e. Similarly, some studies have suggested that 
antiretrovial therapy (zidovudine) may reduce infectivity. 
Several factors have al o been suggested to increase the 
vulnerability of the host. In men, lacl< of circumcision, and 
in women, cervical atrophy (such as in post menopausal 
women) and use of IUDs have both been postulated. Data 
regarding oral contraceptives is very contradictory. 
Whereas some have proposed oral contraceptives as a 
protective factor, others have discussed them as a possible 
cofactor increasing susceptibility of the host. 
It also appears that different strains of the virus could 
differ in theu virulence. Moreover, recent discoverie 
suggest that innate susceptibility to HIV could differ 
between people depending on their genetic make-up . 
Plummer has found that among airob1 prostitutes, tho e 
with certain HLA types seem to be resistant to the viru 
and do not get mfected despite numerous daily 
expo ures. 3•13•16 
Finally at this point it is appropriate to briefly discuss 
the u e of condoms as means of protection. The protective 
role of condoms towards HIV transmission might seem 
trivial, however, over the years, this role has been much 
over-emphasized. Several tudies now suggest that 
although condoms do afford protection to the user, the 
level of protection i not 100%, and is in fact far from it. A 
study done by Waller has uggested that this protection 
could even be as low as only one order of magnitude 
(x10). 19 Although this finding is extreme, it is important to 
accept that condoms do not provide full protection. The 
failures have been attributed to concfom breakage, 
improper use, potential passage of virus through intact 
condoms, and also more ri k taking sexual behaviour 
when condoms are used. 13 
V. PRACTICES AND MEANS OF CONTACT NOT 
ASSOCIATED WITH HIV TRANSMISSION 
As mentioned before, HIV has been isolated from body 
fluids other than blood or genital secretions. This finding has 
raised questions about the transmissibility of virus through 
casual contacts with an infected person. However, viral 
detection in these body fluids has been both infrequent and 
in very small concentrations. There have been anecaotal case 
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reports of people with no obvious risk factors becoming 
infected with HIV through what was believed to be "casual" 
contacts with an infected person. In each case, a better 
investigation uncovered possible risk factors previou ly 
unaccounted for, such as accidental exposure to bfood. 
Many studies both in the United States and in Europe 
have looked at the risk of mv transmission through casual 
contacts in settings such as household or boarding school 
contacts of persons infected with HIV. In most settings 
members had a variety of interactions with the infected 
person. These included sharing household items, sharing 
bathrooms, or even helping the person eat or bathe. All of 
these studies reached the same conclusion: no evidence was 
found of anY. mv transmission to persons lacking other risk 
factors. Similarly, some studies focused on the possibility of 
arthropod transmission of IDV. Again no support was found 
for this mode of transmission. u;n 
This brief overview highlights the magnitude of the 
problem. Undoubtedly, there is much more to be learned 
about IDV transmissibility. A better understanding of the 
cofactors involved, and the role that each flays in the spread 
of the virus, is essential in order to contra the epidemic, and 
possibly assist researchers in finding a vaccine. 
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VIRUSES 
SYSTEM: 
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IMMUNE 
FROM HIV 
I t has become increasingly apparent that out of the multitude of different families of viruses that have co-evolved wi th their higher order vertebrate hosts, 
including Man, only a small minority of these cause any 
discernible disease. In fact, the normal course of events for 
most viruses that have propagated for long periods of 
time within a single host species is for the virus and host 
to co-exist with each other in a relatively benign 
relationship that frequently involves little or no outright 
pathogenesis. As most people know, the retrovirus we 
now call Human Immunodeficiency Virus (HIV ) 
originally evolved in Old World Monkeys, which harbour 
many related lentiviruses collectively referred to as Simian 
Immunodeficiency Viruses (SIVs).The identity of the 
original simian lentivirus strain that entered the human 
population to become HIV-1 has not been rigorously 
established, but in the case of HIV-2 there is a close 
linkage with an endogenous SIV strain from the Sooty 
Mangabey monkey. In any case, the best available 
information is that HIV strains began infecting, and 
adapting to humans in the latter part of this century. In 
evolutionary terms, this is very recent indeed. Since most 
SIVs in their "native" monkey hosts do not cause any 
disease at all, why does the introduction of this apparently 
benign primate lentivirus into humans cause such a 
catastrophic collapse of the cellular immune system? And 
why are our closely related primates, such as 
chimpanzees, so apparently resistant to the development 
of AIDS when infected with the same HIVs? 
To virologists, the observation that normally benign 
viruses, which cause only sub-clinical infections in their 
native hosts, can suddenly induce severe or even lethal 
infections in a non-evolutionary host is not new at all. In 
fact, it is probable that most, if not all, viruses that cause 
outright disease do so only after infecting new non-
adapted hosts. The reasons why a virus might come into 
contact with a new host can be as varied as animal 
migration, ecological changes brought about by alterations 
in environmental conditions, or even chance encounters. 
Whatever the reason for the virus finding and infecting a 
new host species, the end result is that the virus now has 
to survive in the face of a responsive immune system 
dedicated to the task of preventing the spread of the new 
contagion. Who will win the resulting tug-of-war? The 
truth is that the outcome is rarely predictable, but we can 
uncover some clues as to the dynamics of the struggle by 
studying other related virus/host battles. One of the great 
difficulties in dissecting the fundamental mechanisms of 
ABOUT THE AVTHOR 
Dr. Grant Mcfadden is a Professor at the University of 
Western Ontario, and is Director of the Viral Immunology 
and Pathogenesis Laboratories at the John P. Robarts 
Research Institute. 
By Dr. Grant Mcfadden, JPRRI 
AIDS pathogenesis is the absence of a good animal model 
to mimic the virus / host interplay of HIV in humans. To 
that end, our lab has spent many years analyzing one 
particular nonhuman virus/host interaction, namely the 
infection of rabbits by a pathogenic virus named myxoma 
virus. These studies allow us to make some tentative 
predictions about the eventual outcome of the global AIDS 
pandemic in Man. 
Myxoma virus, unlike the relatively smaller RNA-
containing HIV, is a large DNA-containing member of the 
poxvirus family. It is closely related to variola virus, the 
causative agent for smallpox in Man (before the virus was 
eradicated by a global vaccination program in the late 
1970s). Like so many viral pathogens, myxoma virus was 
discovered only after the virus made an unexpected leap 
from its native evolutionary host, the Brazilian jungle 
rabbit (or tapeti), to a host that the virus had never 
encountered before, the European rabbit. This host species 
leap occurred in 1896 when a scientist, Dr. G. Sanarelli, 
brought a collection of European lab rabbits from Italy to 
his new research station in Uruguay for some unrelated 
scientific experiments. Upon arrival in South America, Dr. 
Sanarelli's rabbits began to die unexpectedly of a 
previously unknown acute lethal syndrome that we now 
call myxomatosis. Later, this disease was shown to be 
caused by a virus harboured within the native tapeti 
popula tion from the rain forest, and was spread by 
arthropod vectors, mainly the mosquito. This new virus 
was studied extensively in the early part of this century, 
and achieved a certain notoriety when it was used, first in 
Australia and later in Europe, in an attempt to control the 
serious overpopulation of European rabbits which had 
taken over large areas of the countryside, devastating 
crops and causing widespread ecological damage. 
Virologists have extensively studied this deliberate release 
of myxoma virus into a susceptible rabbit population, and 
our lab in particular has been interested in the molecular 
mechanisms by which the virus is able to so effectively 
disrupt the normal immune responses of its infected host. 
In humans, HIV infection eventually results in AIDS, 
but only years or decades following the initial primary 
infection. In contrast, myxoma virus in European rabbits 
causes lethal immunosupression with brutal rapidity and 
kills over 99% of infected hosts within two weeks. Thus, 
within the initial phases of the myxomatosis epizootic (the 
animal version of an epidemic) in Australia in 1951-52, 
there were massive reductions in rabbit numbers, as the 
mosqui to-born virus decimated the rabbit populations. 
Unexpectedly, however, and within relatively few rabbit 
generations (less than 10 years), the original strain of 
highly virulent myxoma virus gradually evolved into new 
variants of the virus that were dramatically less 
pathogenic, and which allowed for the survival of a higher 
percentage of infected rabbits. At the same time, the rabbit 
populations themselves changed as the selection pressures 
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brought on by the extreme lethality of the virus resulted in 
the repopulation of the infested areas with rabbits that 
were now much more resistant to the disease 
manifestations of the virus. The end result was a dynamic 
series of genetic changes in the virus and the selection of 
rabbit hosts more tolerant to the viius, that together has 
culminated in a new less-pathogenic v irus / host 
relationship which continues to evolve to this very day. 
So what predictions can we make for the future of the 
ongoing AIDS pandemic, in terms of how HIV is likely to 
adapt to the selection pressures exerted by Man? First, it is 
unlikely that HIV will quietly disappear from the human 
population. In fact, sequencing studies of the human D A 
genome reveal the presence of many retrovirus-like 
sequences that were acquired during Man's evolutionary 
past, and there are reasons to suspect that human 
populations have been subjected many times to virus-
driven pandemics similar to that observed in the rabbit 
populations in Australia . Second, as HIV progressively 
replicates and mutates within the human population, the 
severity of the AIDS symptoms will likely evolve to a less 
virulent disease as the human immune system and the 
virus become more adapted to each other. However, just 
because the overt symptomology of AIDS will likely 
become less severe, there is no reason to suppose that the 
transmission of virus itself will abate. Rather, it is 
predicted that as the pathogenesis caused by the evolving 
strains of HIV diminishes, the percentage of the human 
population that is actually infected with the virus will 
Turn your 
continue to increase. Finally, how long can we expect to 
wait to see this predicted attenuation of the AIDS disease 
itself? This calculation is quite difficult because of the high 
mutation rate of HIV and the lack of information 
concerning the extent of allelic varia tions of relevant 
immune loci that might moderate disease progression, but 
the time scale will almost assuredly be in the order of 
many human generations . In fact, for all practical 
purposes, it is difficult to conjure a scenario that actually 
eliminates HIV from the human population, at least by the 
development of vaccines and therapies alone. Rather, as 
advances in the treatment and preven tion of AIDS 
continue to provide real hope for at least the eventual 
reduction in the absolute numbers of AIDS-associated 
mortalities, it is a virtual certainty that the HIV virus itself 
will be with us for the foreseeable future. 
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THE EFFECT OF HIV INFECTION 
TUBERCULOSIS 
ON 
INTRODUCTION 
Mycobacterium tuberculosis infects one third of the 
world's population, resulting in 8 million new cases of 
tuberculosis (TB) and 3 million deaths annually. 1 Before the 
emergence of HIV, the vast majority of M. tuberculosis 
infections were kept in check by the host immune response 
and remained latent for the lifetime of the human host. 
However, worldwide spread of HIV infection has 
undermined human defenses against M. tuberculosis and 
presents a serious risk factor for the progressi~m of latent M . 
tuberculosis infection to active TB. In the Uruted States, for 
. decades, there had been a steady decline in the number of 
ca es of TB. By 1985 the decline levelled off and by the late 
1980 's inciden t TB cases began to increase steadily . 
Worldwide, by mid-1995, nearly 6 million persons were 
estimated to be coinfected with M. tuberculosis and HIV.6 
Tuberculosis has become the most common opportunistic 
infection and the leading cause of death in persons infected 
w ith HIV worldwide. 
PATHOGENESIS 
M . tuberculosis is acquired by inhalation of infectious 
airborne particles that reach the alveolar air spaces. The 
inhaled mycobacteria survive phagocytosis by alveolar 
macrophages and p rodu ce a cell-mediated immune 
response . After ingesting m ycobacteria, macropha~es 
present T-lymphocytes wi th processed mycobactenal 
antigens. The sensitized lymphocytes then proliferate and 
secrete cytokines which are able to recruit aggregates of 
macrophages with increased lytic enzyme concentration 
and enhanced phagocytic activity. A chronic inflammatory 
response develops in which the bacteria are killed by 
repeated phagocytosis. 
INFLUENCE OF HIV INFECTION ON 
PATHOGENESIS 
In the normal host, tuberculosis infection usually 
remains latent, caused by dormant organisms that survive 
the immunologic response. Reactivation TB occurs when 
latent organisms overcome immunologic control, as is the 
case in HIV-induced CD4+ T-lymphocyte depletion. The 
risk of reactivation in HIV-infected patients with latent TB 
is more than 25-30 times higher than HIV-seronegative 
controls. 6 It is also su ggested that persons with HIV 
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(regardless of CD4+ cell counts) who are newly infected 
with M . tuberculosis progre s to active tuberculosis at a ra~e 
as high as 37% in the first 6 months rather than 2 to 5% m 
the first 2 years.5 HIV also confers anergy (diminished 
reactivity to specific antigens) upon the infected 
indiv iduals, making the interpretation of the tuberculin 
skin test (TST) difficult. HIV-related enteropathy in infected 
patients may cause malabsorption of drugs, further 
complicating the treatment of tuberculosis. 
EPIDEMIOLOGY 
There are reasons for the increase in the incidence of 
tuberculosis aside from the emergence of the AIDS 
epidemic, including the deterioration of public health care 
facilities and the rise in the number of persons living in 
crowded settings. However, HIV has had the most serious 
impact on the epidemiology and natural course of TB. 
Cross-matching of TB and AIDS registries has provided 
evidence that the TB epidemic in the United States is, in 
large part, a result of HIV-associa ted immunosuppression. 
Cross-matching the TB and AIDS registries from the 50 
state health departments, the District of Columbia, Puerto 
Rico, and Guam, has yielded estimates that a minimum of 
30% of excess TB cases from 1985 through 1990 can be 
attributed to HIV-induced immunosuppression. 2 The 
largest increases in incidence of TB occurred in 
demographic groups and locations in which the prevalence 
of HIV is highest, particularly in urban areas. 
In addi tion to HIV altering the epidemiology and 
natural history of TB, TB appears to influence the course of 
HIV infection. Case-control studies have shown that 
patients dually infected with HIV and TB had a worse 
outcome as measured by the development of opportunistic 
infections and death, compared with HIV-infected patients 
a t a similar stage but without TB.8 Both groups had a 
similar level of immunosuppression as measured by the 
absolute CD4+ lymphocyte count. The effect of active 
tuberculosis on the HIV-infected patient may be the 
activation of viral production in cells harboring latent virus, 
v ia cytokines from macrophages containing ingested 
m ycobacterial products, and promoting the spread of 
infection to unaffected cells. This process can lead to a 
greater viral load, a decline in the n u mber of CD4+ 
lymphocytes, and an increased risk for opportunistic 
infection and death. 
The rise in the number of cases of tuberculosis in the 
United States has coincided with an increase in the number 
of cases of drug-resistant tuberculosis . Drug resistant 
strains can emerge via incomplete compliance with therapy 
or an incorrect cour e of treatment, such as exposure to 
only one effective drug. When anti-TB drugs are used in 
combination, growth of organisms resistant to any single 
drug is prevented by other drugs in the combination. 
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Primary resistance occurs when patients are infected with 
an already resistant strain of tuberculosis; secondary 
resistance occurs when resistant mutants of an initially 
drug-susceptible infection appear in the setting of p oor 
compliance. Initially it was thought that most cases of 
resistance were secondary. However, recent studies have 
shown that primary resistance accounts for a large number 
of drug-resistant cases, particularly among the HIV-
infected. Coinfection with HIV and drug-resistant TB may 
help explain the drastic rise in the overall incidence of 
tuberculosis. 
CLINICAL PRESENTATION 
The clinical, radiographic, and laboratory features of TB 
in HIV-infected persons vary depending on the patient's 
degree of immunosuppression. Infection with HIV is 
associated w ith increased dissemination of tuberculosis, 
increased number and severity of symptoms, and rapid 
progression to death unless treatment is begun. General 
symptoms of tuberculosis in HIV-seropositive patients 
include fever, night sweats, weight loss, anorexia, and chills. 
Tuberculosis in HIV-infected patients, as in other 
populations, is primarily a pulmonary infection. Symptoms 
include cough, sputum production, dyspnea, and pos ibly 
pleuritic chest pain. However, with advanced HIV infection, 
extrapulmonary disease is a prominent feature. 
Disseminated disease and lymphadenitis are the m ost 
common forms of extrapulmonary TB. It is plausible that 
extrapulmonary TB indicates a poorer outcome than 
tuberculosis alone, as the former appears to be associated 
with a greater degree of immunodeficiency as measured by 
CD4+ cell counts and the presence of oral candidiasis. 
The appearance of chest radiographs from HIV-infected 
patients with TB may vary depending on the degree of 
immunodeficiency, although they are often atypical. Most 
commonly diffuse lobar infiltrates are noted, although focal 
consolidation may also be present. Cavitary lesions are 
uncommon however, possibly reflecting the overall immune 
dysfunction of patients with advanced HIV infection. 
Tuberculin skin testing with purified protein derivative 
(PPD) may be less useful in HIV infected patients w ith 
suspected tuberculosis as the sensitivity is inversely related 
to the degree of immunosuppression. These patients may be 
anergic due to the decreased delayed-type hypersensitivity 
(DTH) response common in those with HIV infection, 
resulting from impaired cell-mediated immunity. In these 
instances at least two control DTH skin test antigens should 
be given concurrently with PPD. Generally, all HIV-infected 
persons with 5 mm or greater induration on PPD skin 
testing are considered positive and should receive 
treatment.3 
DIAGNOSIS 
Isolation of M . tuberculosis via sputum culture is 
required for the definitive diagnosis of TB. Given that 
infection may be present at an extrapulmonary site in HIV-
infected patients, clinical specimens other than sputum (e.g., 
urine, blood, CSF, pleural fluid, pericardia! fluid, purulent 
material, biopsy specimens) should be submitted for culture 
when extrapulmonary TB is suspected.3 Newer methods, 
such as radiometric and continuous culture, allow a more 
rapid cultivation of m ycobacteria than the traditional 
techniques. The combination of newer procedures and a 
D A probe specific for an M. tuberculosis ribosomal RNA 
sequence can identify M. tuberculosis in 1 to 3 weeks.1 This 
may be clinically significant in identifying TB in HIV-
infected patients, due to the accelerated course associated 
with coinfection. Culture techniques are also important in 
obtaining the drug-susceptibility profile of a particular 
strain and in following a patient's response to antimicrobial 
therapy. 
Smears for acid-fast bacilli (AFB) can give an early 
indication of mycobacterial infection, although a significant 
number of bacilli per ml of specimen are required for a 
positive result. There are problems with specificity as the 
smear does not distinguish between different types of 
mycobacteria, and atypical species may be present in the 
immunocomprimised. In general, HIV-infected patients 
have had lower rates of sputum smear positivity, at least in 
part because of a lower incidence of cavitary disease. 
Newer diagnostic techniques promise rapid detection of 
M. tuberculosis based on the polymerase chain reaction 
(PCR). This technique relies on gene amplification in which 
m ycobacterial D A in a clinical sample is extracted, 
amplified, and identified. With PCR, diagnoses can be made 
within hours and is generally more sensitive and specific 
than smear and culture results. This may be important from 
the perspective of the HIV-infected patient in whom sputum 
smear results are unreliable due to the potential for 
extrapulmonary infection. 
TREATMENT 
Standard antituberculosis drugs are effective for 
treating tuberculosis in the HIV-infected patient. Most M . 
tuberculosis strains isolated from patients with AIDS are 
susceptible to first-line agents. A regimen consisting of 
isoniazid, rifampin, and pyrazinamide for two months, 
followed by isoniazid and rifampin for 4 months, is 
recommended as initial therapy. Resistance to any one of 
these drugs requires longer treatment. Published guidelines 
by the Center for Disease Control do not recommend longer 
treatment regimens for patients with TB who are HIV 
infected and treatment should be prolonged only if there is 
evidence of a slow response.7 
The potential for drug-resistant TB should be 
considered in all patients being treated for TB. This is 
especially true for multiple-drug resistant tuberculosis 
(MDRTB), defined as resistance to two or more drugs. 
MDRTB primarily affects HIV-infected patients and is 
associated with mortality rates of up to 89%.7 Most patients 
die within 1 to 3 months.5 Patients with MDRTB were also 
more likely to have pulmonary and extrapulmonary active 
disease simultaneously, although the latter is still prone to 
the drug-susceptible regimen, as first-line agents penetrate 
most tissues well. The treatment regimen usually depends 
on the pattern of susceptibility, but often includes the 
aforementioned first-line agents along with second-line 
agents known to be effective against a resistant strain. These 
include ethionamide, cycloserine, ofloxacin, and 
ciprofloxacin. 
Directly observed therapy (OOT), in which the patient is 
observed taking the medication, is meant to ensure 
compliance with the preventive therapy regimen and thus 
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reduce the risk of reactivation in the patient. Treatment 
noncompliance is also a major cause of secondary resistance 
in tuberculosis, thus DOT can help prevent the increased 
incidence of resistant TB. 
PROPHYLAXIS 
Chemoprophylaxis is recommended for any HIV-
seropositive patient who is PPD+ with a greater than 5 mm 
induration, and has no evidence of active disease. Preventive 
monotherapy with isoniazid can substantially reduce the risk 
of reactivation among IDV -infected patients who are infected 
with TB. As has been stated, the HIV -infected individual with 
latent TB is at extremely high risk for reactivation of active 
disease. One study reported a tuberculosis incidence of 7.5 
per 100 person-years in HIV-infected individuals receiving 
placebo compared with 2.2 per 100 person-years in those 
receiving isoniazid.' Options for preventive therapy are 
limited when the likely exposure is to MDRTB, although 
rifampin has been suggested. Another major concern is the 
effect of using prophylactic isoniazid alone in contributing to 
the evolution of drug resistance. 
CON CLUSION 
The mv epidemic has possibly been the most important 
factor responsible for the increased rates of TB. With the advent 
of increasing drug resistance in strains of M. tuberculosis and the 
spread of IDV in regions with the highest rates of tuberculosis, 
TB has become the most common opportllllistic infection and 
the leading cause of death in persons infected with HIV 
worldwide. As the 21" century approaches we are facing the 
resurgence of an infectious disease once thought to be 
amenable to eradication. Modem techniqu es have enhanced 
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our nnderstanding of the epidemiology of TB and provided a 
more rapid diagnosis and initiation of drug therapy. This 
approach, along with the traditional interventions of rapid 
identification and ensuring compliance with therapy, will 
enable us to control the revival of TB. 
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CHALLENGES OF 
COMBINATION 
HIV DRUG 
THERAPY: 
Psychosocial and Practical Impact Reviewed 
IN THE BEGINNING ... 
From the late 1980's to present, advances in HIV 
therapy have given us a spectrum of m_edications ~nd 
approaches with varying degrees of efficacy. The first 
attempt, AZT, showed some promise in delaying the 
onset of AIDS but had no real effect in prolonging life. 
The virus appeared to develop quick resistance and 
research began on alternative medications. Other drugs 
(a class of drugs called nucleoside analogues_) w ere 
developed demonstrating various levels of effectiveness 
(DOl, D4T). Two years ago , a combination of two 
nucleoside analogues became the standard therapy and 
the combination of AZT / 3TC became widely used. This 
combination suppressed viral replication_ and incr~a~ed 
CD4 counts for a year or more in a vanety ~f clinic~! 
trials. For those patients who had used AZT pnor to this 
new combination, the virus was able to deve lop 
resistance to both medications and only short term 
benefit was achieved. With the recent development of 
protease inhibitors (Saquinavir, Ritonavir, Indina~ir), a 
new class of medications was now added to the nuxture 
and the triple combination became standard therapy. 
Triple and quadruple combinations have recently shown 
that viral activity can be reduced to undetectable levels 
and maintained for one or more years. Finally, another 
class of medications, non-nucleoside re erse 
transcriptase inhibitors ( RTI's) are being developed 
for use in combination therapies. 
CHALLENGES O F HIV DRUG CO M BINATIO N 
THERAPY 
Combination therapies (a.k.a. drug cocktails) provide 
both health benefits and practical challenges to people 
living with HIV. A review of current literature suggests a 
number of obstacles to compliance. One commentator 
writes that taking these medications involves a life 
change, and stresses that most patients taki~g . the 
"cocktail" need to organize their lives around a difficult 
and demanding pill taking schedule. 
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Triple and quadruple drug combinations often 
involve taking at least twenty pills per d~y ,_ each 
medication having differing requirements for hmmg of 
doses, and consideration as to whether or not the 
medications need to be taken with food. Saquinavir, for 
example, must be taken at eight hour intervals with a small 
meal. Indinavir, in contrast, must be taken at least one hour 
before and two hours after eating, three times per day. 
Depending on the specific drug, directions may stipulate no 
food and lots of water, low fat food, or high fat food. All of 
these requirements lead to substantial disruption in normal 
routine and would often have an impact on adherence to the 
regimen. Obviously, changes in diet and sch~uling of meal 
times and snacks (or no snacks) becomes an ISSue. For some, 
disruption in sleep patterns may occur if the patient n~s 
to wake earlier for a dosing or stay up later than the1r 
normal schedule. In regards to dosing schedule, ma~y 
studies have demonstrated that it is not the number of pills 
taken per dose, but the number of doses _whi_ch ~pacts on 
compliance levels. These same studies mdi~ate that 
compliance levels drop off with more than twice a day 
dosing. 2 At present, the dosing sche~ules for _the drug 
cocktail remains three times per day, at eight hour mtervals. 
One must also consider the profile of side effects for the 
medications as a possible barrier to compliance. Common 
effects such as nausea, stomach pain and diarrhea may 
exacerbate compliance. One journalist writes of compli~ce 
issues and states that we are assuming that these medical 
and organizational issues are the main barriers to 
compliance when in fact, financial cost and lack of support 
may deter one from even commencing this regimen. Drug 
costs for protease inhibitors and NNRTI's can well be 
prohibitive if one does not have a~cess to governmen~ dru_g 
plans or private plans. The working poor are o_ften m ~s 
situation with relatively poor access to hfe savmg 
medications. 
Recent data suggests that compliance is also dependant 
on environmental, psychological, and social fact~rs . In _a 
recent study Singh and others found that compliance_ Is 
influenced by a variety of interdependent psy~hosoCial 
variables which "interact in complex ways to influence 
overall quality of life and even longevity". In t_hi s 
longitudinal analysis examining the psycholog~cal b~Ie~s 
associated with compliance, results demonstrate that Within 
the study sample, non-compliant patients demonst:ated 
"significantly greater psychological ~istress~ emotional 
disturbance, depression and poor adaptive copmg assessed 
by standard psychological tests".4 In a related study on stress 
and stressors, researchers discovered that the average HIV 
positive respondent in the study appear~d to have "more 
depressive symptoms and more percel\'_ed .. stress ~han 
would be expected in the general population . Emotional 
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factors such as depression, must then be considered by a 
treating physician as a possible challenge in compliance to a 
difficult and demanding drug regimen. 
WHY IS COM PLIANCE SUCH AN ISSUE? 
Quite simply, if there is any interruption of the drug 
regimen, resistance will occur and the therap y will 
eventually become ineffective. When people stop their 
medicine a resurgence of the virus is evident, to some 
extent, within one day. The trick here is to stop replication 
by suppressing the viral activity. With the extremely high 
rates of replication of this virus (approximately 10 billion 
new copies per day) any interruption of the pharmaceutical 
pressure on replication through repeat cycles of non-
adherence or erratic patterns of compliance likely means 
that those mutations are going to thrive, and you are going 
to end up with a whole population of the virus that is 
resistant to the therapies .6 Chris Tsoukas of Montreal 
General Hospital emphatically states that viral load 
reduction which reduces HIV's replication opportunities is 
"the only demonstrated way to postpone the development 
of viral resistance". 
ROLE OF PHYSICIANS IN PROM OTING 
COM PLIANCE 
For the most part, commentators believe that medical 
schools have been inadequate in addressing the issue of 
recognizing the optimal conditions for compliance to 
medical advice. Eracker and colleagues note that "few 
medical schools teach their students to recognize the 
conditions under which the patient can be expected to 
follow advice (much less the methods for communicating 
effectively with patients), or the interview skills needed to 
assess what the patient knows, believes, or is concerned 
about".7 With the reorganization of lives around a difficult 
pill regimen, Mirken believes that physicians must spend 
time understanding a patient's life before recommending a 
specific regimen? Customizing the treatment to a patient's 
lifestyle, attitudes, and beliefs will impact on the patient's 
willingness and ability to follow a treatment plan. As 
prev iously mentioned, paying attention to emotional 
factors such as depression may also enhance compliance 
through active treatment of the emotional condition. 
Providing referrals for emotional and practical supports (i.e. 
access to financial supports or payment programs) are also 
appropriate interventions for patients. 
PSYCHOSOCIAL TRANSITIONS 
It appears that the introduction of these powerful 
combination therapies has de-stabilized many people living 
with HIV from a psychological and social standpoint. In the 
writer's own practice, a number of people now question 
their goals and possibilities for long term survival. It is as if, 
one client states, the world has been turned on its side and 
something new and frightening has been created. At first 
thought, logic would dictate that people would rejoice at 
new possibilities for a prolonged and healthy life. It appears 
that those individuals who have developed clear self 
identifications as (a) I am ill with HIV and (b) I will have a 
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shortened life because of HIV, are now being asked to 
redefine themselves and their world. Derek Scott of the 
AIDS Bereavement Project of Ontario defines this as an 
existential crisis. Scott describes the formation of Self as 
transition between Self-as-uninfected to Self-as-infected.8 
The writer would expand on these Self identifications by 
stating that we have three identifications happening in this 
process. First, the indiv idual would identify Self-as-
uninfected-and-living. Second, the individual would 
identify Self-as-infected-and-dying. With the advent of 
combination therapies, the most recent addition would be 
Self-as-infected-and-living. Movement from one of these 
Self identifications to the next would provoke an existential 
crisis. An individual may question his/ her identity, have to 
refocus goals and beliefs for the future, and in many cases 
redefine relationships and careers. Scott believes that for 
people who have resigned themselves to what they have 
been told is inev itable, "the hope and uncer tainty 
surrounding these therapies can contribute to a feeling of 
cri s is, as once again, the Self and identity undergo a 
profound shift".8 
CONCLUSIONS 
It appears that the introduction of HIV combination 
therapies has been a promising medical breakthrough, a 
practical challenge for compliance and minimizing 
resistance, and a p sychosocial challenge for many living 
w ith HIV . It becomes evident that simply giving the 
medications will not suffice. Complex and interacting 
variables such as lifestyle, beliefs, resources, and emotional 
health have to be considered when developing a treatment 
regimen. A customized approach to treatment is essential 
for ensuring efficacy of the drugs. 
Educators are now struggling with the possibility of 
relaxed safe-sex behaviours due to the misperception that 
new drug regimens represent a cure. This is perhaps an area 
for further discussion and research as mortali ty rates 
decrease (due to the effectiveness of the therapy) and 
infection rates increase. 
ACKNOWLEDGEMENT 
Reviewed by Clarence Crossman, AIDS Committee of 
London 
REFERENCES 
1. Mirken B. Haw 1mtch does it really matter if you take your pills on time?. 
Beta 1997; September:9-13. 
2. Eldred L et a/. Medication adherance to long tem1 therapy in HN disease. 
XI International conference on AIDS. Vancouver, B.C. Ju ly 1996. Abstract 
Mo.B. 1165. 
3. Trow R. Miracle drugs or AZT redux?. XTRA 1997; 325:23. 
4. Singh N et a/. Determinants of compliance with antiretroviral therapy in 
patients with human immunodeficiency virus: prospective assessment with 
implications for enhancing compliance. AJDS Care 1996; 8(3):261 -269. 
5. Thompson SC, Nanni C. Levine A. The stressors and stress of being HIV-
positive. AIDS Care 1996; 8(1):5-14. 
6. Medical Education Network Canada Inc .. Insights into compliance with 
HIV treatment. New Frontiers in Medicine: HN/AlDS 1997; April. 
7. Tsoukas C. Navigating the maze of protease inhibitor therapies: efficacy and 
compliance. Medical Aspects of HN Infection 1997. 
8. Scott D. Beyond diagnosis: Finding a framework for counselling. Canadian 
AIDS News 1996/97; 9(3):5. n 
U. W .O. Medical Journal 67 (1) 1998------------------------- 45 
Feature Articles 
HIV/AIDS: 
Epidemiology, Advances in Therapy, Prevention 
INTRODUCTION 
As the HIV pandemic continues well into its second 
decade, the global picture continues to be bleak. 
According to the UNAIDS there are 8,500 people infected 
every day. Greater than 40% of these new infections occur 
in women. More than half of these new infections occur in 
people between the ages of fifteen and twenty-five years. 
One thousand children are infected every day. Of the 
children living with HIV I AIDS, 75% of them have a 
mother who is also HIV infected. Nineteen percent of the 
children have a mother living with AIDS and 6% have had 
a mother die of AIDS.1 There is no doubt that the impact 
of this disease continues to be devastating. The developing 
world has been most hard hit. In parts of Africa, 30-40% of 
all adults are HIV infected. In Hurare, Zimbabwe, 40% of 
pregnant women were found to be HIV infected. Life 
expectancy at birth has decreased by as much as 25% in 
severely affected countries. Mortality from AIDS 
continues to increase in the developing world. 
In the developed world (Canada, United States, 
Western Europe and Australia) the rate of new infections 
has stabilized, and even decreased in some areas. For the 
first time ever the death rate from AIDS in North America 
decreased in 1996. Recent developments have led to 
improved understanding of the pathogenesis of the 
disease. Several new antiretrovira1 medications have been 
developed and are now accessible to some people with 
HIV. These recent advances have resulted in a sense of 
cautious optimism. 
A cause for considerable concern however, is a recent 
resurgence of infections among Canadian and American 
men who have sex with men. Additionally, in Vancouver 
and Montreal, HIV is currently spreading with alarming 
speed among injection drug users (IDU's). In Ontario, as 
well, the situation in lOU's is very unstable. Presently, 
heterosexual women comprise the group with the greatest 
increase in rate of new HIV infections. At the HIV Care 
Programme in London, more than 20% of new referrals 
are heterosexual women, with no history of IOU or 
prostitution. 
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VIRAL LOAD MEASUREMENT 
New methods have been developed that can 
reproducibly measure the amount of HIV-1 RNA in 
plasma. Plasma HIV-1 RNA concentration (viral load) is 
reported as number of copies per ml serum. Viral load has 
been shown to be the best predictor of clinical outcomes 
of all markers studied to date.2 Measurement of viral load 
has rapidly been adopted as integral to the management 
of HIV infection. Besides providing valuable prognostic 
information, change in viral load in response to 
antiretroviral therapy has proven to be a reliable 
prediction of clinical response to antiretroviral treatment.3•4 
ANTIRETROVIRAL THERAPY 
The last two years have seen significant changes in 
treatment of HIV infection . Currently there are three 
classes of antiretroviral medications available (to a 
variable degree) to treat HIV infection: nucleoside 
analogue reverse transcriptase inhibitors (NRTI's), such as 
Zidovudine, (AZT); non-nucleoside reverse transcriptase 
inhibitors (NNRTI 's), and protease inhibitors (PI) . 
Combinations of medications (three or more) are used to 
provide greater, more durable virologic suppression. 
Clinical trials have shown that combinations of two 
NRTI's and one PI significantly decrease both morbidity 
and mortality.5 
Treatment guidelines now strongly support earlier 
more aggressive antiretroviral therapy than ever before. 6 
Clinical trials are ongoing, studying the effects of initiating 
antiretroviral therapy at the time of acute infection. For 
the first time, scientists and clinicians are designing 
studies to address the possibility of eradicating the virus. 
Just one year after protease inhibitors have become 
widely available, many people have already benefited 
greatly from their use. Undoubtedly their widespread use 
has contributed to the decrease in death rates due to AIDS 
that we have seen across orth America . How durable 
their effects will be remains to be seen. Even so, despite 
the successes that have occurred, much needs to be done 
for treatment of HIV-1. Many patients treated with 
available medications fail to achieve virologic control. 
Others are unable to tolerate the significant side effects 
associated with these treatments that, as of yet, do not 
offer even the hope of a cure. Most limiting is the fact that 
the majority of the people in the world with HIV infection 
do not have access at all to any of these medications, by 
virtue of their high cost. (Approximately $1,000 per month 
for "standard" triple therapy- see Table 1). 
PREVENTION 
Success has also been achieved in preventing 
transmission of HIV -1. Vertical transmission can be 
reduced by 67% with use of Zidovudine. The vertical 
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transmission rate of 26% can be reduced to approximately 
8% with Zidovudine taken from 14 weeks gestation 
through labour and deliveries, and administered to the 
infant for six weeks following birth. 7 A voidance of breast 
feeding where there are good alternatives can reduce HIV 
transmission by 15-30%. HIV testing should therefore be 
offered to all pregnant women, as part of routine prenatal 
screening. 
Zidovudine (AZT) has also been proven effective at 
reducing HIV infection (seroconversion) following 
occupational exposure.8 To be effective post-exposure 
prophylaxis (PEP) needs to be initiated as soon as possible 
following the exposure, ideally within 1-2 hrs. Many 
hospitals have a standard PEP policy accessible through 
the emergency department or via occupational health and 
safety offices. Whether PEP would be effective following 
sexual exposure has not been determined. The use of 
barrier prophylaxis significantly reduces sexual 
transmission of HIV, but does not eliminate it. People 
whose lifestyle put them at risk for acquiring HIV need to 
be provided with information about risk reduction and 
harm reduction techniques. 
Thus, while the last few years have seen significant 
progress in the understanding and treatment of HIV-1 
infection, the pandemic is far from controlled. In 1996 
alone, 1.5 million people died of AIDS. More than 23 
million people have been infected with HIV-1 to date. All 
estimates predict that by the year 2000 this number will 
exceed 40 million. 
Without a cure or vaccine, the most effective strategy 
for fighting HIV I AIDS is prevention. Studies done in 
several countries have shown that prevention programs 
can result in behavioural changes. More effort needs to be 
directed toward implementing effective education and 
prevention programs worldwide. 
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TABLE 1. MEDICATION EXPENSE 
TYPE OF APPROXIMATE 
ANTIRETROVIRAL MEDICATION COST/MONTH 
NRTI's Zidovudine 
(AZT) 
RETROVIR $325.31 
Zalcitabine 
(DOC) 
HIVID 193.50 
Didanosine 
(DOl) 
VIDEX 184.80 
Larnivudine 
(3TC) 315.50 
Stavudine 
(d4T) 
ZERIT 250.00 
Protease Inhibitors Saquinvir 
(PI's) (Invirase) 550.79 
In dina vir 
(Crixivan) $510.00 
(wholesale price) 
Ritonavir 
(Norvir) $554.00 
Nelfinavir Study Med.-
(Viracept) Expanded Access 
NNRTI's Delavirdine Study Med. 
- Expanded Access 
Nevirapine Study Med. 
(Viramune) Expanded Access 
U. W. O. Medical Journal 67 (1) 1998------------------------ 47 
Fea t u r e Ar ti c l es 
A GLIMPSE OF 
IN 
THE FACE 
TANZANIA 
OF AIDS 
I nnocence lives in a mud hut on the outskirts of 
Arusha, Tanzania. 
The interior is 
decorated with 
magazine clippings 
of white fashion 
models and black 
sports stars, taped 
to mildewing 
cardboard, and 
hammered into the 
dirt walls by Coke 
bottletops pierced 
with nails. As a 
result of his 
constant diarrhea 
and frequent lung 
infections, 
Innocence is too 
fatigued and 
emaciated to work 
any longer. When 
Innocence 
he and his wife were clinically diagnosed with AIDS a 
couple of months ago, she took their four year old 
daughter and moved in with another man. Innocence has 
not seen either of them since then. His family does not 
speak about him any longer, and does not help to support 
him. They do not visit him, give him food, or help pay for 
rent or medicines. Occasionally, a neighbour will leave 
food outside his door. 
Richard had two wives . He and one wife died of 
AIDS-related illnesses a few months ago, leaving his other 
wife, Gladness, to look after her own five children and the 
four children born to the deceased wife. Two simple 
wooden crosses mark their shallow graves in a nearby 
corn field, easily visible from the mud hut that is 
Gladness' home now. Gladness' family and friends have 
abandoned her. Her two youngest children died recently, 
and her four year old is frequently ill. Her oldest son is not 
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The making of sugar cane juice for people living with Aids in Arusha 
yet of legal age to own land, and Gladness is afraid that 
when she dies her children and step-children will be 
forced into the streets when neighbours and relatives 
divide up her belongings and land. 
These are some of the stories told to medical and 
nursing students involved in MedOutreach, a student 
group from the University of Western Ontario, as they 
visit the homes of families coping with the daily realities 
of living with AIDS in Arusha, Tanzania. A 1988 census 
estimated that there were approximately 1.3 million 
people in the Arusha region, with about 130,000 people in 
Arusha town itself.1 In the summer of 1997, students in 
MedOutreach had the opportunity to work with Sister 
Denise Lynch of the Medical Missionaries of Mary 
(MMM), coordinator of the AIDS Prevention Programme 
in the Diocese of Arusha. By participating in the MMM 
AIDS outreach programs, these students were able to see 
for themselves that many people with AIDS in Arusha 
suffer in isolation and most die in their homes without 
adequate care. 
Fortunately, the MMM programs are making inroads. 
In the first six months of 1997, team members from the 
AIDS Prevention Programme made 2,488 home visits in 
Arusha to provide emotional support, food, medicine for 
concurrent illnesses, funds for rent, legal aid, and ongoing 
education for family and friends .2 Recently, outreach 
workers have been bringing sugar-cane, ginger and lime 
juice along on their home visits. In addition to providing 
AIDS patients with energy, this juice is produced and will 
be marketed locally in support of the AIDS Prevention 
Programme. 3 Besides home visita tion, the AIDS 
Prevention Programme also runs a number of community 
education programmes, such as "Behaviour Change", for 
young adults in secondary schools. In an informal survey 
done in Arusha by the AIDS Prevention Programme, 
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about 75% of both boys and girls declared that they had 
their first sexual experience between 10 and 12 years of 
age, emphasizing the need for early education about HN 
transmission.2 Of special concern for girls in secondary 
school is the "sugar-daddy" factor : there are reports of 
parents who can no longer afford to pay the fees for 
econdary school advising their daughters to "find 
someone to pay for them" and giving them condoms to 
prevent pregnancy. Unfortunately, young girls in thi 
ituation who aspire to a future through higher education 
often find themselves at increa ed risk of becoming HN 
po itive.3 
While working in more remote areas of Tanzania 
students from MedOutreach had the additional 
opportunity to learn about the impact AIDS is having in 
the e regions of the country. Cultural practices amongst 
the Maasai, a proud tribe of nomadic warrior herdsmen, 
offer insight into the spread of HN in such locations.• It is 
not uncommon for a Maasai elder to have five wives and 
25 living children, all living within a single "boma" (a 
collection of round mud huts surrounded by a hedge of 
dense thorns to guard their cattle and goats from lions and 
leopards). When a warrior from a distant boma comes to 
visit, it is culturally proper for the village elder to offer the 
visiting warrior one of his wives for the night. The 
husband welcomes the prospect of a visiting warrior 
impregnating his wife since the social status of the elder is 
enhanced with each new child that is born. This is one 
rea on why the Maasai have been resistant to using 
condoms.' 
Another tradition potentially increasing the risk of 
HIV transmission amongst the Maasai is the practice of 
group circumcision of young boys . Circumcision is a 
required ritual in which a Maasai boy must participate in 
order to become a young adult warrior, or "Moran". 
Traditionally, the ritual i held in the early morning 
following a night of celebration and excitement. A group 
of up to 20 boys, ranging in age from approximately 12 to 
18 (ages are actually unknown to most Maasai), are 
circumcised with the same knife. If a boy flinches or shows 
fear, both his family and the boy will lose respect in the 
village. The concern with regards to HIV is that by the 
time the cohort of boys become circumcised, it is likely 
that some of the older boys will have travelled to the 
cities, met with sex workers, and may be HIV positive. 
Efforts to encourage the use of a separate knife for each 
circumcision, or at least to clean the blade between 
procedures, have been met with reluctance because, like 
many populations, the Maasai are very resistant to make 
changes to their traditional practices.' 
Perhaps one of the most disturbing reasons for HIV 
transmission in the Maasai is a well known "cure" that a 
Maasai medicine man advised for a HIV positive man. 
The medicine man had explained to the patient that "the 
AIDS" in his body could be reduced by half if he were to 
have sex with a young virgin girl because half of his virus 
would be passed on to her. If he had sex with enough 
virgin girls, he would be cured. This "dilution effect" cure 
dramatically demonstrates the need for education of the 
Maasai people about HN and how it is spread.' 
Various epidemiological studies have shown that the 
picture of AIDS in Tanzania is serious. As in the rest of 
Feature Articles 
sub-Saharan Africa, the majority of HIV in Tanzania is 
transmitted through heterosexual contact with an infected 
person.5•6 Condom use is not widespread; in a recent 
western Tanzanian study, 88% of men and 63% of women 
had heard of condoms, but only 20% of men and 3% of 
women had ever used one.7 In the Arusha region, HIV 
prevalence rates are estimated to be higher in women than 
in men, in urban than in rural areas, in urban areas of low 
socioeconomic status than tho e of high socioeconomic 
status, and in divorced and separated individuals than in 
married and cohabitating individuals.8 Factors associated 
with higher HN prevalence rates in women in the Arusha 
region include having travelled outside of Arusha in 
Tanzania and abroad, having multiple sexual partners, 
and having sexual intercourse while under the influence 
of alcohoP 
Epidemiology is nece sary for revealing the context of 
HIV and AIDS in Tanzania, but it is the opportunity to 
meet with people living with HN and AIDS that gives this 
picture its colour and texture . Students with 
MedOutreach were privileged to have a glimp e of how 
AIDS exists in the Tanzanian setting; the haunted look in 
Gladness' eyes is a memory that will not easily be 
forgotten. Clearly, any interventions aimed at reducing the 
spread of HN in Tanzania will have their greatest effect if 
they are able to address the personal experience of living 
with this disease. 
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THE GEOGRAPHY OF AIDS 
Spatial diffusion and the Canadian Experience 
INTRODUCfiON 
In 1981, the Western world was introduced to a new 
disease that seemed distant and unimportant to the 
general public as it was labeled a "homosexual disease". 
However, within just a few years of the first recognized 
cases, Acquired Immune Deficiency Syndrome (AIDS) has 
gained such a strong foothold that it is now a global 
epidemic. It is estimated that since 1981, over 6.8 million 
cases of AIDS, and 1 million deaths due to this disease, 
have occurred worldwide. 1 Considering that most 
Western countries are in the later stages of demographic 
transition, the appearance of an infectious disease as a 
major cause of deaths is alarming. Already, in 1989 it 
became the number one killer of men 25-34 years of age in 
Toronto. In that year, it also entered the top four 
contributors to potential years of lost life superseding 
diabetes, chronic lung disease and kidney disease.2 The 
spread of the disease has followed a complicated path. 
Distinct geographical patterns of transmission have 
emerged which reflect the behavioural patterns of infected 
people and the interaction networks of the population as a 
whole. Intricate epidemiologies exist both in and within 
different regions of the world. Today, we know a lot about 
the disease but not enough to stop it. In an attempt to 
better understand this pandemic, the study of this disease 
through geographical paradigms has been employed.3 
SPATIAL DIFFUSION 
Medical geography has many tools available to help 
explain the spread of diseases. One of these devices is the 
spatial diffusion theory defined as the "process by which 
behaviour of characteristics of the landscape change as a 
result of what happened elsewhere earlier".• Loosely 
translated for the purposes of this topic, it is the spread of 
a disease both spatially and temporally from limited 
origins. The spread of a disease is dependent on several 
factors including the presence of suitable agents to 
transmit the disease and appropriate hosts. The nature 
and spread of the disease usually reflect the geographical 
and temporal patterns of individual contacts. Spatial 
diffusion is characterized by a disease origin and changes 
in the prevalence rate over time. 
There are four main models of spatial diffusion: 
Expansion diffusion, Relocation diffusion, Contagious 
diffusion and Hierarchical diffusion. Expansion diffusion 
is a relatively simple model. It simply describes the 
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expansion and diffusion of the disease resulting in more 
agents possessing the disease. Relocation diffusion is also 
a simple pattern that is characterized by a change in 
location of infected agents. Often, relocation diffusion is 
characterized by great leaps in movement, potentially 
bypassing intervening populations; however, there is no 
change in the prevalence of the disease. Contagious 
diffusion is a slightly more complex archetype involving 
dose contact of individuals. It is often explained in terms 
of a wave phenomenon in which there is an epicentre with 
high rates of infection, with a gradual decline in 
prevalence moving outwards - a distance decay effect. The 
last type, Hierarchical diffusion is typified by the spread 
of a disease from a large city to smaller cities over time. 
This diffusion type is also related to diseases where 
spread is closely associated with contact of individual .•.s.6 
These diffusion types are not mutually exclusive; often, 
disease diffusion processes are a combination of the above 
types or may have several types occuring at different 
times depending on the state of progression of the disease 
cycle. 
As with any sort of diffusion, there are situations that 
may promote the spread of the disease as well as 
situations that may not favour the movement. Situation 
that promote the diffusion of disease are known as 
diffusion networks. These networks consist of the intricate 
system of people, locations and the links that connect 
these places -- both physical links and communication 
links that allow the movement of people, goods and 
diseases . Factors that serve to prevent diffusion of 
diseases are known as barriers. There are three 
manifestations of barriers: absorbing, reflecting and 
permeable barriers. Absorbing barriers tend to stop a 
disease from moving at all. Immunization or genetic 
immunity often has this effect as the disease as unable to 
seed itself into a population. Reflecting barriers tend to 
concentrate or deflect diseases towards a certain 
unblocked area preventing infection of another locale. For 
example, if two towns are separated by a dense forest, a 
disease will tend to stay on the side of the forest that it is 
on and concentrate its effects there. The final type of 
barrier is a permeable type. This barrier serves to dilute 
the process of infection or slow down the progression. All 
of these barrier types can either be physical barriers or 
cultural practices developed over time to prevent spread 
of infection. Examples of physical barriers include deserts 
or vast expanses of water. The e physical barriers are not 
as effective in modern times due to the accessibility of 
rapid transport over vast distances. Cultural barriers tend 
to be more effective. These include religious and cultural 
practices, such as drinking tea in Asia to prevent infection 
with cholera as the water must be boiled first. As well, 
these barrier types are not mutually exclusive. Often 
combinations of the various barriers may exist in an area. 
50 
------------------------ U. W.O. Medical Journal 67 (l) 1998 
GLOBAL TRENDS 
~orld~ide, ~ere are at least three distinct patterns of 
HIV mfechon with a fourth one suggested. Pattern I is 
usually the trend seen in Western countries such as the 
~~~ed States _and Fr~ce. Here, the predominant group 
Imhally afflicted With this infec tion is the male 
homosexual/bisexual population spread through 
homosexual sexual activity . As well, an almost 
simul taneous secondary wave of infection occurs in 
intr~venous drug users . Heterosexual infection initially 
begms at low levels but increases with time. Women are 
largely unaffected with ratios above 10:1 male to female. 
~erinatal infections are rare due to the low prevalence of 
mfected females, however, the pervasiveness is 
increasing.7 
Pattern II is typical of sub-Saharan Africa where the 
epidemic began in the mid to late 1970's. The disease is 
most p~e~alent in the heterosexual population with 
transmissiOn occurring through heterosexual sexual 
activity . Generally, the male to female ratio is 1:1. 
Consequently, perinatal infections are also a major 
problem in these regions.7 
The third pattern of infection is characteristic of Asian 
count~ies such as Thailand and eastern European 
countries where the epidemic began in the mid to late 
1980's. C~rently, Pattern ill countries account for a very 
s~all £I:action ?f cases. However, future projections show 
disturbmgly high levels of infection, greater than those in 
other parts of the world. It appears that introduction of 
HIV to these areas is usually through contact with people 
or blood products from Pattern I and II countries. 
~rostitutes ap~ear to be the most heavily infected groups 
m these countries.7 
The fourth pattern suggested is derived from 
observations of countries like Brazil and Honduras. This 
p~ttern_ stresses the importance of bisexuals as the major 
dissemmator of the virus spreading the disease from the 
homosexual population to the heterosexual population. 
However, caution should be taken as the sexual 
ori~ntation o~ these individuals is self-reported. These 
Latm countnes tend to have a ' macho' attitude and 
describing oneself as bisexual is favoured over being 
homosexual.' 
These patterns are broad and general observations. In 
f~ct, some co~tries may have several patterns occurring in 
d_Ifferent reg.ons or even within the same metropolitan 
aty. As well, the patterns of the disease should be expected 
to change as the disease makes its course through the 
population of these areas.8 
EPIDEMIOLOGY IN CANADA 
According to the World Health Organization, Canada 
had 8,232 cases of AIDS reported at the end of June 1993. 
Early predictions for the cumulative total of cases were 
estimated_ at_ll,OOO cases by the end of 1993.9 These reports 
and predictions must take into consideration the level of 
co~pleten~ss _i ~ reporting and the delay in reporting 
w~?' can significantly affect the accuracy of the statistics. 
Imhally, the mode of transmission eluded scientists. 
However, as the scientists learned more, it became evident 
that transmission occurred through contact with infected 
bodily fluids, especially blood and semen. 
Fea t u r e A rti cle s 
The major methods of transmission include sexual 
activity, injection drug use, contact with blood or blood 
p~od_ucts and through perinatal routes.9 The prevalence 
Within the ?,ay comm~ty was largely due to the "party 
atmosphere of the gay lifestyle. The mentality of the gay 
population at the time included multiple sexual partners, 
unprote~ted sex (as there was no risk of pregnancy), and a 
perception that a cure for most sexually transmitted 
diseases existed. Initially, all of the cases in Canada were 
attributed to gay men. However, as the epidemic spread 
through the community, strong educational programs to 
erect cultural barriers were initiated. The incidence of new 
cases amongst the gay community has stabilized and even 
dropped. Current prevalence levels are approximately 10-
15%.2 However, there are indications of a second smaller 
increas: in incidence attributable to young gay m;ues who 
are havmg unprotected sex. 
Since the first cases reported in 1981, the 
eJ?idemiology of HIV I AIDS has changed drastically. The 
disease has spread to injection drug users and from there 
~o ~he het~rosexual population. It is reported that the 
mcidence m 1993 was at 2% with regional variations. 
Rec:nt studies have estimated that the prevalence may be 
as high as 15-20% in the general population with incidence 
rates of 6-7%.2 Other people became infected after 
~eceiving tainted blood products, although this sub-group 
IS rapidly _declining as blood products are now thoroughly 
screened m Canada. As women became infected so did 
children who were either in utero or breast-f~eding . 
Seventy-four percent of pediatric cases in Canada have 
been attributed to perinatal transmission as of July 1993.9 
Other sub-populations at risk of contracting the disease 
are health care workers, although universal precautions 
have made the chances of being infected extremely low.9 
In an interesting turn of events, HIV I AIDS is now 
prea?ing rapidly within the heterosexual population, 
espeoally among heterosexual young women. It is clear 
that heterosexual transmission has become an important 
contributor in this disease's progression. 
THE NUMBERS GAME IN CANADA 
ot surprisingly, research and literature into 
HIV ! AI£?S is very scarce in Canada. The majority of 
publicatiOns are from the provincial and federal 
governments. However, this information is sufficient to 
illuminate patterns and trends in the HIV epidemic here in 
Canada. According to statistics from Health Canada 
adjusted for reporting delays and under-reporting, as of 
September 30, 1995, Canada had a total of 15,926 cases of 
AIDS re~orted . -!"s _of December 31, 1995, the provinces 
hardest hit by this vuus were Ontario with 40.6% of cases, 
Quebec with 31.1 %, British Columbia with 17.1% and 
finally Alberta with 6.2% of cases. Together, these four 
provinces account for 95% of the cases of AIDS reported in 
Canada.10 
. Within these four provinces, epidemiological 
differences exist. Ontario, Quebec and Alberta can 
attribute approximately 70-78% of AIDS cases to 
homosexual activity while British Columbia has a higher 
rate at 88%. The other provinces can attribute 66% of 
their AIDS cases to homosexual activity. It is interesting 
to note that Quebec has a significantly higher rate of 
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females infected (6.0% compared to 1.6% in the rest of the 
country) and a higher rate of heterosexual infection. This 
anomaly has been attributed to the high rate of immigrants 
from Africa where the disease is prevalent in the 
heterosexual population.2 Regarding infections occuring in 
the smaller provinces, there is a greater number of 
heterosexuals infected compared to homosexuals. This 
variation in demographics can be ascribed to the lack of 
large metropolitan cities with large gay populations. 
The spread of HIV in Canada largely follows a 
hierarchical diffusion. These results are similar to findings 
in Finland and the United States, countries which are in 
similar states of maturity.11 The areas in Canada that 
reported the highest number of AIDS cases (78.1%) in 1983 
were in the large metropolitan cities of Toronto, Montreal 
and Vancouver -- cities with strong international 
connections. Only six percent of cases were in medium 
sized cities with populations between 50 000 to 750 000 
people with the remaining cases (15.6%) in other areas. 
However, by the end of 1987, the proportions changed to 
63 .1 %, 21.6% and 15.3% respectively. These numbers 
indicate the disease originated in urban cores of large cities 
and gradually spread to suburbs, smaller cities and rural 
areas. This diffusion process is very similar to patterns 
seen in other developed countries such as the United States 
and Finland.12 
THE SMALLER PICTURE: ONT ARlO 
While global and national patterns are interesting, 
they can often overshadow important underlying spatial 
variations within smaller regions. 13 This is especially 
evident in Canada due to its sheer size and diversity 
within each region. According to statistics from Health 
Canada, Ontario is the province with the greatest 
number of AIDS cases. This is not surprising as Ontario 
is the largest province in Canada consisting of 
approximately 40% of the population. Within the 
province, it appears as if Toronto was the epicentre. This 
is expected as the city serves as a major international, 
commercial and transportation hub. As well , the 
presence of the country's largest urbanized area contains 
the country's largest gay community. Although these 
characteristics were unlike the occurrences found in the 
United Kingdom, they were similar to those of Helsinki 
and the Finnish experience. 11•14•15 Due to the tremendous 
variation in demographics within the province, 
variations in the spread of the epidemic exist. 
Over a five year span from 1988 to 1993, the spread 
of AIDS moved rapidly in Ontario. Initially, the areas of 
primary infection were in the urbanized areas of Ontario 
particularly Windsor, London, Ottawa, Toronto and the 
rest of the Golden Horseshoe.16 Within Metropolitan 
Toronto, the cases were concentrated within the Central 
Business District, due to the presence of the "gay village". 
Parts of northwestern Ontario were still devoid of any 
cases of AIDS. However, by the end of 1993, a significant 
number of cases appeared in the outlying regions of the 
metropolitan areas. The most updated statistics show 
that even the northwestern regions of Ontario are not 
free of AIDS cases either. 10 
It is interesting to note that although the Central 
Business District of Metropolitan Toronto still has the 
highest cumulative number of cases, the number of new 
cases in this area has actually decreased. In stark 
contrast, the outlying regions have seen tremendous 
increases not only in cumulative cases, but also in 
incidence. This trend appears to be typified by a 
hierarchical diffusion superimposed by an expansion 
diffusion. As the initial wave spread from downtown 
Toronto, it hit other larger cities, appearing to miss 
intermediate locales. However, as the disease 
progressed, outlying regions began to feel the effects. 17 
The possibility also exists that the movement of AIDS to 
the more rural parts of Ontario could be due to migration 
of people diagnosed with AIDS in cities returning to 
their home towns - a relocation diffusion. This pattern 
has been documented in North Carolina and helps to 
explain the rapid diffusion of the disease. 1 
Curiously, the spread of AIDS cases appears to occur 
along an east-west axis within Southern Ontario. This is 
possibly explained by migration patterns and the social 
and family networks in existence in the province similar 
to situations in New York City.19 Vehicular traffic along 
the 401 highway is the busiest in the country with 
Toronto as the centre of the highway system. Everyday, 
over 46 000 people travel into the downtown core from 
the eastern and western areas of the Golden Horseshoe 
by rail alone.20 It appears as if the disease followed the 
network in place to spread to other communities. These 
observations would be in agreement with those found in 
Uganda where the disease spread along its trucking 
routes. 21 ' 22 
Other factors, which may help to explain the initial 
spread of the disease in Toronto, may include the 
behavioural patterns of homosexuals in Toronto. In a 
survey, it was reported that gay men who lived in 
smaller cities were more likely to live in a relationship 
than their counterparts in large metropolitan cities. This 
also correlated with the number of people in 
monogamous relationships.23 Thus homosexuals in the 
urban areas tended to have greater numbers of partners, 
thus facilitating the diffusion of the virus. 
CO NCLUSIO NS 
Geography is a particularly useful tool in medicine, 
especially in helping to elucidate the current epidemic 
with HIV I AIDS. Geography is able to illustrate the 
spatial-temporal variation in patterns of HIV infection 
and AIDS Y As well, it can provide direction for 
researchers and help predict future trends, thus aiding in 
effective deployment of scarce health care resources . 
Lastly, it is able to combine various sources of 
information from various disciplines and synthesize 
more useful information than the parts alone. While the 
current epidemic is disturbing and striking a largely 
ignorant population, intervention programs can help 
stabilize the current infection rate, and perhaps someday 
extinguish this disease. It is obvious that cities play key 
roles in the dissemination of this disease. However, it is 
also obvious that the outlying areas are at the greatest 
risk of becoming infected as HIV makes it way through 
the population. The general trend of HIV infection and 
AIDS cases in Ontario thus appears to be following a 
combination of hierarchical, expansion and contagious 
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diffusion . The purpose of this paper was to perhap 
integrate and synthesize some new ideas in th e 
geography of HIV I AIDS. However, only the "tip of the 
iceberg" has been observed. There is a tremendou 
opportunity for further research . More research in 
Canada can only help bring a better understanding of 
this epidemic, and help parties interested manage the 
progression of this disease more suitably. 
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HIV/AIDS IN THE 
Public awareness of the issue of the Human Immunodeficiency Virus (HIV) in sport grew on ovember 7, 1991 when Earvin "Magic" Johnson 
announced his retirement from professional basketball due to 
his HIV positive status. The statement made by a physician, 
that a Montreal woman had claimed to have slept with "nearly 
50" professional hockey players before she died of AIDS, 
reinforced that high risk behavior outside of the sporting 
context could bring HIV into the sport arena.• Magic Johnson 
was not the first professional athlete known to be HIV 
positive. The death of Jerry Smith, a former Tight End with the 
Washington Redskins, of AIDS in 1987 didn't capture the 
same media attention as Johnson's case.2 The New England 
Journal of Medicine reported a case of a bodybuilder with 
AIDS as early as 1984.3 
Awareness of AIDS in the athletic community continues 
to grow with the stories of Arthur Ashe, Greg Louganis and 
boxer Tommy Morrison who recently returned to the ring. • A 
1992 survey of NCAA institutions reported 8 schools known 
to have HIV infected athletes and 4 schools with athletes 
known to have AIDS, one of whom is still playing. 5 
The majority of official statements have concerned three 
issues: testing of athletes, the participation of HIV positive 
athletes, and the practice of universal precautions by the 
athletic health care team.5 Several groups have published 
guidelines to address these issues. These include the World 
Health Organization (WHO), in association with several 
sports medicine bodies, in 1989. In 1991, The American 
Academy of Pediatrics published guidelines on HIV in the 
athletic setting.6 A comprehensive joint position statement 
entitled Human Immunodeficieny Virus (HIV) and Other 
Blood- Borne Pathogens in Sports, was published by the 
American Medical Society for Sports Medicine and the 
American Academy of Sports Medicine in 1995.7 The 
Canadian Academy of Sports Medicine published its first 
brochure on this issue entitled AIDS and the Athlete in 1989. 
This was replaced by a more current, bilingual document: 
HIV and the Athlete: Question and Answers about AIDS in 
1992.1.8 
The National Basketball Association took the lead among 
professional organizations in taking responsibility to make 
players aware of HIV after the Magic Johnson issues arose.9 
On November 19, 1991, the National Hockey League 
encouraged all league officials to provide HIV testing and 
counseling but no mandatory testing. The ational Football 
League sent letters to all club general managers, presidents 
and trainers on December 5, 1991 regarding HIV. This letter 
stated, "It is important that we all become better informed 
about HIV and AIDS." 
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The consensus reached by all of these groups, athletic or 
medical, is that there is no need for routine testing for athletes, 
no justifiable restrictions due only to HIV infection, and that 
appropriate attention to infection control in training facilities is 
necessary.5 Their concern is related more to off-field risk 
behavior than to risk during competition.9 
Major sports organizations have been supportive of the 
HIV positive athlete and in protecting their athletes from 
infection. They all stress the need for education regarding off-
field risk behaviors as the greatest risk to athletes lies in sexual 
practices and parenteral drug use.7•9 They also advocate the use 
of common sense precautions when dealing with bleeding, 
such as the use of gloves, not reusing towels and bandaging 
wounds. Most sports organizations have permitted unlimited 
time-outs to control bleeding? 
The NFL's HIV I AIDS policy, in effect since July 6, 1992, is 
a good example of what most organizations uphold. The aim 
of their policy is to provide the best possible information to all 
players and staff. Most of the education is on off-field risk 
behaviors. They also advocate no mandatory testing and no 
mandatory disclosure of test results. Policy on disclosure can 
be complicated as some states require the reporting of positive 
test results}0 There is more variance in policies of the CAA 
schools where 33 schools have policies on participation of HIV 
positive athletes. Fifteen schools ban the activity of these 
individuals in some or all sports according to the 1992 survey.' 
There are no data for HIV prevalence in any sport group. 
Using data related to the NCAA age range (18 - 24) we may 
estimate that there are around 216 athletes in the NCAA with 
HIV. Actually, intercollegiate athletes may be at a slightly 
higher risk compared with non- athletic controls due to an 
increased frequency of sexual partners and the decreased use 
of contraception in this population. 
Nor are there any data assessing the risk of HIV 
transmission from athlete to athlete, or from athlete to medical 
personnel. There is only one reported case of an athlete 
contracting HIV during competition. 11 The authors of the 
report claim that a 25-year old Italian soccer player bumped 
heads with an HIV positive player during a game in 1989. This 
player had tested negative for HIV one year earlier. He denied 
any risk behavior and claimed to be in a long-term 
monogamous relationship. This case has been dismissed by the 
medical and sporting communities as invalid.9 This case was 
based on flimsy evidence and there was doubt as to the 
lifestyle of the player. Experts have dismissed the possibility 
that sport was responsible for transmission after reviewing all 
aspects of the case.2 
There has never been a report of HIV transmission from an 
athlete to the training staff. It is estimated that for healthcare 
workers exposed to HIV there is one case of seroconversion for 
every 250 needle stick exposures. This risk increases with 
hollow bore needles. 
Statistically, we can be certain that there are HIV infected 
athletes competing at all levels of sport from high school to 
professional. However, the lack of documented cases is 
significant considering the known prevalence of HIV.7 The risk 
of transmitting the virus, even during contact sport, although 
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not zero, is far too small to quantify. It may be useful to 
compare the risk of contracting illY to that of contracting 
Hepatitis B which is more common and more likely to be 
transmitted during sport. As of 1994, there were only 3 reports 
of Hepatitis B among NFL players.10 All of these infections were 
due to off- field behaviors. The only validated case of Hepatitis 
B transmission during sport was between two high school 
Sumo wrestlers in Japan in 1982.7 
The NFL has actually attempted to quantify the risks of 
mv infection during a game. They es timate this risk to be 
approximately one infection per 85 million game contacts.• This 
is about equal to one infection for every million games. The 
NFL is one of the few organizations that does not necessarily 
interrupt play due to blood.10 There is an average of 4 to 5 
bleeding injuries per game in the NFL Most of these are 
abrasions that do not represent measurable risk. inety percent 
of the body is covered by NFL equipment and uniforms. This 
further reduces the possibility of exchanging blood during a 
game. 
There was a report in 1984 of a bodybuilder with AIDS.3 
This athlete admitted to a 4 year history of sharing needles to 
u e anabolic steroids once per week. He discontinued this 
practice two years previously when he contracted Hepatitis B. 
He denied any other risk factors. This case reinforces that the 
major risk to athletes is in off-field behavior. It is estimated that 
38% of anabolic steroid users inject the steroids parenterally.• 
According to the 1992 survey, 4% of CAA schools have 
routine illY testing within an education program.5 Two of 
these schools have mandatory testing. Seventy-eight percent of 
CAA schools offer no testing through their athletic program. 
The CAA guidelines recommend against mandatory testing. 
HIV testing for those at risk should be accompanied by pre-and 
post-test counseling and an education program. Also, the team 
physician should be aware that the patient 's right to 
confidentiality prevents disclosure of an athlete's test results to 
the rest of the team or training staff. Physicians are advised to 
counsel the HIV positive athlete about transmission and, if the 
athlete participates in a combative sport (i.e. football, wrestling), 
they should strongly suggest an alternate sport choice. 
At the present time there is no medical or public health 
justification for screening of athletes for HIV. The process of 
screening is neither effective nor practical? Such testing would 
have to be done at least every three months. Also, mass 
screening for widespread infections among a low risk group 
leads to a high false positive rate. Although some organizations, 
such as the evada Boxing Commission, require testing of all 
their athletes, this is contrary to the current recommendations. 
The best way to deal with this issue is to educate the athletes 
and then provide testing and counseling for those at risk on a 
voluntary basis. 
Universal Precautions refers to a group of hygienic 
guidelines used in the handling of potentially infectious bodily 
fluids in order to prevent or minimize the transmission of 
pathogens.5 Universal Precautions hould be followed by all 
health care providers. The World Health Organization and 
Center for Disease Control recommend that all skin lesions 
hould be cleaned immediately and covered, gloves should be 
u ed when handling blood, and that participation should 
immediately stop if bleeding occurs. The athlete can return to 
play once the bleeding has stopped and the wound has been 
cleaned and covered . Most leagues will not permit 
participation if blood is on the uniform regardless of the 
source. 
Feature Art i cles 
The 1992 survey showed that 80% of CAA school ' 
athletic departments are familiar with Universal Precautions, 
62% have education programs for their training staff and only 
one quarter of the schools post the Universal Precautions in 
their training rooms. 
The effect of athletic participation on the mv infected 
individual is also a concern. Magic Johnson originally retired 
from the NBA because his doctors believed that the stress of 
training and competing at the professional level may worsen 
the course of his infection. It is now believed that moderate 
exercise can cause an increase in immune system function.2 
Moderate exercise may cause a decrease in the occurrence of 
orne cancers as well as cause an increase in endogenous 
opioids that can also protect immune function. Exercise and 
athletic participation reduces stress and anxiety. Some believe 
that stress and anxiety may open a window of opportunity for 
AIDS to develop. Athletic activity probably does not make HIV 
infection progress to AIDS. It may in fact delay the onset of 
AIDS. Individuals symptomatic with AIDS are usually unable 
to continue playing at a high level of intensity. 
While the risk of contracting HIV during sport is a 
theoretical possibility, the likelihood of this occurring is 
extremely small. Therefore, there are no justifiable grounds for 
involuntary restriction of an HIV positive athlete. The physician 
hould counsel the athlete about the risks of transmitting the 
infection and strongly encourage him or her to choose a low 
risk sport option In all cases the athlete's right to confidentiality 
must be protected. Universal Precautions should be adhered to 
by all athletic and medical staff. All sources acknowledge that 
recommendations will have to be modified if the available 
information changes in such a way as to warrant new 
initiatives. 
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INFECTIOUS SKIN 
MANIFESTATIONS OF HIV 
AND AIDS 
H uman Immunodeficiency Virus (HN) can result in many dermatologic disorders, some of which may be the presenting sign of the disea e. Many of the 
cutaneous disorders that are HN specific, but also some 
common dermatoses, can present atypically when an 
individual is infected with AIDS. Usually, skin conditions 
can be broadly divided into those that are of an infectious 
nature and those that are non-infectious. 
Non-infectious conditions can be further divided into 
neoplastic cutaneous lesions and various eruptions such 
as psoriasis, seborrheic dermatitis, Reiter's syndrome, 
eczema and other dermato es. 
Infectious conditions are the major cause of dea th in 
patients with AIDS.2 These may also be divided into 
several categories. These conditions, and the presentation 
of some of the more commonly seen infections, will be 
concentrated on in the following discussion. 
In an individual who i HN positive, very few T -cells 
in the circulation actually harbour HN( about 1 in 1,000-
10,000); however, a much higher percentage ofT-cells 
(about 1 in 10) and other cells in the lymph nodes ar HN 
infected. 2 This leads to destruction of CD4+ T -cells, 
reduction in their formation, and loss of their normal 
functions .2 Therefore, in individuals who are infected with 
HN, infections of the skin by agents that would normally 
cause only a minimal eruption, will proliferate and thrive 
because of the lack of normal numbers of CD4 helper T-
lymphocytes.1 The steady drop in the CD4 counts of HN 
patients causes multiple interrelated malfunctions of both 
the humoral and the cellular branches of the immune 
system.3 The infectious skin manifestations that may occur 
fall largely under three headings: Bacterial, Viral, and 
Fungal and Yeast. Physicians should be aware of specific 
eruptions of HN, as well as of the increase in incidence of 
some more common dermatologic conditions which may 
have an atypical presentation. Recognition of these may 
lead not only to a diagnosis but also to more timely 
treatment. 
BACTERIAL INFECfiONS 
Staphylococcus Aureus 
The most common organism causing cutaneou and 
systemic infection is 5. Aureus.• This is attributable (i) to 
the fact that the nares can be colonized by the organism 
(ii) to subsequent skin infections which are due to lack of 
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normal immune defenses (iii) to the high frequency of 
eczematoid dermatoses, and (iv) the regularity of 
indwelling catheters in many of these patients.1 5. aureus 
usually occurs in the form of impetigo, cellulitis or 
folliculitis .5 Fortunately, therapy with appropriate 
antibiotics is usually curative.1 
Syphilis 
Syphilis seems to be on the rise in North America . 
The lesions usually develop in a similar manner to those 
in HN negative persons, but may have an altered course.1 
The presence of ulcerating genital lesions is not only 
painful, but also eases the spread of HN after exposure to 
an infected partner. 6 Treatment of syphilis may be 
difficult, and increased doses of drugs may be required. 
VIRAL INFECfiO NS 
Herpes Simplex 
This viral infection occurs in about 20% of AIDS 
patients, usually as an ulcer a t the perianal or perioral 
mucocutaneous junction.6 It may also present as a 
blistering or bullous disease, or resemble impetigo.6 As 
defenses become impaired, herpes simplex becomes 
chronic. In the past, chronic Herpes simples virus was 
used as a marker for suspicion of underlying HN. Most 
strains respond well to acyclovir, although resistant 
strains that require combination therapy have also been 
found. 7 
Varicella Zoster 
Thi s infec tion is normally more severe and 
widespread in HIV infected patients than is herpes 
simplex. 6 Cutaneous lesions occur due to a lack of 
suppression of latent infection of dorsal root ganglia by 
the virus. The virus becomes reactivated by depression of 
cell mediated immunity, and this allows the virus to move 
along a dermatome and cause an eruption of clustered 
vesicles on an erythematous base.1 The possibility of 
systemic involvement must also be remembered in 
varicella zoster infected patients.8 Treatment is usually 
acyclovir, or a combination of acyclovir with foscarnet 
and other drugs.5 
FUNGAL AND YEAST INFECfiONS 
Candidiasis 
Oral candidasis is an important cutaneous 
manifestation of HIV disease, and is often used to 
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diagnose AIDS in a person w ith no other cause of 
immunodeficiency.1 Mucosal candidiasis occurs in most 
HIV infected persons during their illness, and can be 
persistent and may cause d ysphagia .7 Commonly it 
produces white pseudomembranous plaques on the 
mucosa .9 Treatment is instituted when the lesions are 
symptomatic, and consists of good hygiene and topicals 
such as nystatin or systemic treatment with ketoconazole 
or fluconazole.1 
DERMATOPHYTOSIS 
Infection with dermatophytes occurs in about 20% of 
patients with HIV infection.1 The infection is more severe 
than in non-immunosuppressed individuals. Well defined 
erythematous lesions with scaling are typical, although 
unusual presentations such as tinea faciale have also been 
reported .1 Dermatophytosis is usually treated with 
ketoconazole given with a carbonated cola beverage for 
acidity. This is the more commonly used treatment since 
ketoconazole also eradicates candida. Topicals can also be 
used for localized infections. 1 
Many individuals with HIV will develop cutaneous 
manifestations of their disease. Skin changes may be the 
first signs to alert a physician to a diagnosis of HIV or 
AIDS. Changes in the skin can alert the doctor to further 
deterioration in the patient's immunocompetence. 
Knowledge of the numerous cutaneous disorders that 
exist in individuals with HIV I AIDS are of great 
importance in lessening morbidity, and prolonging life . 
. ; .: :~ 
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UNDERSTANDING THE ROLE OF 
CHEMOKINE RECEPTORS IN HIV 
INFECTION 
Shortly after the identification of HIV as the agent responsible for AIDS, researchers were able to demonstrate that the T-cell CD4 surface molecule 
served as a receptor for HIV. Subsequent work, however, 
showed that murine cells transfected with the human CD4 
gene were not susceptible to virus entry, thus revealing 
that while CD4 was necessary for incorporation of the 
virus into host cells, it was not sufficient on its own. • More 
recent studies have identified chemokine receptors, 
namely fusin and CCRS, as co-receptors for the en elope 
glycoprotein (Env) of HIV.•.2.3.•.s 
Seminal work by Fiorenza Cocchi and co-workers 
gave the first indication that chemokine receptor may be 
involved.• Culture supernatants containing an activated 
CDB+ T-cell clone were shown to inhibit HIV replication, 
as manifested by a decrease in HIV -1 p24 (an HIV 
structural protein) production in the supernatant. Cocchi 
isolated various proteins secreted by the T-cell clone and 
identified them, via direct sequencing of various peptide 
fragments derived from the secreted proteins, as the b-
chemokines RANTES, MIP-1a and MIP-1b, which function 
in the body as chemoattractants for the body's leukocytes, 
which direct them to sites of infection. Treatment of the 
supernatants with antibodies to RA TES, MIP-1a and 
MIP-1b resulted in p24 levels comparable to tho e found 
in supernatants devoid of CDB+ lymphocytes, thus 
identifying these chemokines as HIV-suppressive factors. 
However, it was discovered that certain strains of HIV 
were not sensitive to this suppression. In particular, it 
was noted that those strains of HIV which preferentially 
infected CD4+ macrophages (macrophage-tropic strains) 
were susceptible to b-chemokine-mediated suppre sion 
whereas other strains of the virus, which preferentially 
infected transformed T -cells (T -tropic strains), were 
unaffected by these chemokines.• Becau e macrophage-
tropic and T-tropic strains of HIV were thought to differ 
only in the Env portion of the HIV genome/ there was 
speculation that the observed HIV-suppressive effects of 
the b-chemokines came at the level of viral entry into the 
host cell! That is, that b-chemokines interfered with fusion 
of the viral glycoprotein envelope with the ho t cell 
membrane. 
Subsequent studies by Deng et al. showed that this 
indeed was the case. They employed a modified strain of 
HIV -1, known as a lucile rase reporter virus, in which a 
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frameshift mutation had been introduced into the Env 
gene. While the modified virus was fully capable of 
infecting cells, the mutated Env gene ensured that further 
replication of the virus would not be possible, thus 
allowing researchers to quantitatively assess HIV-1 entry 
into target cells by measuring luciferase activity in the 
cells following exposure to HIV. Using this assay system, 
Deng et al. demonstrated conclusively that RANTES, MIP-
1a and MIP-1b inhibited infection of target T-cells by 
macrophage-tropic HIV, further implicating chemokine 
receptors in the HIV infection process. At this point it 
appeared likely that such receptors act as co-receptors for 
HIV.t 
Several labs employed various methods to identify 
possible co-receptor candidates. In one approach, human 
embryonic kidney cells were co-transfected with CD4 and 
one of several b-chemokine receptors and then challenged 
with the HIV-1 based luciferase reporter virus described 
earlier! It was discovered that cells transfected with CCRS 
became susceptible to infection by macrophage-tropic HIV 
strains, which was not the case for cells transfected with 
any other chemokine receptor. Furthermore, cells 
transfected with only the CCRS gene were resistant to 
infection, indicating a co-operative mediation of viral 
entry by both CCRS and CD4. A separate study by 
Alkhatib et al. utilized cells expressing the lacZ gene of 
Escherichia coli. Cells containing the lacZ gene and 
expressing the HIV Env gene were mixed with murine 
cells co-transfected with CD4 and CCRS. The lacZ gene 
was integrated in such a way that fusion of the two cells 
would result in the production of b-galactosidase.3 As 
predicted, fusion only occurred between Env-expressing 
cells and murine cells expressing both CD4 and CCRS. 
Similar fusion studies were extended by Dragic and co-
workers, who were able to successfully block fusion 
between Env-expressing cells and cells containing CD4 
and CCRS by adding RANTES, MIP-1a and MIP-1b to the 
cell cultures. However, they found that if a certain amount 
of time elapsed before the chemokines were added to the 
culture, then fusion could not be blocked. This evidence, 
they thought, was suggestive of a competitive mechanism 
of inhibition of HIV .2 The latter observation was 
presumably due to an overexpression of CCRS, which 
then negated the inhibitory effect of the chemokines. 
Thus, in the span of a few months, it was proven that 
CCRS was the co-receptor for macrophage-tropic HIV. 
Meanwhile, parallel studies sought to identify the co-
receptor used by T-tropic HIV in gaining entry into host 
cells. Fusion experiments were performed where the CD4-
expressing cells were transfected with a whole cO A 
library derived from a human cell line ! Repeated 
subfractionation and screening allowed the investigators to 
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isolate the co-receptor on a single 1.7 kb cO A insert. This 
insert contained an open reading frame encoding a protein 
352 amino acids in length. Analysis of the nucleotide 
equence revealed that this protein was a member of the 
superfamily of G protein-coupled receptors with seven 
transmembrane segments, the same family to which all 
chemokine receptors belong. Termed 'fusin', this new 
protein was found to serve as a co-receptor for T -tropic 
HIV in much the same way that CCRS mediated 
macrophage-tropic HIV infection. A stromal cell-derived 
chemokine was eventually identified as a ligand for this 
newly characterized co-receptor, and interestingly enough, 
it was also found to have an inhibitory effect on T-tropic 
HIV infection of T-cells.7 
A puzzling observation that surfaced amidst all the 
work on AIDS in recent years was the observation that 
amongst cohorts of individuals with extensive exposure to 
HIV, there existed a tiny subset of persons who remained 
seronegative for the virus. Shortly after its discovery as an 
HIV co-receptor, investigators looked to determine if CCRS 
would provide a clue. A team led by Michael Dean was 
able to map the CCRS locus to chromosome 3p2I.B Using 
complex molecular techniques, the CCRS loci of more than 
600 individuals from cohorts of various risk groups for 
AIDS were screened for genetic variants of the CCRS gene. 
One such variant was detected in 10% of all screened 
individuals and was characterized by a 32-base pair 
deletion mutation, resulting in a receptor which lacked 
three transmembrane segments, including the region 
involved in G-protein coupling.8•9 one of the individuals 
homozygous for the defective gene showed any obvious 
phenotype and all such individuals were seronegative for 
HIV despite having been exposed to the virus.8• 9•10 o 
seropositive individuals were found to be homozygous for 
this deletion, suggesting that perhaps a defective CCRS 
protein was responsible for conferring immunity to HIV. In 
a separate study, Liu and co-workers discovered two 
seronegative individuals who were both homozygous for 
the 32-base pair deletion and whose white blood cells were 
extremely resistant to macrophage-tropic HIV infection, 
and sought to investigate this immunity to HIV at the 
molecular level. 10 The gene encoding CCRS in these two 
individuals was transfected into CD4-expressing cells and 
then assessed for ability to either fuse with Env-expressing 
cells, or permit infection by the luciferase reporter virus. 
The mutated CCRS protein was capable of supporting 
neither cell fusion nor infection by HIV. To determine 
whether defective CCRS was expressed at the cell surface, 
the gene was tagged with hemagglutinin prior to 
transfection. Subsequent probing of the transfected cells 
with fluorescing anti-hemagglutinin antibodies revealed 
that the defective molecule was not e-xpressed at the cell 
surface. These findings provided the molecular basis for 
immunity of certain individuals to HIV. A point of interest 
was the finding that white blood cells from an HIV-
resistant individual were shown to secrete ten times the 
normal amount of b-chemokines. This suggested another 
resistance mechanism, whereby an excessive amount of 
chemokines inhibits CCRS binding to HIV Env, either by 
desensitizing the co-receptor through over-stimulation of 
the receptor or by competitive inhibition. More recent 
work has disproved the former possibility. Using pertussis 
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toxin to arrest chemokine-mediated receptor signalling, 
researchers were still able to observe the same degree of 
HIV inhibition by the b-chemokines as that observed in 
earlier studies. 11 
Another point of interest was that while leukocytes 
derived from individuals homozygous for the 32-base pair 
deletion are known to be highly resistant to macrophage-
tropic HIV, it had been shown that the same leukocytes 
were susceptible to T -tropic HIV infection. 2 This 
observation was explained by the theory that macrophage-
tropic HIV is the dominant form of HIV in asymptomatic 
HIV-infected individuals.9 Following initial infection, it is 
believed that the macrophage-tropic strain then evolves 
into a T-tropic strain of HIV.12 This presumably correlates 
with the gradual loss of CD4+ T-cells and the onset of 
AIDS-related symptoms in the individual. Because the 
macrophage-tropic HIV cannot undergo replication in 
resistant individuals, the switch to a T-tropic strain never 
occurs and the individual remains uninfected. Support for 
this theory came with the discovery of a dual-tropic strain 
of HIV which has a demonstrated ability to use either 
CCRS or fusin as a co-receptor. 12 This dual-tropic strain 
would take its place in the hypothesis as a transitory strain 
of HIV which would appear temporarily during the 
evolutionary process. Such speculative insights, however, 
await to be firmly proven or disproven. 
With convincing evidence that fusin and CCRS served 
as co-receptors for HIV in hand, researchers began to work 
out the specific details regarding the nature of the HIV-
chemokine receptor interaction. Using various HIV 
chimeric constructs, researchers were able to ascribe 
susceptibility to chemokine-mediated inhibition of 
infection to the V3 loop domain of gp120. 11 Analogous 
studies involving chimeric constructs of the chemokine 
receptor itself has allowed investigators to further 
characterize the structural determinants of HIV-chemokine 
receptor binding.13 Another area of related interest is the 
development of chemokine analogues as possible 
candidates for anti-viral therapy. One such analogue is a 
derivative of RANTES with a slight modification at the 
amino terminus. 14 This analogue, named 
aminooxypentane- or AOP-RANTES, has been shown to 
lack any chemotactic or leukocyte-activating activities 
while retaining a marked HIV-inhibitory effect. 
While much of the work in this area of AIDS research 
is promising, one must be cautious as well. In recent 
months, several groups have claimed to identify other 
co-receptors for HIV and SIV, thus confounding the HIV 
infection story somewhat.15 The presence of multiple co-
receptors, each one ready to do HIV's bidding, would 
make the development of an effective anti-viral 
compound very difficult indeed. Nonetheless, in light of 
the considerable amount of progress made in the 
research of HIV co-receptors, there is reason to remain 
optimistic. The struggle towards a more complete 
understanding of HIV infection has, in the past two or 
three years, led us on a rapid and exciting journey of 
discovery. Uncovering the secrets of the HIV co-receptor 
and further characterization of its role in the entry of HIV 
into host cells has already begun, and will continue to 
yield valuable insights into the treatment and possible 
prevention of HIV infection. 
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OCULAR MANIFESTATIONS OF AIDS 
Since its discovery almost 16 years ago, acq~ired immunodeficiency syndrome (AIDS) has qUickly developed into a major public health concer_n 
worldwide . It represents the end-stage of a systemtc 
infection triggered by Human Immunodeficiency Virus 
(HIV). This infection essentially cripples the immune sys_tem 
leaving the host prone to the develop?'ent o~ multiple 
opportunistic infections and / or mah?nanCles . Such 
complications have both shortened the life_ span of AII?S 
patients, and also severely affected the quality of what_ life 
they have left. With the advent of new ~easur~s to fi?ht 
AIDS/ HIV such as improved prophylaXIs, antiretro~u~l 
drugs, and more effective treatment of oppo_rtumshc 
infections, the expected life span of AIDS pahe':ts _has 
steadily risen. As a result, those AIDS-related complications 
which arise relatively late in the progression of AIDS are 
beginning to be seen at greater frequ~.ncies. 1 Oc':lla~ 
manifestations are an example of these late-bloommg 
complications experiencing an increase in incidence due to 
the extended life expectancy of AIDS patients. Su~ ocular 
afflictions of AIDS were first noted by Holland et al. m 1982, 
and today it is estimated that over 70% of _ratie~ts with 
AIDS will develop some sort of ocular manifestation, and 
90% will have ocular disease at autopsy.2 According to their 
respective etiology and course, these complications ~an be 
grouped into four main categories: microvascular diseas~, 
opportunistic infections, neoplasms, and neuro-oph~almic 
manifestations. The purpose of this review is to provtde the 
medical student with a brief, systematic overview of such 
manifestations and possible treatments. It is through 
effective diagnosis and management that vision loss can be 
circumvented, thus enhancing the quality of life for patients 
suffering from AIDS. 
MICROVASCULAR DISEASE 
Retinal microvasculopathy (RM) is the most common 
ocular manifestation of AIDS with between 40 - 60% of 
patients affected.3 The hallmark of this disease process is the 
presence of cotton wool spots (CWS) on retinal examination 
(HGURE 1). These appear as fluffy white lesions identical to 
those seen in hypertension, diabetes, and cytomegalovirus 
(CMV) retinitis (see later). They represent nerve fiber layer 
infarcts which arise due to focal occlusions of the retinal 
capillaries. In addition to cotton wool spots, RM may 
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FIG URE 1. HIV retinopathy is characterized by the presence of multiple 
cotton wool spots. 
manifest itself as intraretinal hemorrhages, microaneurysms, 
and Roth spots (retinal hemorrhages with a white center) . . 
The etiology of RM remains unknown. Some .theones 
put forward to explain this phenomenon mclu~e 
microvascular occlusion due to either immunoglobm 
deposition or hyperviscosity. Alternatively, se~ond~ry 
swelling and microvascular obstruction due to HIV infection 
of endothelial cells may also be to blame. 
It is important as clinicians to be able to distinguish 
between the cotton wool spots seen with RM and those seen 
with CMV retinitis. The main difference is that unlike CMV 
retinitis, the cotton wool spots due to microvasculopathy are 
not due to a direct infection of the retina. Therefore, RM 
cotton wool spots cause little alteration in vision and resolve 
spontaneously over a course of six to eight weeks ~thout 
treatment. CMV retinitis , on the other hand, 1s best 
characterized as a progressive lesion which, if left untreated, 
invariably and very quickly causes blindness. The poss~b~ty 
of such differing results, stemming from the same rmtial 
symptom, conveys the importance in following up any 
AIDS patients presenting with cotton wool spots. 
OPPORTUNISTIC INFECTIONS 
Many organisms are able to take advantage of the 
immunocompromised state of AIDS patients and t~en 
manifest themselves in ocular lesions. They may be vual, 
bacterial, parasitic, or fungal. 
VIRAL INFECTION 
Herpes zoster ophthalmicus 
Herpes zoster ophthalmicus (HZO) is aD A virus that 
elicits a characteristic vesicular rash in the region of the 
ophthalmic division of the trigeminal nerve. Swollen 
eyelids, conjunctivitis, and keratitis (inflammation of the 
cornea) may also be associated with this disease. Although 
HZO is not considered an AIDS defining illness, it may be 
the initial sign of a HIV infection and any individual under 
the age of 50 who presents with HZO should be suspected 
of harboring HIV.4 Treatment usually involves oral 
acyclovir, a synthetic purine nucleoside with selective 
activity against herpes virus infections. 
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Cytomegalovirus 
Cytomegalovirus (CMV) is another example of a virus 
capable of producing ocular lesions in AIDS patients. The 
lesion is commonly retinitis and is the most common 
intraocular infection associated with AIDS.2 With more than 
25% of AIDS patients succumbing to blindness due to CMV 
retinitis, it is also the leading cause of blindness within this 
sub-population.5 CMV retinitis also tends to be a rather late 
manifestation of AIDS and hence survival after initial 
diagnosis is only 8-12 months.6 
As mentioned earlier, the initial lesions of CMV retinitis 
appear as cotton wool spots on ophthalmoscopic exam. The 
difference between these CWS and those seen with retinal 
microvasculopathy is that these spread rapidly over a 1-2 
week period to produce a retina characterized by white 
fluffy retinal necrosis with hemorrhages and vasculitis 
(FIGURE 2). These diseased portions of the retina have 
distinct borders which abruptly meet areas of normal retina. 
This m<\Y lead to retinal detachment further complicating 
the clinical picture for the patient. 
Cmrently approved medications for CMV retinitis are 
gancydovir and / or foscarnet. Since neither of these agents 
are able to eliminate the virus, treatment must be continued 
for the lifetime of the patient. Gancyclovir is a guanine 
analogue which inhibits viral D A replication and 
forscarnet is a pyrophosphate analogue which inhibits CMV 
DNA polymerase. For maximum effectiveness, these drugs 
should be given at a high induction dose for 2-3 weeks, 
followed by a lower maintenance dose which is kept unless 
the retinitis flares up again. 
Molluscum contagiosum 
Molluscum contagiosum is caused by a D A po virus 
and commonly presents as raised eyelid lesion with 
umbilicated centers. It may also be associated with a 
chronic, low grade conjunctivitis. Treatment option involve 
excision, curettage, or cryotherapy. Given the 
immunocompromised state of AIDS patients, molluscum 
contagiosum tends to behave very aggressively leaving 
larger and more numerous lesions than usually seen in the 
endemic population. 
BACTERIAL INFECTION 
Syphilis 
Syphilis is a chronic infectious disease caused by the 
bacterium Treponema pallidum. If left untreated, syphilis 
will gradually progress through primary, secondary, and 
tertiary s tages of pathology, each of which may have 
ophthalmic manifestations. Primary syphilis may display 
chancre of the eyelids and conjunctiva. Secondary syphilis 
can exhibit a wide varie ty of complications including 
conjunctivitis, scleritis, interstitial keratitis, anterior 
uveitis, and papillitis (inflammation of the optic papilla). 
The third stage of this condition may display cranial nerve 
palsies, ptosis, optic atrophy, and for neurosyphili , the 
Argyll Robertson pupil (pupil reacts to accommodation 
but not light). 
A recent resurgence of syphilis in AIDS patients has 
been noted7, and like other infectious agents, syphilis 
follows a more aggressive course in AIDS patients. High 
dose IV penicillin G has been found to be effective in the 
treatment of both syphilis and neurosyphilis.7 
FIGURE 2. Typical feahlres of CMV retinitis. The retinitis is characterized by 
a discrete, fluffy, white retinal necrosis, with retinal hemorrhages and 
vasculitis. There is a sharp, distinct border betweer1 the diseased and normal 
retina. 
PARASITIC INFECTION 
Ocular Toxoplasmosis 
Toxoplasma gondii is a protozoan that commonly 
infects mammals and birds throughout the world. T. 
gondii infection in humans is usually asymptomatic, but in 
cases where the patient is in an immuno-compromised 
state such as AIDS, infection can be exceedingly 
progressive and fatal if left untreated. Ocular 
complications of such an infection include vitritis where 
the vitreous humor appears hazy. Retinal lesions may also 
be present and appear as white infiltrates which become 
pigmented scar when the initial inflammation subsides. 
T. gondii may also adversely affect the choroid. 
Definitive diagnosis of toxoplasmosis in AIDS patients 
essentially relies on histological s tudies, isolating the 
parasite, and/or isolating T. gondii D A from lesion sites. 
Drugs available to treat ocular toxoplasmosis are 
pyrimethamine, sulphadizine, and clindamycin. 
Fungal Infection 
Fungal complications are very common in AIDS, but 
ocular involvement is relatively rare. Candida albicans 
commonly infects the gastrointestina l tract of 
immunocompromised patients and may also afflict the eye. 
The typical Candida lesion consists of a fluffy white-yellow 
superficial retinal infiltrate. This may lead to the 
development of an overlying vitreous haze and ultimately 
vi tritis. Treatment involves systemic therapy with 
amphotericin B. 
NEOPLASMS 
Kaposi's Sarcoma 
Kaposi's sarcoma is a disease characterized by multiple 
vascular skin malignancies. It may present as a multifocal 
lesion with manifestations within the ocular adnexae 
(eyelids and orbit); or anterior segment (conjunctiva, cornea, 
iris) of the eye in addition to visceral invol ement. Within 
the adnexae, flat or slightly-raised purple papules may be 
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FIGURE 3. Kaposi's sarcoma of the conjunctiva resembles a subconjunctival 
hemorrhage. 
visible on the eyelid. The orbit may also be involved, giving 
rise to proptosis (forward displacement of the eye) and 
double vision. 
The effect of Kaposi's sarcoma on the anterior segment 
of the eye is usually limited to either the palpebral or bulbar 
conjunctiva. This commonly presents as a reddish plaque 
localized in the conjunctiva of the lower fornix (FIGURE 3) 
and may be misdiagnosed as a subconjunctival hemorrhage 
or a hemangioma. 
Treatment of Kaposi's sarcoma involves excision of the 
lesion, use of chemotherapeutic agents such as vinca 
alkaloids, daunorubicin, and bleomycin, or radiation. If the 
Kaposi's sarcoma is multifocal, systemic chemotherapy may 
then be the only viable option. 
NEURO-OPHTHALMIC MANIFESTATIONS 
Over 39% of AIDS patients uffer from some form of 
intracranial disease.7 This may arise from neoplasms such as 
non-Hodgkin's lymphoma or Kaposi's sarcoma, 
opportunistic infections causing encephalitis or meningitis, 
or cerebral ab cesses. As a result of such lesions, patients 
may present with ocular manifestations of increased 
intracranial pressure and/ or inflammatory or neoplastic 
neuropathy. Initially, these may include double vision or 
pupillary abnormalities. With time these may progress to 
more serious neuro-ophthalmic manifestations such as 
cranial nerve palsies, papilloedema, optic atrophy, gaze 
palsies, and visual field defects. Treatment of such neuro-
ophthalmic manifestions largely depends on the correction 
of the initiating factor of the ocular alterations as well as 
symptomatic relief. 
CONCLUSION 
In summary, a multitude of distinctive ocular 
manifestations may appear in AIDS patients. The most 
common complication is retinal microvasculopathy, 
whereas opportunistic infections like CMV retinitis pose the 
greatest threat to vision. With the improved survival rates of 
AIDS patient , these ocular afflictions and other "late-
blooming" AIDS complications will be seen at greater 
frequencies. It is important to recognize and treat these 
complications as our job in the treatment of AIDS is not only 
to extend the life of patients afflicted with AIDS but to also 
improve the quality of what life they have left. 
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NAME OF DRUG 
ZfTlfROMAX 
(azithromycin dihydr.~te) 
• Capsules 250 mg USP 
• Tablets 2SO mg 
• Tablets 600 mg 
• Powder for Or.ll Suspension 100 mg/S ml and 200 mg/ S ml 
• Single Dose 1 g Packet 
TliERAPEUTIC CLASSIFICATION 
Antibiotic 
INDICATIONS AND CUNICAL USES 
TREATMENT 
ZfTlfROMAX (azithromycin dihydnote) is indicated for lreatment ol mild to moderate infections 
caused by susceptible str.lins ol the designated microorganisms in the following diseases and specifoc 
conditions. As recommended dosages, dur.~tions ol therapy, and applicable patient populations vary 
among these infections, see DOSAGE AND ADMINISTRATION for specific dosing recommendations. 
ADULTS 
Upper Respiratory Tract 
Pharyngitis and tonsilfotis caused by Stnptococcus ~ (group A 6-hemolytic streptococo) occuring 
in individuals who cannot use firn-line therapy. 
NOTE: Penicillin is the usual drug ol choice in the lreatment ol S. ~ pharyngitis, including the 
prophylaxis ol meumatic lever. ZfTlfROMAX is often effective in the en>dication ol susceptible str.lins 
ol slreptococci from the oropharynx. However, data establishing the ellicacy of ZITHROMAX in the 
subsequent prevention of meumatic fever are not available at presenL 
lower Respiratory Tract 
Acute bacterial exacerbations ol chronic ol>structNe pu1monaty diseases caused by lloemoptM ~ 
MorrluJio cotorrholis. or Strq>tococcus pneurriOfliOe. Community-.Kquired pneumonia caused by 
S. ~. H. inllumzoe. Mycupjosmo pneutTIOflitN or Chlamydia~ in patients for whom 
oral therapy is appropriate. 
Skin and Skin Structure 
Uncomplicated skin and skin structure infections caused by Stap/Jyjococcus oureus, S. ~ or 
Strq>tococcus ~-
Genitourin..-y Tract 
Urethritis and cervicitis due to Neisseria goncxrt>o«Je or Chlamydia trochomotis. Genital ulcer disease in 
men due to Hoemophilus ducreyi (chancroid). Due to the small number ol women included in clinical 
trials, the effocacy of azithromycin in the lreatment of chancroid in women has not been established. 
Patients should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at 
the time ol diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should 
be initiated if infection is confirmed. 
Appropriate culture and susceptibility tests should be initiated before treatment to determine the 
causative organism and its susceptibility to azithromycin. Therapy with ZfTlfROMAX may be initiated 
before results of these tests are known; O<OCe the results become available, antibiotic lreatment should 
be adjusted accordingly. 
PREVENTION OF DISSEMINATED MYCOBACTERIUM AVIUM COMPLEX (MAQ DISEASE 
ZITHROMAX, uken at a dose of 1200 mg weekly, alone or in combination with rifabutin at its 
approved dose, is indicated for the prevention ol disseminated Myroboctmum <Mum complex (MAQ 
disease in penons with advanced HIV infections. 
TREATMENT 
CHILDREN (see DOSAGE AND ADMINISTRATION; Use In Children, PRECAUTIONS section) 
Acute otitis media caused by H. intiJenzoe (JHactamase positive and negative Str.liru), M. rotorrl>olis or 
S. ~- (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION section.) 
Pharyngitis and tonsillitis caused by S. ~ (group A ~hemolytic streptococci) occuring in 
individuals who cannot use firn-line therapy. (For specifoc dosage recommendation, see DOSAGE 
AND ADMINISTRATION section.) 
NOTE: Penicillin is the usual drug of choice in the lreatment ol S. ~ pharyngitis, including the 
prophylaxis of rheumatic fever. ZfTlfROMAX is often effective in the eradication of susceptible str.lins 
ol streptococci from the oropharynx. However, dau establishing the elfocacy of ZJTMROMAX in the 
subsequent prevention of meumatic fever are not available at presenL 
~ pneunonia caused by H. ~ S. pt1tiii10tliot. M. pna.moniot or C pna.moniot. 
(For specifiC dosage recommendation, see DOSAGE AND ADMINISTRATION section.) 
Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for 
outpatient oral therapy because ol moderate to severe illness. 
Safety and e!fec!M!ness for pneumonia due to H. inlluenzoe and S. ~ we-e not documented 
bacteriologically in the pediatric clinical trial due to diffoculty in obuining specimens. Use ol 
azithrornycin for these two microorganisms is supported, however, by evidence from adequate and 
weli<ontroUed studies in adults. 
CONTRAINDICATIONS 
ZITHROMAX (azithromycin dihydrate) is contr.lindicated in patients with known hypersensitivity to 
azithromycin, erythromycin, or other macrolide antibacterial agents. 
WARNINGS 
Ra re serious allergic reactions, including angioedema and anaphylaxis (with r.1re reports of fatalities) 
have been A!pOrted i-l patients on Zl1liROMAX (azillwomydn clihydratr) lherapy (see CONTRAINOICATIONS 
section). Allergic reactions may occur during and soon after lreatment with ZITHROMAX. Despite 
initially succ...tul symptomatic treatment ol the allergic symptoms, when symptomatic therapy was 
discontinued, the allergic symptoms recurred soon thereafter in some patients without further 
azithromycin exposure. These patients required prolonged periods ol observation and symptomatic 
treatmenL ~ an allergic reaction occurs, the drug should be discontinued and appropriate therapy 
should be instituted. Physicians should be aware that reappear.~nce ol the allergic symptoms may 
occur when symptomatic therapy is discontinued. 
In the treatment of pneumonia, azithromycin has only been shown to be safe and effective in the 
lreatment of community-.Kquired pneumonia due to C pMUmonioe, H. inlluenzoe, M. pnet.manioe, or 
S. pneumonioe in patients appropriate for oral therapy. Azithromycin should not be used in patients 
with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe 
~lness or risk factors such as arry ol the following: patients with cystic fibrosis, patients with noscocomialy 
acquired infections, patients with known or suspecled bacteremia, patients requiring hospitaliution, 
elderly or debilitated patients, or patient> with signifiGint underlying health problems that may comprornise 
their ability to respond to their illness (including immunodefociency or functional asplenia). 
P>eudomemlnnous colitis has been reported with nearly an antibacterial agents including ZJTMROMAX 
and may r.~nge in severity from mid to life-threatening. Therefore, it is imporunt to consider this 
diagnosis in patients who present with diarrhea subsequent to the administr.ltion of antibacterial 
agents. Treatment with antibacterial agents alters the normal flora ol the colon and may permit 
overgrowth of clostridia. Studies indicate that a toxin produced by Oostrid"tUm diffidk is a primary 
cause ol "antibiotic-<WO<iated colitis". After the diagnosis of pseudomembranous colitis has been 
esublished, therapeutic measures should be initiated. Mild cases ol pseudomembranous colitis usually 
respond to discontinuation ol the drug alone. In moderate to severe cases, consideration should be 
given to management with fluids and electrolytes, protein supplementation, and treatment with an 
antibacterial drug dinically effective against OoSIIidium diff/Cile. 
In lhe absence d data on lhe metaboism and pharmacokinetic i-l patients with lysosomal ipid storage diseases 
(e.g.. Tay-Sadls <isease, ~ disease) lhe used ZJTHROMAX in these patients ~ not ltcO I I I tel ded. 
PRECAUTIONS 
General; 
Siroce liver is the major route of elimination lor ZfTlfROMAX (azithromycin dihydrate), the use of 
ZfTlfROMAX should be underuken with caution in patients with signifocant hepatic disease. 
No dose adjustment is needed in patients with mild renal impairment (creatinine clear.~nce > -40 ml/min), 
but there are no data regar<ftng ZfTlfROMAX usage in patients with more severe renal impairmenL 
Thus caution should be exercised before prescribing ZfTlfROMAX in these patients. 
The following adverse events have been reported with macrolide products: ventricular arrllythmias, 
including ventricular tachycardia and tor><J<kl rk poinres. in individuals with prolonged QT intervals. 
Although these adverse events have not been reported in clinical trials with azithromycin, one AIDS 
patient dosed at 750 mg to 1 g daily experienced prolonged QT interval and tor><J<kl rk pointes. 
Use In Pnegnancy: 
Animal studies have demonstrated that azithromycin crosses the placenu. Safety ol ZITHROMAX 
for use in human pregnancy has not been esublished. 
Use In Nursing Mothers: 
There are no data on secretion in breast milk. Safety of ZrTHROMAX for use in human lactation has 
not been established. 
Use In Children: 
Acute Otitis Meda or Cornrn.nity-Acqed Pnelrnonia: Safety and efficacy ol ZJTHROMAX in lhe treatment 
ol children with acute otitis media or corntnLnity-«quired pneumonia (dosage regimen: 10 mg/kg on day 
1 followed by S mg/kg on days 2-5) under 6 months ol age have not been established. 
Pharyngitis and tonsilitis: Safety and ellicacy d ZJTMROMAX in the treatment d children with phatyngitis 
and tonsilitis (dosage regimen: 12 mg/kg on days 1-S) under 2 years ol age have not been established. 
Slides evaluating the use ol repeated counes ol thenopy have not been conducted. Safety dab with 
the use ol ZJTHROMAX at doses higher than proposed and lor dlnlions longer than reooo101oetlded 
are lmited to a smal numl>er ol irnrnurwxomprom c:hlldren who I.Olderwent chronic: treatment. 
In animal studies, treatment w;th azithromycin is associated with accumulation in various tissues, 
including the extr.t<ranial neur.~l ganglia ~ .e. , retina and sympathetic nervous system). Tissue 
accumulation is both dose and time dependent. and is associated microscopicaly with the development 
of phospholipidosis ~ntr.l-iysosomal drug phospholipid complexes). The only evideroce in animals 
that azithromycin is associated with alterations of intracellular phospholipid meubolism has been the 
documentation of small increases in phospholipid content after prolonged lreatment (6 months) or 
exaggerated doses. Phospholipidosis has been observed at total cumulative doses only 2 multiples of 
the clinical dose. One month alter withdr.~wal of treatment the cO<OCentr.ltion of azithromycin and 
the presence of phospholipidosis in tissue, including the retina, is at or near predose levels. 
No data C!Xist in humans in regard to the extent of accumulation, duration ol exposure, metabc:>'ism 
or excretory mechanisms of azithromycin in neural tissue such as the retina and the cochtea. 
Rare cases ol hearing loss have been reported (see ADVERSE REACTIONS section). 
No data are available on the metabolism and pharrnacolunetics of azithromycin in children with 
lysosomal lipid storage diseases (see WARNINGS section). 
Prevention of Disseminated Mycobacterium Allium Complex (MAQ Disease: 
Safety and ellicacy ol ZfTlfROMAX lor the pr.--.tion ol MAC in children have not been .,...blished. 
Umited safety data are available for 24 children 5 months to 14 years of age (mean 4.6 years) who 
received ZfTlfROMAX lor lreatment ol opportunistic infections. The mean duration ol ther.lpy was 
186.7 days (""'90 13-710 days) at doses ol < S to 20 mg/kg/day. Adverse events were similar to those 
observed in the adult population. ..- d whidl involved lhe gastrointestinal tocL Whie none ol these 
children prematlRiy discontinued treatment due to a side tlfe<L one child discontr.Jed due 10 a laboratory 
abnormality (eosinophilia). Based on available pediatric pharrnacokinetic data, a dose ol 20 mg/kg in 
children would provicle drug exposure similar to the 1200 mg adult dose but with a higher Cmax. 
Use In Elderly: 
The pharmacokinetics in elderly volunteen (age 65 to 85) were similar to those in younger volunteers 
(age 18 10 -40) lor the 5-day therapeutic regimen. Dosage adjustment does not appear to be necessary lor 
elderly patients with normal renal and hepatic ILnction receilling treatment with this dosage regimen. 
Drug lnteroctlons 
Antacids 
Aluminum and magnesium containing anucids (Maalox") reduce the peak serum levels but not the 
extent ol azithromycin absorption. These drugs should not be taken simuluneously. 
Cimetidine 
Administr.ltion ol cimetidine (800 mg) two hours prior to ZfTlfROMAX had no effect on 
azithromycin absorption. 
Theophylline 
CO<OCurrent use of macrolicles and theophylline has been associated with increases in the serum 
cO<OCentr.ltions of theop/lytline. ZITHROMAX did not affect the phannacokinetics of theop/lytline 
administered either as a single intr.lvenous infusion or multiple oral doses at a recommended dose of 
300 mg every 12 hours. There is one post-rnarlteting report of supraventricular tachycardia associated 
with an elevated theophylline serum level that developed soon alter initiation of lreatment with 
ZITHROMAX. Until further data are available, prudent medical practice d ictates careful monitoring 
of plasma theop/lytline levels in patients receiving ZITHROMAX and theophylline cO<OComitantly. 
Warfarin 
ZITHROMAX did not affect the prothrombin time response to a single dose of warfarin. 
However, prudent medical practice dictates careful monitoring of prothrombin time in all patients 
lreated with ZITHROMAX and warfarin cO<OComiuntly. CO<OCurrent use ol macrolicles and warfarin 
in clinical practice has been associated with increased anticoagulant effects. 
Zidovudine 
Single 1 g doses and multiple 1200 mg or 600 mg doses d ZITHROMAX did not affect the plasma 
pharmacokinetics or urinary excretion ol zidovudine or its glucuronide metabolite. However, 
administr.ltion of ZfTlfROMAX increased the cO<OCentrations of phosphorylated zidovudine in 
peripheral blood mononuclear cells. 
Didanosine 
Daily doses ol 1200 mg ZITHROMAX had no effect on the phannacokinetics of didanosine. 
Rifabutin 
Co-adm inistr.ltion of ZITHROMAX and rilabutin did not affect the serum cO<OCentr.ltions ol 
either drug. 
---------- ---------
Carbamazepine 
In a pharmacokinetic interaction study in healthy volunteer<, no significant effect was observed on 
the plasma levets of carbamazepine or its active metabolite in patients ~Kefving concomitant 
ZITHROMAX. 
Concomitant Therapy 
The following drug interactions have not been reported in dinical trials with ZITHROMAX and 
no specifoc drug interaction studies have been perlormed to evaluate potential drug-drug 
interactions. Nonetheless, they have been observed with macrolide products, and there have been 
rare spontaneously reported cases with ZITHROMAX and some of these drugs, in postmarl<eting 
experience. Until further data are developed regarding drug interactions, when ZITHROMAX and 
these drugs are used concomitantly, careful monitoring of patients ~ advised both during and for 
a short period following therapy: 
Digoxin : Elevation of digoxin levels. 
Disopyramide: Increase in pharmacological effects. 
Ergotamine o r d ihydroergotamine: Acute ergot toxicity characterized by severe peripheral 
vasospasm and dysesthesia . 
Triazolam: Decreases in the dearance of triazolam and increases in the pharmacologic effect 
of triazolam. 
Drugs metabolized by the cytochrome P450 system: Elevations of serum cyclosporine, 
hexobarbital, c~pride. and phenytoin levels. 
Antihistamines: Prolongation of QT intervals, palpitations or cardia< armythmias with 
concomitant administration of astemizole or terfenadine. 
No data are available on the concomitant dinical use of ZITHROMAX and gentamicin or other 
amphiphilic drugs which have been reported to alter intracellular lipid metabolism. 
ADVER5E REACTIONS 
TREATMENT 
The majority of side effects observed in controlled d inical trials involving patients (adults and 
children) treated with ZITHROMAX (azithromyd n d ihydrate) were of a mild and transient nature. 
Approximately 0.7% of both adult patients (n=3812) and children (n=2878) who had multi~ doses 
of ZJTH ROMAX discontinued therapy because of drug related side effects. Most of the side effects 
leading to discontinuation were related to the gastrointestinal tract. e.g., nausea, vomiting. diarrhea. 
or abdominal pain. Potentially sMous side effects induding angioedema and cholestatic jaundice 
occured in less than 1% of patients. 
Clinkal: 
Single 1-gram dose regimen (adults): 
In adult patients (n=904), side effects that occurred on the single one-gram dosing regimen of 
ZITHROMAX with a frequency greater than 1% included diarmea (6 .1% ), nausea (4.9%), 
abdominal pain (4.9%), vomiting (1.7%), vaginitis (1.3%), loose stools (1.2%), and dyspepsia (1.1%). 
Single 2-gram dose regimen (adults): 
Overall, the most common side effects in patients receiving a single 2-gram dose of ZITHROMAX 
were related to the gastrointestinal system. Side effects that occurred in patients in this study with 
a frequency of 1% or greater included nausea (18.2%), diarrtlea/loose stools (13.8%), vomiting (6.7%), 
abdominal pain (6.7%), vaginitis (2.2%), dyspepsia (1.1 %), and dizziness (1.3%). The majority of 
these complaints were mild in nature. 
The following adverse experieroces have been reported in patients under conditions (e.g ., open trials, 
mari<eting experience) where a causal relationship is uncertain or in patients treated with signifocantly 
higher than the recommended doses for prolonged periods: 
Alle rgic arthralgia, edema, anaphylaxis (with rare reports of fatalities), serum sickness, urticaria, 
vasculitis; 
Cardiovascular: cardiac arrythmias (including ventricular tachycardia), palpitations; 
Gastrointestinal : anorexia, constipation, dehydration, dyspepsia, flatulence, pancreatitis, 
pseudomembranous colitis; 
Ge neral: asthenia, paresthesia, muscle pain; 
Genitourinary: interstitial nephritis, acute renal failure, nephrotic syndrome; 
~r/8iliary: abnormal liver function including drug-induced hepatitis and choliestatic jaundice, 
hepatic necrosis; 
Nervous System: dizziness, headache, seizure, somnolence; 
Skin / Appendages: serious skin reactions including erythema multiforme, exfoliative dermatitis, 
Stevens-johnson syndrome, toxic epidermal necrolysis; 
Specia l Se nses: hearing disturbances including hearing loss, deafness and/or tinnitus, vertigo, 
reports of taste disturbance. 
PREVENTION OF MYCOBACTERIUM AVIUM COMPLEX (MAC) DISEASE: 
Chronic therapy with ZITHROMAX 1200 mg weekly regimen: The nature of side effects seen with 
the 1200 mg weeldy dosing regimen for the prevention of Mycobocterium ovium complex infection 
in severely immunocompromised HIV-infected patients were similar to those seen with short-term 
dosing regimens. 
lncideroce' (%) of Treatment Related' Advene Events~ in HIV-Infected Patients 
Receiving Prophylaxis for Disseminated MAC 
Study 155 Study 174 
Placebo Azittv"omyOO Azittv"omyOO Rifabutin Azittv"omyOO 
1200mg 1200mg 300mg & Rlabutin 
weekly weekly daily 
(n=91) (n=89) (n=233) (n=236) (n=224) 
Mean D.Jration "'Therapy(~) 303.8 402.9 31S 296.1 344.4 
Discontinuation of Therapy (%) 2.3 8.2 13.S 15.9 22.7 
AUTONOMIC NERVOUS SYSTtM 
Mouth Dly 0 0 0 3.0 2.7 
CENTRAL NERVOUS SYSTEM 
Diz2iness 0 1.1 3.9 1.7 0.4 
Headache 0 0 3.0 5.5 4.5 
GASTl!OINTESTlNAI. 
DiafThea 15.4 52.8 50.2 19.1 50.9 
loo5e Stools 6.6 19.1 12.9 3.0 9.4 
Abdominal Pain 6.6 27 32.2 12.3 31.7 
Dyspepsia 1.1 9 4.7 1.7 1.8 
FlallJience 4.4 9 10.7 5.1 5.8 
Nausea 11 32.6 27.0 16.5 28.1 
\OOliting 1.1 6.7 9.0 3.8 5.8 
GENERAl 
F..., 1.1 0 2.1 4.2 4.9 
Fatigue 0 2.2 3.9 2.1 3.1 
Malaise 0 1.1 0.4 0 2.2 
MUSCULOSK£l..ETAI. 
Arthralgia 0 0 
I 
3.0 4.2 7.1 
PSYOiiATRIC 
Anorexia 1.1 0 2.1 2.1 3.1 
SKIN & APPENDAGES 
Pruritus 3.3 0 3.9 3.4 7.6 
Rash 3.2 3.4 8.1 9.4 11.1 
Skin Discoloration 0 0 0 2 .1 2.2 
SPECIAL SENSES 
Tnnitus 4 .4 3.4 0 .9 1.3 0.9 
Hearing Decreased 2.2 1.1 0 .9 0 .4 0 
Taste Pl!rverlion 0 0 1.3 2.S 1.3 
Side effects related to the gastrointestinal tract were seen more frequently in patients receiving 
azithromycin than in those receiving placebo or rifabutin. In one of the studies, 86% of diarmeal 
episodes were mild to moderate in nature with d iscontinuation of therapy for this reason occurring 
in only 9/ 233 (3.8%) of patients. 
PREVENTION OF MYCOBACTERIUM AVIUM COMPLEX (MAC) DISEASE: 
In these immuncocompromised patients with advanced HIV infection, it was sometimes necessary to 
assess laborato<y abnormalities developing on study with additional criteria ~ baseline values were 
outside the normal range. 
~intt Disseminated MAC 
I Laborato<y Values 
Study 155 Study 174 
Criteria' Placebo Azittv"omyOO Azittv"omyOO Rifabutin Azittv"omyOO 
1200mg 1200mg 300mg & Rlabutin 
weekly weekly daily 
Nt.mber at SuiJjecU' (n=88) (n=89) (n=208) (n=205) (n=199) 
Hemoglobin <0.8xUN' 31% 30% 19% 26% 21% 
Platelet C0<rt < 0.75 x UN 19% 16% 11% 10% 16% 
WBCCO<rt < 0.75 X UN 48% 49% 60% 53% 60% 
NeutropiWs <0.5 X UN 16% 28% 23% 20% 29% 
<SfYJ/mm' 6% 13% 5% 6% 8% 
AST (SGOl) > 2.0 X lJLN I> 28% 39% 33% 18% 30% 
>200 U/1. 10% 8% 8% 3% 6% 
AI.T (SGPT) >2.0 X ULN 24% 34% 31% 15% 27% 
> 2SO U/1. 2% 6% 8% 2% 6% 
. ~~~~e;=:~ ~~~~~~T<St~~~~ 
• ~limit ol norTNI 
b """"' ..... ol nonnol 
c I"''UU''"lbef of sub;ecU evaluabte ., ~ LaboratOty test is at le.st 98ftft of the toQI number of sub;Kts 
In a phase I drug interaction study perlormed in normal volunteers, 1 of 6 subjects given the combi-
nation of azithromycin and rifabutin, 1 of 7 given riiabutin alone and 0 of 6 given azithromycin 
alone developed a dinically significant neutropenia(< 500 cells/mm'). 
OVERDOSAGE 
Symptoms: 
There are no data on overdosage. 
Treatment; 
Gastric lavage and general supportive measures are indicated. 
Up to 15 grams cumulative dose of ZITHROMAX (azithromydn dihydrate) over 10 days has been 
administered in clinkal trials without apparent adverse effect. 
DOSAGE AND ADMINISTRATION 
TREATMENT 
Adults: 
CAPSUUS: ZJTHROMAX (azithromydn dihydrate) Capsules should be given as a single daily dose 
at least 1 hour before or 2 hou" after a meal . 
TABLETS: ZITHROMAX Tablets can be taken with or without food. 
SINGU DOSE 1 g PACKET: ZITHROMAX powder for oral suspension as Single Dose 1 g Packet can 
be taken with or without food after reconstitution. 
Mixing Directions: 
Directions for administration of the powder for oral suspension as a Single Dose Packet ( 1 g): 
The entire contents of the Packet should be mixed thoroughly with 60 ml (two ounces) of water. 
Drink the entire contents immediately, add an additional 60 mL (two ounces) of water, mix. and 
drink to assure com~te consumption of dosage. 
Fot- skin and skin structure infections, upper and lower retpirato<y tract infections: The 
recommended dose of ZITH ROMAX for the treatment of individuals 16 yea" of age and older ~ 
500 mg as a single dose on the first day followed by 2SO mg once daily on days 2 through S for 
a total dose of 1.5 grams. 
Gen itourinary: The recommended dose of ZITHROMAX for the treatment of genital uker disease 
due to Hoemophilus ducreyi (chancroid) and non-goncococcal urethritis and cervicitis d ue to 
C trochomotis is: a single 1 gram (1000 mg) oral dose of ZJTHROMAX. This dose can be 
administered as four 250 mg capsules, four 250 mg tablets, or as one Single Dose Packet (1 g). 
The recommended dose of ZITHROMAX for the treatment of urethritis and cervicitis due to 
Ntisserio gonorrl>oeoe is: a single 2 gram (2000 mg) dose of ZITHROMAX. This dose can be adminis-
tered as eight 250 mg capsules, eight 250 mg tablets, or as two Single Dose Packets (1 g each). 
For prevention of disseminated Mycoboctnium avium complex (MAC) disease: 
TA8L£TS: ZITHROMAX tablets may be taken without regard to food. The recommended dose of 
ZJTHROMAX for the prevention of d~inated Mycobocterium ovium complex (MAC) disease ~ 
1200 mg (two 600 mg tablets) taken once weeldy. This dose of ZITHROMAX may be continued 
with the approved dosage regimen of rifabutin . 
In patients with mild to moderate hepatic impairmen~ there is no evidence of a marked change in 
serum pharma<:okinetict of ZITHROMAX compared to those with normal hepatic function. in these 
patients urinary recovery of azithromydn appea<l to increase. Heroce no dose adjustment is 
recommended for patients with mild to moderate hepatic impairmenL Nonetheless, since the liver 
is the principal route of elimination for azithromydn, the use of ZITHROMAX should be undertaken 
with caution in patients with significant hepatic disease. 
TREATMENT 
Children: 
POWDER FOR ORAL SUSPENSION: ZITHROMAX Powder for Oral Suspension should be g iven as a 
single daily dose at least 1 hour before or 2 hou" after a meal. 
Mixing Directions: 
ZITHROMAX Powder for Oral Suspension: 
Tap bottle to loosen powder. Acid the directed volume of water. Shake well before each use. 
Oversized bottle provides shake space. Keep tightly closed. The table below indicates the volume of 
water to be used for reconstitution: 
Amount of water Nominal volume alter Azithromycin concentration 
to be~ reconstitution (azithromycin content) after reconstitution 
9 ml (300 mg ~) IS ml (300 mg ~) 100 mg/5 ml 
9 ml (600 mg ~) 15 ml (600mg~) 200 mg/5 ml 
12 ml (900 mg ~) 22.5 ml (900 mg bottle) 200mg/S ml 
-Otitis Mecio 0< ~Pneumonia: 
The 11!000. I ... ded dose of ZITHIIOMAX oral !U!flOJlSion for the treatment of children with acub! otitis me<ia 
0< cornnunity--acq pneunona is 10 mg/1<g as a single dose on the first day (not to exceed 500 mg/day) 
lolowe:l by 5 mg/llg on days 2 tlvough 5 (not to exceed 250 mg/day). for a tc1a1 dose of 30 mg/llg of 
ZITHROMAX (see chart below). 
PEDIATRIC DOSAGE GUIDEUNES FOR ACUT£ OTTTlS MEDIA 
OR COMMUNITY-ACQUIRED PNEUMONIA 
(Age 6 months and a~) 
Based on Body Weight 
ACUT£ OTTTlS MEDIA OR COMMUNITY-ACQUIRED PNEUMONIA 
Dosing Calculated on 10 mg/l<g on Day 1 dose, followed by 5 mg/1<g on Days 2 to 5. 
Weight 100 mg/ 5 ml Suspension 
200 mg/5 ml 
Suspension 
Total ml 
per 
Treatment 
Course Kg lbs Day 1 Days 2-5 Day 1 Days 2-5 
5 11 2.5 ml ( 1/, Up) 1.25 ml ('/• tsp) 7.5 ml 
10 22 5 ml(1 t.p) 2.5 ml (1/ 2 Up) 15ml 
20 44 5 ml (1 tsp) 2.5 ml rt, Up) 15 ml 
30 66 7.5 ml (1'/2 tsp) 3.75 ml (11. Up) 22.5 ml 
40 88 10 ml (2 tsp) 5 ml (1 tsp) 30ml 
Pluoryngltb and Tonsillitis: 
The recommended dose for children with phal)'ngitis and tonsillitis is 12 mg/kg once a day (not to 
exceed 500 mg/clay) for 5 days for a total dose of 60 mg/kg of ZITMROMAX (see chart below). 
PEDIATRIC DOSAGE GUIDEUNES FOR PHARYNCffiS AND TONSIWTlS 
(Age 2 years and ~) 
Based on Body Weight 
PHARYNGffiS AND TONSILliTIS 
Dosing Calculated on 12 mg/1<g once daily Days 1 to 5. 
Weight 200 mg/ 5 ml Suspension Total ml per 
Kg lbs Days 1-5 Treatment Course 
8 18 2.5 ml (1/, t.p) 12.5 ml 
17 37 5 ml (1 t.p) 25 ml 
25 55 7.5 ml (1 1/ 2 tsp) 37.5 ml 
33 73 10 ml (2 tsp) SOml 
40 88 12.5 ml (21/, t.p) 62.5 mL 
AVAILABlUTY OF DOSAGE FORMS 
CAPSULES: ZITHROMAX (azithromycin dlhydn~te) Capsules each contain azithromycin dihydrate 
equivalent to 250 mg of azithromycin. The red, No. 0 hard gelatin capsules imprinted with " Piizer" 
and "ZZTHROMAX" in black ink, are packaged in white plastic (high density Polyethylene) bottles of 
30 and 100 or in a single treatment package (Z-PAK) of 6 blister packaged capsules per box. 
TABLETS 250 mg: Each pink, film<oated, modified capsular-shaped ZITMROMAX table~ engraved 
"pfizer" on the upper face, and scored on the lower face, contains azithromycin dihydrate equivalent 
to 250 mg of azithromycin . The tablets are packaged in white plastic (high density pofyothylene) 
bottles of 30 and 100 or in a single treatment package (Z-PAK) of 6 blister packaged tablets per box. 
600 mg: Tablets, engraved on front with "Piizer", are white, modified capsular-shaped film<oated 
tablets containing azithromycin dihydrate equivalent to 600 mg azithromycin. These are packaged 
in HOPE bottles of 30 and 1 00 tablets. 
POWDER FOR ORAL SUSPENSION: ZITHROMAX Powder for Oral Suspension, alter reconstitution, 
contains a cherTy flavoured suspension. Each ~ (high density Polyethylene) provides 
azithromycin dihydrate equivalent to: 300 mg per 15 ml (1 00 mg/ 5 ml); 600 mg per 
15 ml (200 mg/ 5 ml); 900 mg per 22.5 ml (200 mg/5 ml). Dropper is inclucled in the package. 
SINGLE DOSE 1 g PACKET: ZITMROMAX powder for oral suspension as a Single Dose 1 g Packet 
contains azithromycin dihydrate equivalent to 1000 mg of azithromycin in a sealed, laminated 
aluminum foil and Polyethylene pouch. 
Product Monograph available upon request. 
t Product licensed from Pliva 
lithrornax is a Scfiedule F drug. 
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Antihypertensive Agent 
Symptomotic Treatment ol Benign PIOslatic Hyperplasia (BI'H) 
IIIOICATlOIIS AIIO CliiiCAI. USE ~ Treatment ol rid to moderate esseOOal hypertension, in a general treatment 
program in association witfl a thiazide diuretic and/or other ~ agents, as needed lor proper patient response. 
Doxazosin may be tried as a sole therapy in patients lor whom treatment witfl other agents C3M ~ effects or is 
inappropriate . ...., Pr1111tic ~ (II'H): Treatment ol symptoms ol beniJn prostati: hypelplasia (BI'H). Onstt ol 
e11ect is rapid, witfl irnproolanent in peak !low and symptoms seen within 1·2 weas, and mainlained owr tile me study 
dilation (up to 4 years). tt may be used in hypertensiYe or normotensive BI'H patients. A number ol clinical conditions can 
mimic symptomatic BP!i (i.e. stricture ol ure ra, stricture ol bladde! neck, urinary bladder stones, neurogenic bladder 
dyslunction secondary to diabetes. Partinsoo's ~- etc.). These conditions should tllerelore be ruled out belore 
dolQzosin therapy IS iritiated. 
COIITRAIIOICATlOIIS: Patients witfl a known saasitiYity to dol<3lOsin or qtinazotines. 
WARMIIIGS: S,...,. 1101 "Fin! Dose" Etloct: Doxazosin can cause rnarUd hypotension, especially postural hypotensiorl 
and syncape in association will tile fiB! dose or tnt lew doses ol therapy. A sililar effect can ocxur ~ therapy is reils1ated 
-.g interruption lor mar! thon a lew doses. Pustural effects are most to occ..- betMen 2-6 hours aftes dose. In 
controlled studies ol dol<3lOsin tile incidence ol syncopal episodes was 0.7, . Initial dose ol 1 ~ resulted in a 4, 
incidence ol :MlSiural side effects witfl no cases ol syncope. In c:ontroled trials ol normotensive BI'H patien1s, tile occurrence 
ol syncape witfl dolQzosin was 0.2'l.. In c:ontroled trials in hypertensiYe BI'H patients receim;j doxa2osin, tile incidence ot 
syncape was O.S'l.. The itelilmd ol syncopal episodes or l!liiZSSive hypotension can be rninirri1!d b¥ limiting tile initial dose 
ol dol<3lOsin to t mg, b¥ increasing tile dosa9e slowly and b¥ iltrodur:ing .,., odditior1al ~ drugs ido tile 
patient's revimerl with cautiorl (see DOSAGE AND ADMINISTRATION). Advise patients ol tile possibility ol syriCOflil and 
orthostatic symptoms and to a'IOid drMr1Q or hmrdous tasks lor 24 hours a er Initial dose ol dolQzosin, aftes tile dose is 
increased and after interruptioo ol therapy when treatment is resooled. Ciution patients to a'IOid sibAtions where injury crud 
resutl sh<Ul syncape occ..-. ff syncape ocrm. place patient in tile SIJI)ine positin ff lllis measure is inadequate, .oorne 
expansion with intravenous fluids or vasopressor therapy may be used. A transient hypotensive response is not a 
contraindication to lurther doses ol doJWOSin. ~:Rarely (probably <0.1%), af!lhat·antagmists such as dolQzosin 
have been associated witfl priapism. This COI1Iiion can lead to permanent impotence il not piOfTll1lly treated. Advise patients 
ol tile seriousness ol tile c:onditiorl. 
PRECAIITMIIS: Geoertl: Doxazosin therapy does not modify tile nallnllistory ol benign prostati: hypelplasia (BI'H). tt does 
not retard or stop tile progression ol BI'H, nor does ~  urine !low sufficiently to significatCiy reduce residual urine 
volume. However. SIQflilir:ant reduction ol meaA residual volume has been shown in patients witfl baseline residual volumes 
> 50 IlL The patient may axmue to be at risk ol dMioping lli1ary retention and other BI'H complications duritQ dol<3lOsin 
therapy. Loot· T ... Sallly 1101 e.acy: The 1oog-1erm sa1<ty and efficacy [Le. , 4 years) has not yet been estabished in t11e 
treatment ol benign prostati: hyperplasia. Prlllltic c-. ewnoma o1 tile prostate and BI'H cause many o1 tile same 
symptoms. These two diseases lrequently ooexist. Tlterelore, patients thouQht to have BI'H should be wmined prior to 
starlnJ dolQzosin therapy to "* out tile presence ol cartinorna ol lhe prostate. DoJWOSin sh<Ul not be used in patients 
witfl PSA > 1 0 r¢11. ooless prostate cancer has been ruled out. Or1llesUiic ..,...._ While syncape is tile most severe 
orthostatic effed ol doxazosin (see WARNINGS), other symptoms of lowered bklod pressure like diz2iness, ightheadedness 
or wettigo can ocxur. They were commoo in clinical trials, occurrinO in 1111 to m ot al patients treated and causing therapy 
discontinualion in about ~- In platebcH:ontrollerl titration trials tile lrequency ot orthostatic enects in patients givel1 a mg or 
mar! was1 0'1., oompared to 5% at 1--4 mo. and 3'lo in tile placebo-treated group. 
In placebo c:ontroled trials in BI'H, tile incidence ol orthostatic hypotension witfl dol<3lOsin was s 1%. With main1el1ance 
doses ol up to a mg/day in normotensive BI'H patients, tile mean decrease; in sitting and standi1g bklod pressure were smal: 
512 rnmHg with dol<3lOsin vs 1/1 rnmHg with placebo. Patients with occupations in wllich such Mnts represent pcUntial 
problems should be treated with partiaJtor cau1ion. Advise patients ol tile need to le down when symptoms at lowered bklod 
pressure occur and to be carelul wllen arising lrom a lying position. II dizzioess. · htfleadedness or palpiUtions are 
bothersome, they should be reporled to tile physician. and dose adjustment considered. Patients should also be told that 
drowsitess or somnolence can occur witfl doxa2osin, requiring cautiorl in people who most drive or operate heavy machinery. 
ff llypotensaoo ocars, place tile patient 11 recumbent position and institute supportive measures as necessary. Plliells ,.;a 
'-'" l.iftf FwtiGI: No intormatiorl is Miable regarding use o1 dol<3lOsin it patients with impaired iver lunctiorl or in 
patients taking drugs known to ailed hepatic metabolism. Doxazosin is extensively rne13bolized and excreted b¥ tile iver. Use 
in patients witfl impaired iver looctior1 is not recorM1ef1ded. PatiHis will -,aiM lleul flodilo: Use in patients witfl 
impaired renallunctiort requi'es carelul monitoring. Clinical studies indicab! that tile cispositi1n ol dolQzosin in pa · witfl 
renalinsufticiencyassrnilartothatinpatientswitflnormatrenalhn:tion.'-iiCal-oltfledrugwitflclwoni: 
dosing may occur. Less than 10'1. ol tile dose ol doxazosin is exaeled in urine as unchanged drug and metaboliles. 
Caocomi!Jot Cooolitioos: Ooxazosin should not be presaibed to patients witfl symptomatic BP!i who have tile lollowing 
c:oncomitant conditions: Chronic lli1ary retention. high residual urine (OYer 200 ml). peak urine !low ol 5 mlJs« or less. 
history ol prior prostabt Sllgery, clvonic fibriiJS or granulomatiiJS prostati:is, urelhril stricture, listory ol pelvic irradiation. 
presence ot prostati: calcui, presence ottarge rnedi¥11obe ot prostate, presera ol calaJi in lli1ary bladder, recent listory ot 
epidJdymitis, gross hematuria. presence ol neurogenic bladder dyslunction (diabetes metfitus, partinsonism, uninhibited 
neuroon bladder, etc.). hydroneplvosis, presence ol cartinorna ol tile prostab!. Patients witfl recent history ol myocardial 
llllardion, transient isdlernic at!acls, or c:erebrovascdar ar:Odent wiU1in tile past 6 II1Dr1IIIS. 1'1...-r. There are no studies 
11 pregnant women. Doxazosin use not recornmeOOed in pregnant women triess lhe po4erltial benefit OIJIWeigl1s tile potential 
nst< to mother and letus. Doxazosin aosses tile placental barrier. Studies in pregrgnt rabl1its and rats at daiy oral doses ot 1111 
to 40 and 20 mg/'<g respectively re'lealed no Mlence o1 teratoon e11ect. A dosage regimen o1 82 ~day in tile rabbit 
was associated witfl reduced leta! suMval, an increase in embryo mortality and increase; in 1eta1 and ptacenta1 Wl!ights. 1n 
~tal rat studies. postnatal dMiopment, at maternal dol<3lOsin doses ol 40 or 50 ~day. was delayed as 
evidenced IJy slower body weight gain and sightly later appearance ol anatomicalleatures and rellexes. UcbliM: Studies in 
lac1ating rats indicate that doJWOSin accumuta es in rat breast milk. h is ooknown w!lether lllis drug is exaeled in human 
mil Exertise cautiorl when administering doxazosin to a rmilg mother. In general, nuBitg sh<Ul be interrupted. Clilftt: 
Use ot dol<3lOsin is not reomnended since saldy and ellicacy have not been estabished. Ellllly: Use cautiously in elderly 
patJen1S due to possOiity ot postural hypotension. An age-<elated trend towards increased incidences ot postural hypotension 
and postural diuiness was seen in elderly hyperlensive patients treated witfl this drug. l'lr;,tllnl E*tu: Auid retention 
resulting il ftiglrt gain may OCCUI duri1g dol<3lOsin therapy. In platebcH:ontrol rnonotherapy trials, patients I!Ctiving 
dol<3lOsin gained a mean ol 0.6 kg oompared to a mean toss ol 0.1 kg lor placello-treate patients o.eratl incidence ot body 
weight gain rl!10fled as a side ellect in c:ontroled trials was 0.8"4. U.U,.Io.lcolo""* Anat;sis ol hematologic data 
lrorn patients receiving doxazosin in c:ontroled trials showed that mean white bklod eel (WBC) (N~74) and mean neutrophil 
cooots (PI-..419) were decreased IJy 2.4% and 1.0'1. respedNely, oompared 1o placebo. A data base Stald1 ol2.400 patients 
r!'lealed 4 cases in wllich drug-fetated neutropenia crud not be n*d out. Two had a single tow value oo tile 1as1 day ot 
treatment Two had sta11te. 1101111fOOressive neutrophi caunts it tile 11m'mm' oooe owr periods o120 and 40 weas. No 
patients became symptomatic as a result ol tile tow WBC or netJ!Jophil cooots. In BI'H patients tile incidence ot clinicaly 
signilicant WBC abnormalities was 0.4% with doxuosin. Car•IIC Tuicity 11 Ali•als: See Product Monograph. 
~- .............. ,...... .. ftttifity: See Product Monograph. Dnlllllnclila: DoJWOSin is highly 
(98'l.) - to plasma protein. In iilro daU in human plasma indicate 1hal dol<3lOsin mesytate has no elled oo protei~ 
binding ol digoxin, warlarin. phenytoin or indomethacin. Dowosin has been administered to patients taking thiazide 
diuretics, beta-adrenergic blocking agents and non-steroidal anti-inflammatory drugs wi1l1 no unexpected interactions 
reported. An additive hypotensive ellect was obserwd when dol<3lOsin was co-admiistered with thiazide diuretics and beti-
adrenergic btoctinl) agents. There is lin1i1ed experience with CARDURA in axnllination with /a inlliitors or cakium cMtnel 
~*mrs. Oigoxirr Serum digoxin c:oncentrations were not alleded b¥ treatment will doxazosin. Cimtli16lt: In a randomized, 
open-label, aoss-over study in 22 male subjects, tile single co-administration of 1 mg doxazosin wi1l1 400 mg b.i.d. 
c:imebdine resutled in a 10'1. increase il mean AUC ot dol<3lOsin (p • 0.006), and a siglrt but not statisticaly siglificant 
increase in IID1 C.... and mean hall-ire ol doxazosin. The ellect ollur1!1er i1dnWiistratiJn ot cimetidine has not been studied. 
AIIVBIS( RfACTIOIIS: ~ Doxazosin has been administered 1o approxinately 4,1XXJ patients in clinical trials ol 
w!tonl1 ,679 patients were in controlled trials. The most serious ~ reaction occurring in controlled trials was syncape 
ocxurring in O.l'K. ol patients and resulting in a discontinuation rae ol 0.2'l.. The most lrequent adverse reactions in 
c:ontro11er1 ctinical trials were: headache (16.5%), latiguelmalaise (14.8'A.), diz2iness (14.6'11.), postural diz2iness (8.7'K.) and 
edena (6.6'11.). Oisc:ontinuatio ol dol<3lOsin due to ~ reactions occurred in 7'K. ol patien1s, The lolowing ~ 
reactinns occurred witfl an incidence ol ~ 0.5% it tile c:ontro11er1 ctinical trials program (n:1,679): ~~ 
(3.6%); vertigo (3.0'1.); taclrjcaldia (1.6'11.); postlnl hypotension (O.!lr.); arrhythmia (0.8%); syncape (O.l'K.). Skin and 
Ajtpendages:rash (1.7'K.); pnritus (0.8"4). Uusrubs ........ rnyalgia (1.3'/o~ .unlgia (0.8"4~ Nenous ~em: somnolence 
(4.9r.); sexual dyslll1ction (3.5%); dry mouth (14%); anxiety/nervousness (2.3'/o); insorMa (2.2'l.); paresthesia (1.7'K.~ 
depfession/apat!ly (1.6%); increased sweating (1.4%); hypoesthesia (1 .6%); ag~tion (O.l'K.); Hushing (O.l'K.); tremor 
(0.6%); paroriria (0.5%). Spel:ial Stnses: visiorVaa:orMtotion abnormality (2.4%); conjurlctM1is/! pain (1.2'l.); tinnitus 
(0.8"4). Gastrointts/NI: nausea (3.9r.); diarrhea (2.9r.); dyspepsia (2.1%); abdominal pain (1.6%); ftatulence (1.4%); 
~ (1.3'/o); vomiting (O.l'K.). ~lory: dyspnea (3.9r.); rf1initis (3.0'1.); epistaxis (0.8"4); sinasitis (0.6'11.); 
brondtospasm/bfonc:Mis (0.5%). Urinaly: micturition lrequency (1.~); polyuria (1 .0'1.); urinary incontinence (0.8'A.); 
UINy disorder (O.l'K.). Genmi/Jody: d1est pain (2.7'K.); asther1ia (2.7'K.); muscle cramps (1.7'K.); pain (1.3'/o); lace edena 
(0.8"4); weight increase (0.8'A.); general edena (0.5%). HetnaiD/ogy: decrease; in platelets (l!lr.), wlite bklod eel (2.4%~ 
hernatocri (1.6'11.), 11emogto11in (1 .4%), neutrophiiiXIII1! (1.0'1.) (see PRECAUT10NS). The -.g adverse reactinns were 
reported in at least 2 but < 0.5% ol1 ,679 patients who received dolQzosin in tile controlled trial program: ~
System: angina pecloris, peripheral ischemia. hypotension; NtrVOus System: paresis. twilching, migraine, amnesia, 
movement disorders, emotional lability, abnormallhinking, depersonamtil1. palor, hypertonia, ataxia; Met1bofc thirst, gout. 
hypc*aternia; Her7Yiopoieti;: lympltadenopatl, purpura; ~ 5)5ttm: breast pain; Skin Disorrlets: alopecia, dry 
skin, eczema; Spel:ial Stmcs: taste perversion, pllot011hobia. abnormal lacrimation; Gasrrointtstinal ~em: increased 
appetite, anorexia, lecal incon1inence; lrespintory S)'Siern: c:oughing, pharyngitis; Genml Body System: hot !lushes, bact 
pain, infection, leverl!igors, muscle weal:ness. In II1COI1Iroled trials or post-marteling experience tile lolowing occ..-red with 
an incidence ol <0.5%: myocardial inlarttion, c:erebrovasa& aa:ident, c:onlusion, in1pand c:oncentration, palor, parosmia, 
en:he. tinnitus. renal cala*Js, inlluenza-ib ~ priapism and jMdice. No c:iicaly relevant adverse effects were 
noted on serum potassium or glucose, uric acid. bklod urea nitrogen or aeatinine. Doxazosin has been associated witfl 
decrease; in WBC IXIII1t (see PRECAUTlONS). lsotaled case ot elevated iver transaminases have occurred . ...., Prlllltic 
"""'lasia: Doxazosin has been ad · · ered once daily to 665 both hypertensive and normotensive BI'H patients in 
c:ontroled trials. The most serious~ reaction 1hal occ..-red was syncape (0.5%). The 110stlrequent ~reactions 
in c:ontroled trials ~m: diz2iness (15.6%). headache (9.8'A.) and latigue (8"4). Disc:on · uation rate ol doxalosin due to 
~ reactions: !lr.. The lollowing ~ reactions occurred witfl an incidence ol ~ 0.5% in tile controlled BP!i trials 
(n:665 dowosin patients): Catdiovascular. dilliness (15.6%); edema (2.7'K.); hypotension (1 .7'K.); palpitation (1.2'l.); 
lad1ycardia (0.9'1.); angina (0.6'11.); syncape (0.5%); posturalllypoter1sion (0.3'/o). Skin and Aj1pendages: increased M3ling 
(1.1%); pnritus (0.5%); rash (0.5%). Uusrubs ........ onyalgia (0.6'11.). CSnl and f'etiplr9 Nenous System: headache 
(9.8"4); paresthesia (0.6'11.). Autonomic: dry moullh (1.4%); Hushing (0.6%). Special Senses: abnonnat vision (1 .4%); 
~ (0.5%); tinnitus (0.5%). Psychiatric: somnotenco (3.0'1.); insomnia (1.2'l.); anxiety (1 .1%); decrease libido 
(0.8"4); depression (0.6%); nervousness (O.S%). ~diarrhea (2.3'/o); alldorninal pain (2.3'/o); dyspepsia (1.8'l.); 
nausea (1.5%); 11atu1ence (0.8"4). Rtspi'atory:tlyspnea (2.6'11.); respiratory disorder (1 . 1 %~ rf1initis (0.8"4); epistaxis (0.6,). 
~ Disoniets: impotence (1 .1%). Neoplasm: cartinorna (0.5%~ Urinary: urinary tract inledion (1.2'l.); t1ys00a 
(0.5%). Genml: latigue (8"4); pain(~); bact pain (1.8"4); c11est pain (1.2'l.); asther1ia (0.8"4); inHuenzHke symptoms 
(0.8"4); vir3l inlection (0.6'11. ); lever (0.5,); weight increase (0.5%); malaise (0.5%). Additional~ reactinns have been 
reported, but are. in general, not cistinguishallt 1rorn symptoms 111a1 may have occ..-red in lhe absence dol<3lOsin exposare. 
The lollowing ~ reactions were reported IJy < 0.5% ol 665 patients who received dol<3lOsin in c:ontroled or open, 
short· or long-term dinical studies: Cardiovascular S)'Siem: myocardial inlarttion, bradycardia, sudden death; Autonomic 
Nerlous System: palor; MeJa1Joi:: hyperglyr2mia, goul ~~ l/eprotlrM;1Ne Systern: prostatic 
disorder. ejaculation lailure. epididym~; Skin Disorders: dry skin, gen~al pruritus, urticaria, maculopapular rash , 
erythematous rash. aggravated psoriasis, eczema; Ctnlnl Netvous Systern: hypoesff1esia, hyperlonia, leg cramps, c:onlusion, 
speech disorder, ataxia; Psychiatric: abnormal thin ·ng , depersonalization. paroniria, emotionallab~ity, impaired 
c:onc:entration amnesia; Sptda/ Stnses: earache. tas1e perversion, eye pain, visual field deled. cataract; Gastmintminai 
~tm: melena. constipation, vomiting, gingivitis, increased appetite; Rtspintory Systtrn: coughing, brondlospasm, 
brorlditis, upper respmory tract inledion, sinusitis, pneumonia; Urinaly System: urinary retention, micturition disorder, 
abnormal urine. renal pain, urinary incontinence, cystilis; Musculoskelela/ System: arthrtis. tendon disorder, arthralgia, 
hernia; Genml Body S)'Siem: rigors, hot !lushes, allergy, sepsis, lungal inledion; Plafdel /JietdD; and CkJIIiJg Oison1tr. 
llema1wia. sul1aract1noid hemorrtlage. Da1a lrorn lonitfam (1111 to 50 months), open BI'H studies (11:>450) indicale a higher 
rate ol diz2iness 11 !fU1!jer hyperlensive (27'K.) and normotensive (22'11.) patients, impotence in !fU1!jer hypertensiYe (8"4) 
patien1s, and discontinualion rates in patients due to adverse Mills (16.7',(,) ~ed to daU 1rorn short·1erm plactbo-
c:on1roled BI'H studies (n:665). See Product Monograph lor oomple1e Adverse Reaction inlormafion. 
SYIPTOIIS AND TREAYIOO OF OVERDOSAGE: No data available regarding overdosa9e with doxazosin in humans. ff 
adnWistration ot CARDURA leads to hypotension. supp<rt ot tile c:ardiovasaar system is ollist importance. Restoration ot 
bklod pressure and normaization ollleart rate may be atCOfl1l1ished IJy ~ tile patient in tile supine positin ff lllis 
measure is inadequale, shod< should list be treated witfi.OOme expanders. ff necessary, vasopressors should be used. Renal 
lunctiorl should be monitored and supported as needed. As CARDURA is liri1ly protein boon!. dialysis may not be ot benell 
DOSAGE AIIO ~ Dosage most be indMduail!d. The absorption ol CARDURA (dolQzosin mesytate) is not 
alleded b¥ lood. W11en dolQzosin is being added to tile existing antihypertensiv therapy, rnoritor tile patient tafelully tor tile 
ocamnce ol hypotension. ff a diuretic or other ~ agent is being added to dol<3lOsin regimen, dolQzosin dose 
reduction and retlrallon with carelut monitoring may be necessary, H dol<3lOsin adrmstration is discontinued lor several 
days or longer, therapy siWd be reinsitu1ed using tile iritial dosing regimen. Hyperllaiol-1-11 .. OI1CI Daily: The iri1ial 
dose ot dol<3lOsin in hypertensiYe patients is 1 mg givel1 once dUy and 1tus dose sh<Ul not be exaeded. This starting dose 
is in ended to minimize postural hypotensive effects. The maximum bklod pressure reduction normaly occurs beMerl 
2·6 hours after a dose. The dose may be slowly increased to achieve tile desired bklod pressure response. Usual dose range: 
1-8 mg once daiy. Maximum recoiM1ended daily dose: 16 mg once daiy. Doses greater than 4 mg increase tile lietillood ot 
l!liiZSSive postural elfects inciJding syncape, postural dizzinesslver1i and postural hypotension. N.. titrated dose ol16 mg 
once daiy, tile lrequency ol postural eHects is about 1~ oompared to 3'lo lor placebo . ...., Prlllltic ,.,..,._ -
H .. Dice Dally: The initial dosa9e ol dolQzosin is 1 mg givel1 once daiy. Depending oo individual patient's urotlynamics 
and BI'H symptomatology. dosa9e may t11en be increased to 2 mg and lhereaftes to 4 mg and 8 mg once daiy, tile maxiloom 
recorMlended dose. ReatrMtended titration interv;t 1- 2 weas. Blood pressure siWd be evaluated routitely. Doxazosin 
sh<Ul be discontinued I tile drug has been increased to maxiloom 1oler.lled dose and irnpovement in lli1ary 1towmetry is 
less thon 25% or ~ doJWOSin side eHects are more bothersome than BI'H symptoms or ~ tile patient develops a urinary 
c:ontplication secondary to BI'H wllite on dol<3lOsin tllerapy. 
Ani!Mitily: Wllile 1abtets containing dol<3lOsin mesytate equivalent to 1, 2 or 4 mg ol doxazosin. Supplied in opaque plastic 
,,.,ctensilypotyetl1ytene)botttesol100tablets. 
ful Product Monograph available on request 
Rfffilf1ICES: 1. CARDURA-1:-2: _. . Product Monograph, Astra Pharma Inc. 2. Lepor H e1 al. Doxazosin lor benign 
prostatic hyperplasia: l0119'term ellicacy and safely in hypertensiw and normotensiw patients. J Uro/1997;157:525-
530. 3. Fulton 8 et al. Doxazosin. An update ot its ctinical pharmacology and t11erapeWc apptications in hypertension 
and benign prostatic hyperptasia. Drugs 1995;49(2);295-320. 
.,.Pliler Products Inc., used under license. 
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---.--NORVASC 
lamlodipine besylate) 
Tablets 2.5, 5 and 10 mg 
Antihypertensive-Anlianginal Agent 
ACT10II AIIO CUMCAL PIIAIIMACOlliGY 
NORVASC (amtodipine besylate) is a calcium ton influx inhibitor (calcium entry blocker or calcium ion antagonist). 
AmkKJipine is a member of the dihydropyridine class of ctlcium antagonisu. 
~TlONS AIIO CUMCAL USE 
NORVASC lamlodipine besytate) is indicated in the treatment of mild-to-moderate essential hypertension. 
NORVASC should normalty be used in those patients in whom treatment with diuretics or beta· blockers was found 
ineffective or has been associated with unacceptable adverse effects. NORVASC can be tried as tn initial agent in 
those patients in whom the use of diuretics and/or beU·bkK:kers is contraindicated or in patients with medical 
conditions in which these drugs frequently causa serious advorn affects. Combination of NORVASC with a 
diuretic, 1 beta-blocking agent. or an angiotensin converting enzyme inhibitor has been found to be compatible and 
showed additive antihypertensive effect 
Clneic- Alotiu 
NORVASC is indicated for the management of chronic stable angina (effort-associated angina) in patients who 
remain symptomatic despite adequate doses of beta-blockers and/or organic nitrates or who cannot tolerate those 
agents. NORVASC may be tried in combinotion with bet>-blockors in chrorMc stable angina in patients with normal 
ventricular function. When such concomitant therapy is introduced, care must be taken to monitor blood pressure 
closety since hypotension can occur from the combined effects of the drugs. 
COIITIMIDICATlONS 
NORVASC lamlodipine besytato) is contraindicated in patients with hyparsonsitivity to the drug 0< othtf 
dihydropyridines and in patients with severe hypotension Uess than !I) mmHg systolic). 
WAIIIIINGS lee,.-Alltiu Ml4/w ~ ..,_ 
Rarety, patients, particularty those with severe obstructive coronary artery disease. have developed documented 
increased frequency, duration and/or severity of angina or acute myourdial infarction on starting calcium channel 
blocker then~py or at the time of dosage increase. The mechanism of this effect has not been elucidated. Oolll w_ l _ __ , 
NORVASC should be used with caution in a presence of fLXed left ventricular outflow obstruction 
I aortic stenosis). 
..... ..__.......,lloplllic_ 
There are no adequate studies in patieru with liver dysfunction and dosage recommendations have noc: been 
established. In a smd number of patients with mitd-to-moderate hepatic impairment given single dose of 5 mg, 
amJodipine hatf-life has been prolonged. NORVASC should, therefore, be administered with caution in these 
patients and careful moritoring should be performed. A lower starting dose may be required I sea DOSAGE AIIO 
-Tll*). 
-.-... w-
NORVASC gives no protection against the dangers of abrupt beto-blocker withdrawal and such withdrawal should 
be done by the gradual reduction of the dose of beta-blocker. 
PIIECAUTIOIIS 
U..io--~-hilww 
Although generally calcium chaMel blockers should only be used with caution in patients with haart fa· ro. it has 
been observed that NORVASC had no overaa deleterious effect on survival and cardiovascular morbidity in both 
shorHerm and long-term clinical trials in these patients. While a significant proportion of the patients ;, these 
studies had a history of ischemic heart disease, angina or hypertension, the studies were not designed to 
evaluate the treatment of angina or hypertension in patients with concomitant heart failure. 
..,...... 
NORVASC lamlodipine besyloto) moy occasionolly precipitate symptomatic hypotension. Careful monitoring of 
blood pressure is recommended, especialty to patients with a history of cerebrovascular insufficiency, and those 
taking medications known to tower blood pressure. 
.....,...._ 
Mid-to-moderate peripheral edema was the most common adverse event in the clinical trials tsee ADVEJISE 
IIEACTIOIIS). The incidence of peripheral edema was dose-<lependent and ranged in frequency from 3.0 to 10n 
in 5 to 10 mg dose range. Care should be taken to differentiate this peripheral edema from the effects of increasing 
left ventricular dysfunction. 
U.. io"'-Y 
Although amlodipine was not teratogenic in the rat and rabbit some dihydropyridine compounds have been found 
to be teratogenic in animals. In rats. amlodipino has been shown to prolong both the gestation period and the 
duration of labor. There is no clinical experience with NORVASC in pregnant women. NORVASC should be used 
during pregnancy onty if the potential benefit outweighs the potential risk to the mother and fetus. 
....... -. 
tt is not known whether amlodipine is excreted in human mitk.. Since amlodipine safety in newborns has not been 
established, NORVASC should not be given to nursing mothers. 
.... io CloiWretl 
The usa of NORVASC is no< reconvnandad in chldren since salety and efficacy have no< been established in that pop<Ution. 
U..iaEWoofy 
In elderly patients 1265 years! ctearance of amtodipine is decreased with a resulting increase in AUC.In clinical 
trials the incidence of adveru reactions in elderly patients was approximately 6~ higher then that of younger 
population ld!i year>). Adverse reactions include edema. muscle cramps and dizziness. NORVASC should be used 
cautiously in elderly patients. Oosage adjustment is advisablelsee DOSAGE AIIO AIIIIIIIISTIIATION). 
--Gr.,.tnoil Jooico Pubishad dato indicata that through inhibition of the cytochrome P450 system. grapefruit juice can increase plasma 
levels and augment pharmacodynamic affects of some dilydropyridino calcium chamel blockers. Following oral 
adrninistmion of 10 mg amlodipine to 20 malo volunteers, pharmacokinetics of amlodipino were similar when 
amlodipine was administered with and without grapefruit juice. 
Dnotl -.ctioM 
As with II drugs, care should be exercised when treating patients with rrultiple medications Oilydropyridino calcium 
channel blocker> undergo biotransformation by the cytochrome P450 system, mainly via CYP 3A4 isoenzyme. 
Coadministration of amlodipine with other drugs which folow the same route of biotransformation may result in 
a~ered bioava~abitity of amlodipine or these drugs. Oosages of sim~arly motobolized drugs, particularly those of 
low therapeutic ratio, and especiatty in patients with renal and/or hepatic Nnpairment. may require adjustment 
when starting or stopping concomitantly administered amlodipine to maintain optimum therapeutic blood levels. 
Orugs known to be inlubitors of the cytochrome P450 system include: azofo antilungals, cimetidine, cyclosporino, 
erythromycin. quinidine, terfenadine, warfarin. 
Orugs known to be inducers of the cytochrome P450 system include: phanobarbital, phenytoin, rifampin. 
Orugs known to be biotnonslormed via P450 include: benzodiazepinas, flecainide, imipramine, propafenone, theophylline. 
Amlodipine has a low Irate of first-pass) hepatic clearance and consequent high bioavailobility, and thus, may be 
expocted ID have a low potential IO< clinically relevant effects associated with elevation of amlodipine pi sma 
levels when used concomitantly with drugs that compete for 0< inhibit tho cytochrome P450 system. 
Cioooli4ieo, _.._ Cydooporioo. Oifoxia: Pharmacoltinetic interaction studies with amlodipine in haalthy 
volunteers have indicated: 
• c- did not alter the pharmacoltinetics of amlodipine. 
• amlodipino did not change ---induced prothrombin response time. 
• amlodipine doos not significantly alter the pharmacotinotics of cycleoporiL 
• amlodipine did not change serum ..- levels or lliflxill renal clearance. 
--
Concomitant administr1tion of Maalo (magnesium hydroxide and aluminum hydroxide) had no effect on the dis-
position of a single 5 mg dose of amlodipina in 24 subjects. 
--...:When beta-adrenergic receptor blocking drugs oro adninistered concomitantly with NORVASC. 
patients should be carefuly monitored since blood pressure lowering effect of beta-blocker> may bo augmented by 
amfodipine's reduction in peripheral vascular resistance. 
AIIYEJIS( IIEACTlOIIS 
NORVASC lamlodipina besylate) has been administered to 1,714 patients 1805 hypartensive and !ll9 angina 
patients) in controled clinical trials lvs placebo alone ar<l with active comparative agents). Most advono 
reactions reported during ther1py were of mild-to-moderate severity. 
~
In tho 1115 hypoftllnsive patients treated with NORVASC in ~ ckica1 trials, advorsa o11acts -• reported in 
~ d patients and required disconlirwtion d therapy duo ID side o11acts in 1~ of patioru. The .- common 
advorsa reactions in conroled clinical triols were: odarna 18.ft). and headache IB.l'JIL The folowing advorsa reactions 
-e reported with an incidonc:e of 2.45% in the controled clinical triols program ln;805~ 
~ ' or. edema IB.ft), palpitations 12-0l!.). tochycanfial0.7~). postural dizziness 111.5~1- stio _. 
pruritusi0-~1- -: musclecramps lll5~L c:...l _. ...,......­
s.,_ hladachola.J'Jil. dizziness IJ.Ol!o). parestha>ialll5~1- -s,_ flushing 13.1 ~1. 
oncreased swutJng IO.ft), dry mouth 10.7~1- l'sydoialric: somnoloncol1.4~). G.D o' ot111iuf: nauseal2.4~ ). 
:nal pain 11 . 1 ~). dyspepsiaiO.&l'). constipation 10.5~) . ~: fatiguel4. 1~). pain 10.5~). 
In the controled clinical triols in !ll9 angn patients treated with NORVASC, adverse effects were reported in 
30.5~ d patients oro! requO"ed disconlinuation of therapy duo to side effects in 0.61' d patients. The .-common 
adverse reactions reported in controled clinical triols were: edema l9.ft) and headache (7 n1. 
The following advone reactions occurred at an incidence of ~5~ in the controled clinical triols program ln.!IJ9t. 
~--edema 19.9~1. palpitations 12-0l!.l. postural dizziness ID.&~). stio _.~rash ILOl!o). 
pruntus lOA). - - muscle cramps ll.Ol!o). c-al_. .......... ..._ s,- hudache 
11n1. dizziness IU~L paresthesial1.11111. hypoesthesiaiO-"'L--!,-flushing 11~1. 
l'lydOalric: somnolence I!~). insormiaiD-9~). nervousness IO.~L-. nauseal4~). 
abdominal pain 1:1.211). dyspepsial1.4~). diarrheall.l~). ftatulencel1.1111), constipotion IO.ft). flnpi.-y 
5,- dyspnea IL 1 ~1- Spocial s.-: abnormal vision 11~1. timitus lo.&~). c.or.l: fatigue 1 4.8~). 
pain 11.11111. astheniaiLOl!o). 
NORVASC has been evaluated IO< safety in about 11.000 patients with hypartension and angina. 
The following events occurred in <1 ~ but >0.1 ~ of patients in comparative clinical trials I double-blind 
comparative vs ptacebo or active agents: n = 2.615) or under conditions of open trials or marketing experience 
where 1 causal relationship is unceroin. 
~ arrhythmia !including ventricular tochycardia and atrial fibrifation). bradycardia. hypotension, 
peripharal ischamia, syncope. bchycardia. postural dizziness, postural hypotension. c:-.1 _. ...,...... 
- s,_ hypoasthesia, tremor, vertigo . ..__......,._ anorexia. constipation, dysphagia. vomiting. 
gingiv~ hyperplasia • ...._,.. asthenia', back pain, hot flushes, malaise, rigors. weight gaWL ~Is,.._ arthralgia, arthrosis, myalgia. PsydlliMric: sexual dysfunction tmale' and female). insomnia, nervous-
ness, depression. abnormal dreams. anxiety, depersonalization.~ s,_ epistaxis. stio _. 
~ prurilus', rash erythematous, rash moculopapula, erythema multiforme. Spociol - conjooctivitis, 
diplopia, eye pain, tinnitus. Uriooory s,_ micturition frequency, micturition disorder. nocturia. -
~ s,.-: dry mouth, increased sweating . .._ic .... -:thirst~ purpura. 
These events occurred m less than 1% in placebo-controlled trials. but the incidence of these side effects was 
between 1 ~ and ~ in al multiple dose studies. 
The following events occurred in sf]. 1ft of patients: cardiac failure. skin discoloration, urticaria. skin dryness. 
Stevens-Johnson syndrome, alopecia, twitching, ataxia, hypertonia, migraine, apathy, 1rrmesia, gastritis, 
pancreatitis, increased appetite, coughing, rhinitis, parosmia, taste perversion, and xerophthalmia. 
Isolated cases of angioedema have been reported. Angioedema may be accompanied by breathing difficutty. In 
postmarteting experience, jaundice and hepatic enzyme elevations (mostly consistent with cholestasisl in some 
c,ases severe enough to require hospitalization have been reponed in association with use of amlodipine . 
SYWTliiiS A111D T1IEAT1IIIEJfT Of 0VE11110SAGE s.,..... 
Overdosage can cause excessive peripheral vasodilation with marked and probabty prolonged hypotension and 
possibly a reflex tachycardia. In humans, experience with overdosage of NORVASC lamlodipine besytate) is limited. 
When amlocfipine was ingested It doses of 105-250 mg some patients remained normotensive with or without 
gastric lavage while another patient experienced hypotension I!IIW50 mmHg) which normalized following plasma 
expansion. A patient who tool< 70 mg of amlodipine with benzodiazepine developed shock which was refractory 
to treatment and died. In a 19 month-old child who ingested 30 mg of amlodipine I about 2 mg/kg) there was no 
evidence of hypotension but tachycardia (180 bpml was observed. Ipecac was administered 3.5 hrs after ingestion 
and on subsequent observation (ovemightl no sequelae were noted. 
T.-
Ciiniclly significant hypotension due to overdosage requires active cardiovascular suppon inctuding frequent 
monitoring of cardiac and respiratory function, elevation of extremities. and attention to circulating fluid volume 
and urine output A vasoconstrictor (such as norepinephrine I may be helpful in restoring vascular tone and 
blood pressure, provided that thoro is no contraindicotion to its usa. As NORVASC is highly protein bound, 
hemodiatysis is not likely to be of benefit Intravenous calcium gluconate may be beneficial in reversing the 
effects of calcium channel blockade. Clearance of amlodipino is prolonged in elderly patients and in patients 
with impaired liver function. Since amfodipine absorption is slow, gastric lavage may be worthwhile in some cases. 
DOSAGE AIIO ADMINISTIIATIOIII 
Dosage should be individualized depending on patien(s tolerance and responsiveness. For both hypertension 
and angina, the recommended initial dose of NORVASC lamlodipine besytate) is 5 mg once daily. H necessary, 
dose can be increased after 1·2 weeks to a muimum dose of 10 mg once deify. 
U.. iolloo EWoriy•io--~--
The recommended initial dose in patients over 65 years of age or patients with impaired renal function is 5 mg 
once daily. H required, increasing in the dose should be done gradually and with caution lsoo PIIECAUTIOIIIS). 
..... ..__.......,lloplllic_ 
Oosage requirements have not been established in patients with impaired hepatic looction. When NORVASC is 
used in these patients. the dosage should be carefully and gradually adjusted depending on patient s tolerance 
and response. A lower starting dose of 2.5 mg once daily should be considered lsee WAIIIIIIIIGS). 
DOSAGE~ 
_...., 
NORVASC is available as white octagonal toblets containing amlodipine besylate equivalent to 2.5, 5 and 10 mg 
amlodipine per to blat. The respective to blot strengths are debossed on one tablet face as ·NRV 2.5·. · NRV 5· 
and "'NRV 10" with "'Pfizer" on the opposite face. The 5 mg tablet is scored. Supplied in white plastic (high density 
polyethylene) bottles of 100 to blots IO< each strength. Also tho 5 mg and 10 mg are supplied in bottles of 250 tablets. 
STOIIAGE 
Store at 1!;-JO"C. Protect from light. 
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And in this morning's rush to get away from it all, he forgot his therapy at home. 
He just became one of the 62% of Canadian hypertensives who regularly miss, forget or delay taking their 
medication (n=301 ). 7 
Of course, patients should be advised to take orvasc* every 24 hours. But even a full 24 hours after a missed 
dose, long-acting1·3565 orvasc* maintains blood levels which can deliver blood pressure reduction.J6.38·41.-H ·65 
With proven tolerability and, at 1.9%, an extremely low discontinuation rate .1 
Once-a-day orvasc *. Because the best things in life usually arrive in their own good time . 
Allows extra time for human nature. 
Norvasc• 15 tndlcated tn the treatment of m1ld-to-moderate essential hypenens10n when dmretlcs or beta-blockers are unsUitable. The most common adverse reactions 
mclude edema (8 9%) and headache (8.3%)' For dosage adjustments m the elderly and hepauc 1mpa1red. consult the product monograph 
and into the next day. 
half-life permits once-daily dosing 
be taken in the morning or the 
of relief with patient-assessed 
observed within 1-2 weeks! 
tained over 
